Brain cell- or nerve cell-protecting agents comprising medicinal ginseng

The present invention provides medicinal or pharmaceutical compositions and preparations for administration, which are useful as cytoprotective agents and a remedy for neurotrauma, comprising ginseng, its extract, ginseng components, metabolites thereof or salts thereof (for example, red ginseng powder or components thereof). More particularly, the present invention provides medicinal or pharmaceutical compositions for inhibiting apoptosis or apoptosis-like cell death, medicinal or pharmaceutical compositions for promoting the expression of a cell death-suppressing gene product BCl-xL, or preparations for oral or intravenous administration, comprising ginseng, its extracts, ginseng components, metabolites thereof or salts thereof preferably at low concentrations. These medicinal or pharmaceutical compositions and/or preparations for administration are characterized by containing, as the active ingredient(s), ginseng, its extracts, ginseng components, metabolites thereof or salts thereof at low concentrations. These drugs are useful for therapy, prevention or treatment of brain and nervous diseases, heart diseases, etc.

Skip to: Description  ·  Claims  · Patent History  ·  Patent History
Description
RELATED APPLICATIONS

This application is a divisional application of U.S. Ser. No. 10/070,209, filed on Jul. 12, 2002, which in turn claims priority to PCT/JP00/04102 filed on Jun. 22, 2000, published as WO/2001/015717 on Aug. 3, 2001, which also in turn claims priority to Japanese Application No. 11/243378, filed on Aug. 30, 1999.

TECHNICAL FIELD

The present invention relates to medicinal ginseng, extracts thereof, ginseng components or metabolites thereof useful as cell-protecting agents. More particularly, the present invention relates to medicinal or pharmaceutical compositions for suppressing apoptosis or apoptosis-like cell death or for promoting the expression of a cell death-suppressing gene product Bcl-xL comprising ginseng, its extracts, ginseng components, metabolites thereof or salts thereof.

Further, the present invention relates to a medicinal or pharmaceutical composition(s) for protecting cells comprising ginsenoside Rb1, metabolites thereof or salts thereof. More particularly, the present invention relates to a medicinal or pharmaceutical composition(s) for preventing, treating or curing brain edema, brain and nervous tissue edema or spinal cord tissue edema comprising ginsenoside Rb1, metabolites thereof or salts thereof; a medicinal or pharmaceutical composition(s) for preventing, treating or curing bedsores caused by spinal cord injuries comprising ginsenoside Rb1, metabolites thereof or salts thereof; a medicinal composition(s) for promoting the expression of a cell death-suppressing gene product Bcl-xL in the nervous tissues, comprising ginsenoside Rb1, metabolites thereof or salts thereof; a medicinal or pharmaceutical composition(s) for promoting the expression of a cell death-suppressing gene product Bcl-xL in oligodendrocytes comprising ginsenoside Rb1, metabolites thereof or salts thereof; a protective agent(s) for oligodendrocytes comprising ginsenoside Rb1, metabolites thereof or salts thereof; a medicinal or pharmaceutical composition(s) for promoting the expression of a cell death-suppressing gene product Bcl-xL in myocardial cells comprising ginsenoside Rb1, metabolites thereof or salts thereof; and a medicinal or pharmaceutical composition(s) for suppressing apoptosis or apoptosis-like cell death of myocardial cells comprising ginsenoside Rb1, metabolites thereof or salts thereof.

Further, the present invention relates to a preparation(s) for intravenous administration comprising medicinal ginseng, its extract, ginseng components, metabolites thereof or salts thereof. More particularly, the present invention relates to the preparation (s) for intravenous administration at low concentrations and low doses.

Further, the present invention relates to the use of components of medicinal ginseng or metabolites thereof as leading compounds for exploring novel active compounds for preventing, curing or treating the diseases or lesions hereinbefore, or for exploring brain cell-protective agents or neuroprotective agents.

Further, the present invention also relates to a novel chemical derivative prepared from ginsenoside Rb1 as a leading compound, namely dihydroginsenoside Rb1 which is useful as a cell protective agent or cytoprotective agent. Further, the present invention relates to a medicinal or pharmaceutical composition(s) for prevention, therapy or treatment of cerebral infarction or cerebral apoplexy, or a medicinal or pharmaceutical composition(s) for suppressing necrosis, apoptosis or apoptosis-like cell death of nerve cells or neurons, comprising dihydroginsenoside Rb1 metabolites thereof or salts thereof. The present invention further relates to a medicinal or pharmaceutical composition(s) in a preparation (s) for intravenous administration comprising dihydroginsenoside Rb1, metabolites thereof or salts thereof, namely, the medicinal or pharmaceutical composition(s) comprising the preparation(s) for repetitive or continuous intravenous administrations or the preparation(s) for a single intravenous infusion at low concentrations and low doses.

BACKGROUND ART

In intractable nervous diseases such as cerebral apoplexy and neurodegenerative diseases, brain cell death or nerve cell death commonly occurs. As a result, irreversible higher nervous functional disorders are developed. Once such functional disorders occur, the improvement, therapy and treatment of the diseases are very difficult and the QOL (quality of life) of patients is damaged for a long term. Consequently, although excellent preparations for oral administration which could prevent damage to these nerve cells are highly desirable for use prior to brain cell death or nerve cell death, such medicinal or pharmaceutical compositions have not been invented up to the present time.

Among the various ginsengs, red ginseng powder is frequently used in Chinese medical prescriptions, and it is positioned as one of the galenicals having various drug effects such as circulation improvement action and activation of the autonomic nervous system—endocrine system. It has also been reported that oral administration of red ginseng powder to patients with cerebrovascular disorder at chronic stage leads to improvement in cold flush or numbness in the lesioned extremities, as well as increased deep skin temperature. The effect is thought to be caused by the circulation-improving action of red ginseng powder (Yamaguchi, Takenori, Effect of medicinal ginseng on sequela of cerebrovascular disorder, in Ginseng '95, pp. 6-18, Kumagaya, Akira Ed., Kyoritsu Publishing Co.). However, if the red ginseng powder is administered orally to patients with cerebrovascular disorder at chronic stage (e.g. cerebral apoplexy patients at chronic stage), no improvement in cerebral apoplectic lesion itself is found. Further, it is not known whether the red ginseng powder is used for the prevention, therapy and/or treatment of cerebrovascular disorders at acute stage (e.g. acute cerebral apoplexy) in common clinical practice. Further, there is no known experimental medical basis for the use of red ginseng powder to treat other neurodegenerative diseases accompanied by nerve cell death, head injury or spinal cord injury in clinical medicine.

One of the inventors of the present invention (Sakanaka) has proved that when red ginseng powder at a dose of 0.9 g/kg/day or 1.5 g/kg/day, was administered to gerbils orally once a day for 7 days prior to a 5-minute transient forebrain ischemia, the learning disability after ischemia was significantly improved. This treatment also significantly prevented nerve cell death in the hippocampal CA1 area (Wen et al., Acta Neuropathol. 91, 15-22, 1996). Gerbils with forebrain ischemia are thought to be an animal model for transient ischemic attack in human. However, when red ginseng powder was administered orally at the same dose for one week after the 5-minute forebrain ischemia, the nerve cell death in the hippocampal CA1 area of gerbils was not suppressed; and the neuroprotective effect of oral administration of red ginseng powder was not so strong. Consequently, application of red ginseng powder to patients with more severe brain infarction than transient ischemic attack, e.g. to patients with permanent cerebrovascular occlusion), was thought to be unreasonable. Furthermore, the mechanism by which the oral administration of red ginseng powder suppresses the delayed neuronal death in the hippocampal CA1 area has not been elucidated. If such a mechanism of action is elucidated, it will be expected that new effects and improved efficacy of red ginseng powder will be discovered.

Originally, the methods for treatment of cerebral apoplexy (cerebral vascular diseases) have been different among cerebral infarction, cerebral embolism, cerebral hemorrhage, transient brain ischemic attack and subarachnoid hemorrhage; and strictly speaking, no effective countermeasures can be taken unless a cerebral CT inspection is performed. For example, thrombolytic agents can be used only for the treatment of cerebral infarction and brain embolism, and they are regarded as a contraindication for the treatment of cerebral hemorrhages. However, cerebral apoplexy is a serious disease resulting in a permanent disorder in higher functional activities, and threatening the survival of patients if no treatment is performed to protect the nerve cells or neurons at the lesion site at the earliest possible opportunity. Consequently, treatment or therapy should be initiated without a moment's delay. Even the period of time required for the CT inspection of the brain is, to put it strongly, a factor in reducing the possibility of recovery for patients with cerebral apoplexy. Surely, the treatment or therapy of acute phase cerebral apoplexy is a struggle against, not only the cerebral apoplectic lesion, but also the time after its onset. Quite unfortunately, at present, whatever is the disease type of cerebral apoplexy (cerebral infarction, cerebral hemorrhage, cerebral embolism, subarachnoidal hemorrhage or transient ischemic attack), the actual situation is that very few drugs are known which show a potent effect, even if they are administered immediately after the onset of cerebral apoplexy.

Ginsenoside Rb1 is a compound having the following chemical structure:

Ginsenoside Rb1 is a known compound described in the reference by Shibata et al. (Shibata at al., Economic and medicinal plant research, World Scientific, Philadelphia, pp. 217-284, 1985).

Intraperitoneal administration of ginsenoside Rb1 has been reported to show a tranquilizing action on the brain (Yoshimura H. et al., Eur. J. Pharmacol., 146, 291-197, 1988), but no mechanism of action has been elucidated. The possibility has been raised that a mixture of ginsenoside Rb1 and ginsenoside Rg1, or ginsenoside Rb1 or ginsenoside Rb1 at extracellular concentrations from 10−6M to 10−7 M is active in the central nervous system and shows some effect against Alzheimer's disease. This effect is the result of activating the liberation of acetylcholine from acetylcholine-containing nerve cells (U.S. Pat. No. 5,137,878: Composition and method for treatment of senile dementia). However, since it can not be said that the main cause of Alzheimer's disease is a functional disturbance of the acetylcholine-containing nerve cells, this hypothesis has many remaining problems to be solved. Further, the above U.S. patent did not disclose problems whether ginsenoside Rb1 could extend the survival of acetylcholine-containing nerve cells, particularly whether it prevents the death of acetylcholine-containing cells or not.

In addition, the nerve cell-protective or neuroprotective action resulting from a single use of ginsenoside Rb1 has been hardly elucidated until we initiated the studies on ginsenoside Rb1. Using the transient forebrain ischemia model in gerbils, we have previously studied how the protective action of ginsenoside Rb1 is exerted for cells other than acetylcholine-containing nerve cells. It has been proved that in this forebrain ischemia animal model, occlusion of the bilateral common carotid arteries for 3 to 5 minutes while maintaining the brain temperature at 37° C. results in neuronal loss of hippocampal CA1 pyramidal cells (containing no acetylcholine). This occurs within one week after ischemia, depending on the occlusion time (this event is called delayed neuronal death). It is also noted that the learning behavioral function of the ischemic animals deteriorates (Wen T.-C. et al., Acta Neuropathol., 91, 15-22, 1996). These facts mean that the transient forebrain ischemia model of gerbils reflects the human pathologic condition which results from a transient ischemic attack (TIA).

One of the inventors of the present invention (Sakanaka) has proved that administering ginsenoside Rb1 (10 mg/kg or 20 mg/kg) into the peritoneal cavity of gerbils, once a day for one week in advance, can significantly prevent delayed neuronal death and the learning disability resulting from occlusion of the common carotid arteries for 5 minutes (Wen T.-C. et al., Acta Neuropathol., 91, 15-22, 1996). However, intraperitoneal administration of ginsenoside Rb1 immediately after a 3- or 5-minute occlusion of the common carotid arteries, produced no effect (Wen T.-C. et al., Acta Neuropathol., 91, 15-22, 1996; Lim J.-H. et al., Neurosci. Res., 28, 191-200, 1997). Consequently, since both the transition rate and the transportation rate of peripherally (intraperitoneally) administered ginsenoside Rb1 to the brain are thought to be very low, no clinical application of ginsenoside Rb1, was considered at that time.

One of the inventors of the present invention (Sakanaka) reported that intracerebroventricular infusion of ginsenoside Rb1 starting immediately after occlusion of the common carotid arteries for 3 or 3.5 minutes in stead of the above peripheral (intraperitoneal) administration suppressed the delayed neuronal death and learning disability (Lim J.-H. et al., Neurosci. Res., 28, 191-200, 1997). Further, the inventors of the present invention (Sakanaka, Tanaka and Maeda) proved that in spontaneous hypertensive stroke-prone (SH-SP) rats, with permanent occlusion of the cortical branch of the middle cerebral artery (MCA) (the cerebral infarction model of rats), intracerebroventricular infusion of ginsenoside Rb1 immediately after permanent occlusion of the MCA caused a significant reduction in the infarcted area in the cerebral cortex and ameliorated the ischemia-induced place navigation disability of the animals (Zhang B. et al., J. Stroke Cerebrovasc. Dis., 7, 1-9, 1998).

Even though ginsenoside Rb1 is effective in direct intracerebroventricular infusion, it appears impossible, however, to apply ginsenoside Rb1 to human transient cerebral ischemic attack (TIA) and cerebral infarction due to problems in the route of administration. These are similar to problems with other peptide growth factors (Sakanaka, M. et al. Proc. Natl. Acad. Sci. USA, 95, 4635-4640, 1998; Wen T.-C. et al. J. Exp. Med., 188, 635-649, 1998).

In order to identify compounds useful for treating, preventing or curing cerebral infarction, the methods for screening candidate substances for preventing, treating or curing cerebral infarction with the use of the cerebral ischemia/reperfusion model in gerbils or rats, have recently been frequently employed. However, it is important to note that the cerebral ischemia/reperfusion model using gerbils or rats does not always reflect, as explained later, the pathologic condition involved in human cerebral infarction. As described earlier, one of the inventors of the present invention (Sakanaka) has reported that in the cerebral ischemia/reperfusion model using gerbils, intraperitoneal administration of ginsenoside Rb1 at a dose of 10 mg/kg/day or 20 mg/kg/day, before cerebral ischemia, rescued approximately 30% of the nerve cells in the hippocampal CA1 area. (Wen T.-C. et al., Acta Neuropathol., 91, 15-22, 1996). Zhang, Y. G and Liu, T. P. reported that a single intravenous administration of ginsenoside Rb1 at doses of 10-40 mg/kg before ischemia, (using the ischemia/reperfusion model of the middle cerebral arteries of rats) reduced the infarction size approximately 20% -49% as compared with the control groups. Such an administration also reduced the infarction size approximately 12% -35% as compared with the control group when it was conducted after the reperfusion (Zhang, Y. G. and Liu, T. P., Chung Kuo Yao Li Hsuech Pao, Chinese Pharmacol. J., 17, 44-48, 1996). However, this effect can not always be said to be superior to the candidate substances of drugs (for example, glutamate antagonists and free radical scavengers) so far developed for treatment of cerebral ischemia/reperfusion, rather it may be inferior (Slusher, B. S. et al., Nature Med., 5, 1396-1402, 1999). Furthermore, the intravenous administration of ginsenoside Rb1 at the dose of 40 mg/kg, which produced a comparatively good effect and high efficacy for the prevention and treatment of cerebral ischemia/reperfusion injuries, as reported earlier by Zhang, Y. G. and Liu, T. P., can be said to be too high in dose. Consequently, we can not deny the possibility of side effects or ill effects appearing following the single intravenous administration of ginsenoside Rb1. This is true when we consider that the LD50 of the intravenously administered ginsenoside Rb1 is approximately 448 mg/kg (Saito, H., et al., Shoyakugaku Zasshi, J. Galenicals, 34, 177-181, 1980). For a single intravenous administration, such a high dose of ginsenoside Rb1 is critical, and intravenous administration on consecutive days (or continuous intravenous administration) may be difficult.

In case of actual human cerebral infarction (cerebral thrombosis or cerebral embolism), except for a few cases in which the thrombolytic therapy is performed after catheterization in the area of the obstructed cerebral artery for recanalization, there are many cases of permanent cerebrovascular occlusion. Consequently, a truly useful remedy for cerebral infarction is that it can be administered after permanent occlusion of a part of the cerebral arteries (for example, the middle cerebral artery), and the drugs which can protect specifically cerebral cells and nerve cells located in the ischemic penumbra until one month after the onset of cerebral infarction are needed. At this point, the cerebral infarct (cerebral thrombosis and cerebral embolism) lesion has entered a stable stage, and hopefully the broken cerebral vascular networks are recovered and reconstructed. It should be noted that the pharmacological analysis of drug candidates for the treatment or therapy of cerebral infarction should be performed by using animals with completely obstructed cerebral arteries. According to the earlier report by Zhang, Y. G and Liu, T. P., intravenous administration of ginsenoside Rb1 at a dose of 10 mg/kg to rats before permanent occlusion of the middle cerebral artery, resulted in absolutely no effect. However, only when ginsenoside Rb1 at a dose of 40 mg/kg was administered intravenously before but not after permanent occlusion of the middle cerebral artery, the size of the infarction was reduced about 14% as compared with the control group. Consequently, even if a single intravenous administration of ginsenoside Rb1 at the high dose (40 mg/kg) was performed earlier in rats with a permanently occluded middle cerebral artery, it produced an obviously weak effect as compared with results obtained from an intravenous administration of ginsenoside Rb1 into rats with ischemia and reperfusion of the middle cerebral artery. Furthermore, when the high dose (40 mg/kg) of ginsenoside Rb1 is administered to rats with permanent occlusion of the middle cerebral artery before cerebral infarction occurs, it produces a very weak effect. If we consider that the LD50 of ginsenoside Rb1 for intravenous administration is approximately 448 mg/kg, then such a high dose (40 mg/kg) of ginsenoside Rb1 for intravenous administration every day (or consecutive days) is thought to be impossible. Based on the experience of the inventors of the present invention, a single or one more intravenous administration of a drug candidate for the treatment or therapy of cerebral infarction into experimental animals with a permanently occluded part of the cerebral arteries (for example middle cerebral artery) may show an effect for 1-2 days after the onset of cerebral infarction. However, if the same drug candidate is not administered on consecutive days thereafter, the cerebral infarct lesion will surely expand, and eventually in one month after the permanent cerebrovascular occlusion (namely, when the cerebral infarct lesion enters the almost stable stage), almost no effect is observed. Consequently, an important qualification for drugs for the treatment or therapy of cerebral infarction is that the compound can be administered intravenously for a long term or intravenously every day. However, based on the previous report of Zhang, Y. G. and Liu, T. P., it was thought to be practically impossible to apply intraveous administration of the high doses of ginsenoside Rb1 in a repeated or continuous manner for treating, preventing or curing cerebral infarction or cerebral apoplexy.

The invention to counteract the previous idea that it was almost impossible to utilize ginsenoside Rb1 for the therapy, prevention or treatment of cerebral infarction, was developed by the inventors of the present invention (Sakanaka and Tanaka). Details are described in the specification of Japanese Patent Application No. Hei 10-365560, PCT/JP99/02550 (Brain cell- or nerve cell-protective agents comprising ginsenoside Rb1) and Japanese Patent Application No. Hei 11-340850, PCT/JP99/06804 (Cerebrovascular regeneration/reconstruction promoters and nerve tissue secondary degeneration inhibitors comprising ginsenoside Rb1). In particular, we have found in the prior patent application that when repetitive or continuous intravenous infusion of ginsenoside Rb1 was conducted at a dose of 60 μg/day or 6 μg/day for 28 days after the middle cerebral artery (MCA) of spontaneous hypertensive stroke-prone (SH-SP) rats was permanently occluded, the volume of the cerebral infarct (cerebral embolism) lesion was reduced to about ¼ as compared to what occurred in a group of cerebral infarction infused with physiological saline (vehicle). That is to say, repetitive or continuous intravenous administration of low doses of ginsenoside Rb1, after permanent occlusion of the MCA, resulted in about a 75% reduction of the volume of the cerebral infarct lesions as compared with those in the control group. Moreover, it was found that even with repetitive or continuous intravenous infusions of such small amounts of ginsenoside Rb1 for 28 days, cerebral vessels which had been destroyed after MCA permanent occlusion were regenerated and reconstructed. This occurred even if the intravenous administration of ginsenoside Rb1 was subsequently terminated, and thereafter the cerebral infarct lesion had no longer deteriorated. Since the body weight of the SH-SP rats used by us (Sakanaka and Tanaka) is about 300 g, the daily dose of ginsenoside Rb1 is about 200 μg/kg or 20 μg/kg. Consequently, when this is compared with the single intravenous administration of ginsenoside Rb1 at a dose of 40 mg/kg that was used in the report by Zhang, Y. G. and Liu, T. P. (Chung Kuo Yao Li Hsuech Pao, Chinese Pharmacol. J., 17, 44-48, 1996), the daily dose to our SH-SP rats is 1/200 or 1/2000 of theirs. In the Japanese Patent Application No. Hei 10-365560, PCT/JP99/02550 and Japanese Patent Application No. Hei 11-340850, PCT/J299/06804, the inventors of the present invention (Sakanaka and Tanaka) invented an excellent method for treating or curing cerebral infarction (cerebral thrombosis or cerebral embolisms), and for the treatment or therapy of cerebral apoplexy and cerebrovascular disorders. This method involved the long-term intravenous repetitive or continuous administration of small amounts of ginsenoside Rb1. Small amounts of ginsenoside Rb1 can be administered as a single intravenous infusion every day, or as a small amount of ginsenoside Rb1 mixed with the other compositions or components for drip infusion so that the intravenous infusion can be performed constantly throughout the day or throughout a certain period. Further the prior report by the inventors of the present invention showed that the intracranial administration or the intracerebroventricular administration of ginsenoside Rb1 suppressed secondary degeneration of the ischemic nervous tissues (Wen T.-C. et al., Acta Neuropathol., 91, 15-22, 1996; Zhang, B. et al., J. Stroke Cerebrovasc. Dis., 7, 1-9, 1998). Also in the prior patent applications, the inventors of the present invention (Sakanaka and Tanaka) demonstrated that repetitive or continuous intravenous administration of small amounts of ginsenoside Rb1 suppressed effectively the secondary degeneration of the nervous tissues. And finally, in the prior patent application, the present inventors (Sakanaka and Tanaka) showed that repetitive or continuous intravenous administration of small amounts of ginsenoside Rb1 can be applied for prevention, therapy or treatment of neurotrauma, head injury or spinal cord injury.

In the pathologic states of cerebral apoplexy, neurotrauma, head injury, spinal cord injury, intracranial hemorrhage, cardiac arrest, hypoxic ischemic encephalopathy or encephalitis, etc., if a large invasion or damage into the brain and nervous tissues occurs, brain edema appears. As a result, the pressure on the brain is significantly increased and this frequently threatens the survival of patients. In the field of clinical medicine, in order to prevent, treat or cure herniation of the brain tissue which accompanies increases in brain edema or brain pressure (intracranial pressure), mannitol, glycerol and/or steroids are frequently used. However, problems from the rebound effect and other side effects following termination of the drug administration have not been solved. Consequently, a safe drug for the therapy or treatment of brain edema, which can be administered over a long time, may certainly be required in the future, but no such drugs are available.

Regarding a mechanism of neuroprotection by peripheral (intraperitoneal) administration of ginsenoside Rb1, the inventors of the present invention have reported that when low concentrations (0.1-100 fg/ml) of ginsenoside Rb1 were added in advance to the culture medium, the necrosis of nerve cells caused by the hydroxyl radical inducer (ferrous sulfate) was reduced (Lim, J. -H. et al., Neurosci. Res., 28, 191-200, 1997; Zhang, B. et al., J. Stroke Cerebrovasc. Dis., 7, 1-9, 1998). We presumed that ginsenoside Rb1 eliminated the hydroxyl radicals and thus reduced the lipid peroxide of the cell membrane and thereby protected the cultured nerve cells. However, no report to prove this hypothesis has been published.

High concentrations (approximately 0.11-11 μg/ml) of ginsenoside Rb1 reduced the neurotoxicity of glutamic acid and prevented nerve cell death (Kim, Y. -C., et al., J. Neurosci. Res., 53, 426-432, 1998; Liu, M. and Zhang, J. T., Acta Pharmaceutica Sinica, 30, 674-678, 1995). Also, the high concentration of ginsenoside Rb1 at 500 μM (550 μg/ml) may protect against apoptosis-like death in cell culture experiments (Tanaka, Tomoaki et al., The Ginseng Review, 24, 61-65, 1998). However, according to cell culture experiments by the present inventors, the high concentration of ginsenoside Rb1 did not suppress nerve cell death (Lim, J.-H. et al., Neurosci. Res., 28, 191-200, 1997; Zhang B., et al., J. Stroke Cerebrovasc. Dis., 7, 1-9, 1998).

It is very difficult to reproduce or maintain such high concentrations of ginsenoside Rb1 in the in vivo lesioned tissues or in the extracellular fluid of the nervous tissues. Furthermore, considering the cost and the possibility of side (ill)effects appearing, the present inventors (Sakanaka and Tanaka) speculate that the administration of large amounts of ginsenoside Rb1 in vivo is not feasible. Actually, in view of the earlier experimental results of the present inventors, it has been demonstrated that high doses of ginsenoside Rb1 do not always produce preferable effects and efficacy (Zhang, B., et al., J. Stroke Cerebrovasc. Dis., 7, 1-9, 1998).

At present, the mechanism of neuroprotection by ginsenoside Rb1 has not been elucidated.

In Japanese Patent Application No. Hei 10-365560, PCT/JP99/02550 (Brain cell or nerve cell-protective agents comprising ginsenoside Rb1), we (Sakanaka and Tanaka) have found that ginsenoside Rb1, at a markedly low concentration range never previously reported suppresses apoptosis-like nerve cell death by increasing the expression of a cell death-suppressing gene product Bcl-xL. These concentrations ranged from 1 ng/ml or less, and preferably from 1 fg to 100 fg/ml. Specifically, in the previous patent application, we (Sakanaka and Tanaka) found that ginsenoside Rb1 is the only non-peptide Bcl-xL expression stimulator in the world. Although ginsenoside Rb1 at a concentration of 100 fg/ml showed a slight suppressive action on the formation of lipid peroxides, no such effect was observed at the lower concentrations. Consequently, the hypothesis presented earlier in relation to the action mechanism of ginsenoside Rb1, namely the hypothesis in which ginsenoside Rb1 decreases cell membrane lipid peroxides as a result of erasing hydroxyl radicals to protect nerve cells, was found to be inappropriate. Further, in the previous patent application, the present inventors (Sakanaka and Tanaka) found that ginsenoside Rb1 inhibited apoptosis-like cell death in vivo.

Since Bcl-xL is expressed not only in nerve cells or neurons, but also in cells of the other peripheral tissues or glial cells, the fact that ginsenoside Rb1 enhances the expression of the cell death-suppressing gene product Bcl-XL, suggests that ginsenoside Rb1 also has the same action on the other cells. Importantly, we (Sakanaka and Tanaka) have described in the prior patent applications (Japanese Patent Application No. Hei 10-365560, PCT/JP99/02550, Brain cell or nerve cell-protective agents comprising ginsenoside Rb1; Japanese Patent Application No. Hei 11-340850, PCT/JP99/06804, Cerebrovascular regeneration/reconstruction promoters and nerve tissue secondary degeneration inhibitors comprising ginsenoside Rb1) the idea that since myocardial cells abundantly express Bcl-xL, they are highly possible targets on which ginsenoside Rb1 at low concentrations and low doses act to show effect and efficacy.

Although ginsenoside Rb1 is a kind of purified saponin which is contained in medicinal ginseng, it can not be detected in the blood following a single oral administration. As a result, the pharmacological action resulting from oral administration of ginsenoside Rb1 has been denied. Consequently, in the Japanese Patent Application No. Hei 10-365560, PCT/JP99/02550, Brain cell or nerve cell-protective agents comprising ginsenoside Rb1 and Japanese Patent Application No. Hei 11-340850, PCT/JP99/06804, Cerebrovascular regeneration/reconstruction promoters and nerve tissue secondary degeneration inhibitors comprising ginsenoside Rb1, we (Sakanaka and Tanaka) have demonstrated that intravenously administered ginsenoside Rb1 at low doses have effects, efficacy and/or usages independent of those of medicinal ginseng.

In the crude saponin fraction(s) of medicinal ginseng, besides ginsenoside Rb1, there are at least approximately 30 different purified saponins similar in chemical structure to ginsenoside Rb1 (Shoji, Ginseng '95, pp. 251-161, Kumagai, Akira, Ed. Kyoritsu Publ. Co.). Quite naturally, as described in our prior patent application (Japanese Patent Application No. Hei 10-365560, PCT/JP99/02550, Brain cell or nerve cell-protective agents comprising ginsenoside Rb1), these other purified saponins are expected to exhibit effects and efficacy similar to those obtained by intravenous administration of ginsenoside Rb1 at low doses. We have also described in our prior patent application (Japanese Patent Application No. Hei 11-243378) the concept that novel useful compounds could be prepared by using components of medicinal ginseng and/or ginsenoside Rb1 as the leading compounds.

As described above, we have referred to the importance of elucidating the mechanisms of action involved in oral administration of medicinal ginseng. We have also described the marked effects resulting from the continuous intravenous administration of small amounts of ginsenoside Rb1, the importance of prevention, therapy and treatment of cerebral edema, the upregulation of bcl-xL expression by ginsenoside Rb1, and the importance of elucidating the physiological actions of the crude saponin fractions of medicinal ginseng or components thereof. In the present invention, we have found that oral administration of red ginseng powder exhibited an unexpectedly excellent suppressive action against cerebral infarction, an ameliorating effect on cerebral edema and an improvement in place navigation disability in rats which had undergone permanent occlusion of the cortical branch of the middle cerebral artery (MCA). This damage caused by permanent MCA occlusion is more severe than the transient forebrain ischemia model of gerbils and is similar to the pathological state of human cerebral infarction. We have also found that oral administration of red ginseng powder enhanced the expression of the cell death-suppressing gene product BCl-xL protein in the nervous tissues. Further, we have found that: the continuous intravenous administration of small or low dosages of ginsenoside Rb1 suppresses the onset of cerebral edema quite effectively; that ginsenoside Rb1 at concentrations of 0.01-104 fg/ml or 1-104 fg/ml enhanced the expression of Bcl-xL in myocardial cells and suppressed apoptosis or apoptosis-like cell death of myocardial cells; and that the continuous intravenous administration of small amounts of a crude saponin fraction of ginseng (red ginseng powder) exhibits therapeutic effects on spinal cord injuries. These effects were similar to those obtained by intravenous continuous administration of low dosages of ginsenoside Rb1. With these findings we have completed the present invention. In addition, we have found a novel chemical derivative of ginsenoside Rb1, i.e. dihydroginsenoside Rb1 which exhibits excellent therapeutic effects against cerebral infarction, and thus we have completed the present invention.

DISCLOSURE OF THE INVENTION

An object of the present invention is to provide medicament exhibiting an excellent brain cell- or nerve cell-protecting effect and protecting cells by promoting expression of a cell death-suppressing gene product Bcl-xL protein. A further object of the present invention is to provide: a preparation which can be used at low dosages by intravenous administration for the prevention, therapy and/or treatment of cerebral edema, brain edema, brain and nervous tissue edema or spinal cord tissue edema; a preparation which can be used at low doses by intravenous administration for the prevention, therapy and/or treatment of bedsores (decubitus) which accompany spinal cord injuries; a preparation for intravenous administration to promote the expression of a cell death-suppressing gene product Bcl-xL in the nervous tissues; a medicinal or pharmaceutical composition to promote expression of the cell death-suppressing gene Bcl-xL in oligodendrocytes; a protective agent for oligodendrocytes; a medicinal or pharmaceutical composition to promote expression of the cell death-suppressing gene Bcl-xL in myocardial cells; and a medicinal or pharmaceutical composition to suppress apoptosis or apoptosis-like cell death in myocardial cells. A further object of the present invention is to provide a preparation for intravenous administration which can be used for the prevention, treatment or therapy of diseases caused by injury or trauma to the nervous tissues or spinal cord tissue, and to provide a medicinal or pharmaceutical composition for suppressing demyelination, apoptosis or apoptosis-like cell death of oligodendrocytes, or secondary degeneration of the nervous tissues, which are caused by injury or trauma to the nervous tissues or spinal cord tissue.

A further object of the present invention is to provide a preparation which can be used at small or low doses by continuous intravenous administration for the prevention, therapy or treatment of cerebral infarction or cerebral apoplexy; and also to provide a medicinal or pharmaceutical composition for suppressing apoptosis of nerve cells (neurons) or apoptosis-like nerve cell death. An additional object of the present invention is to demonstrate methods for preparing novel useful brain cell-protective agents, or neuroprotective agents, by utilizing components or ingredients of ginseng or metabolites thereof as leading compounds.

The present invention provides effective preparations for oral administration comprising medicinal ginseng, its extracts, components of ginseng or metabolites thereof which are useful as cytoprotective agents. More particularly, the present invention provides medicinal or pharmaceutical composition(s) for preventing apoptosis or apoptosis-like cell death comprising ginseng, its extracts, components or ingredients of ginseng or metabolites thereof. It also provides medicinal or pharmaceutical composition(s) for promoting the expression of a cell death-suppressing gene product Bcl-xL protein comprising ginseng, its extracts, components of ginseng or metabolites thereof. Further, the present invention(s) provides a preparation for oral administration which is useful for the therapy, prevention or treatment of brain or nervous diseases or cerebral edema comprising medicinal ginseng, its extracts, components of medicinal ginseng or metabolites thereof.

In addition, the present invention provides: a preparation(s) which can be used at low or small dosages by intravenous administration for the prevention, therapy or treatment of cerebral edema, brain edema, brain and nervous tissue edema or spinal cord tissue edema, comprising ginsenoside Rb1, metabolites thereof or salts thereof. It also provides a preparation(s) at low doses by intravenous administration which can be used for the prevention, therapy and/or treatment of bedsores (decubitus) associated with spinal cord injuries, comprising ginsenoside Rb1, metabolites thereof or salts thereof. Additionally it provides a preparation(s) for intravenous administration to promote the expression of a cell death-suppressing gene Bcl-xL in the nervous tissues, comprising ginsenoside Rb1, metabolites thereof or salts thereof; a medicinal or pharmaceutical composition(s) for promoting expression of the cell death-suppressing gene Bcl-xL in oligodendrocytes, comprising ginsenoside Rb1, metabolites thereof or salts thereof; a protective agent(s) for oligodendrocytes comprising ginsenoside Rb1, metabolites thereof or salts thereof; a medicinal or pharmaceutical composition(s) for promoting the expression of the cell death-suppressing gene Bcl-xL in myocardial cells, comprising ginsenoside Rb1, metabolites thereof or salts thereof; and a medicinal or pharmaceutical composition(s) for suppressing apoptosis or apoptosis-like cell death in myocardial cells, comprising low concentrations of ginsenoside Rb1, metabolites thereof or salts thereof.

The present invention further provides a medicinal or pharmaceutical composition(s) for the prevention, treatment or therapy of diseases caused by injuries or trauma to the nervous tissues or spinal cord tissue, comprising the crude saponin fraction(s) of ginseng, any one of constitutional components thereof, metabolites thereof or salts thereof. More particularly, the present invention provides a medicinal or pharmaceutical composition(s) for prevention, treatment or therapy of the secondary degeneration of nervous tissues resulting from injuries to the nervous tissues; a medicinal or pharmaceutical composition(s) for prevention, treatment or therapy of diseases caused by spinal cord injuries, head injuries or neurotrauma; and a medicinal or pharmaceutical composition(s) for prevention, treatment or therapy of diseases caused by nervous tissue or spinal cord tissue injuries that are accompanied by demyelination. The present invention also provides a medicinal or pharmaceutical composition(s) for suppressing the apoptosis or apoptosis-like cell death of oligodendrocytes comprising the crude saponin fraction(s) of ginseng, any one of the constitutional components thereof, metabolites thereof or salts thereof. The present invention further provides the crude saponin fraction(s) of medicinal ginseng, any one of constitutional components thereof, metabolites thereof or salts thereof which are useful as suppressive agents against the secondary degeneration of nervous tissues.

The present invention provides a method for the use of components of medicinal ginseng or metabolites thereof, as leading compounds for exploring novel active compounds or ingredients for the prevention, treatment or therapy of diseases or lesions described above, and for exploring brain cell-protective agents or neuroprotective agents.

Further, the present invention provides a novel ginsenoside Rb1 derivative, i.e. dihydroginsenoside Rb1 which is useful as a cytoprotective agent. Dihydroginsenoside Rbi can be prepared by using ginsenoside Rb1 (one of components of ginseng) as a leading compound. More particularly, the present invention provides a medicinal or pharmaceutical composition(s) for prevention, therapy or treatment of cerebral infarction or cerebral apoplexy, or a medicinal or pharmaceutical composition(s) for suppressing apoptosis or apoptosis-like nerve cell death, comprising dihydroginsenoside Rb1, metabolites thereof or salts thereof. The present invention also provides a medicinal or pharmaceutical composition(s) for intravenous administration comprising dihydroginsenoside Rb1, metabolites thereof or salts thereof, namely the medicinal or pharmaceutical composition(s) for repetitive or continuous intravenous administration or single intravenous infusion at low concentrations or low dosages.

As described earlier, the present invention describes experiments on the oral administration of medicinal ginseng, experiments on the repetitive or continuous intravenous administration of ginsenoside Rb1 at low dosages, cell culture experiments using ginsenoside Rb1, experiments on continuous intravenous administration of small amounts of the crude saponin fraction(s) of medicinal ginseng, and experiments on the intravenous administration of a novel chemical derivative of ginsenoside Rb1, i.e. dihydroginsenoside Rb1. In the following description, the experiments on oral administration of medicinal ginseng, which were demonstrated in the prior patent application, Japanese Patent Application No. Hei 11-243378 (Brain cell or nerve cell-protective agents comprising ginseng), will be explained. Thereafter, the experiments on the intravenous administration of the crude saponin fraction(s), the experiments on the repetitive or continuous intravenous administration of ginsenoside Rb, at low doses and the cell culture experiments using low concentrations of ginsenoside Rb1 will be described. Finally, the results of the experiments using the novel chemical derivative of ginsenoside Rb1, dihydroginsenoside Rb1, will be explained.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows results of water maze tests of rats administered orally with distilled water or red ginseng powder before and after MCA permanent occlusion. In FIG. 1, the upper figure shows results at the 2nd week, and the lower figure shows results at the 4th week. In FIG. 1: open circles indicate distilled water-administered ischemia group; closed circles indicate sham-operated group; open squares indicate red ginseng powder (0.6 g/kg/day)-administered ischemia group; closed squares indicate red ginseng powder (0.75 g/kg/day)-administered ischemia group; open triangles indicate red ginseng powder (0.9 g/kg/day)-administered ischemia group; closed triangles indicate red ginseng powder (1.2 g/kg/day)-administered ischemia group.

FIG. 2 shows results of ratio of cerebrocortical infarction of animals administered orally with distilled water or red ginseng powder before and after MCA permanent occlusion.

FIG. 3 shows photographs of cerebrocortical infarct lesions. The upper photographs are 4 cases of distilled water-administered ischemia group and the lower photographs are 4 cases of red ginseng powder (0.9 g/kg/day)-administered ischemia group.

FIG. 4 shows a schematic illustration summarizing the results of example 1.

FIG. 5 shows results of water maze tests of rats administered orally with distilled water or red ginseng powder after MCA permanent occlusion. In FIG. 5, the upper figure shows—results at the 2nd week, and the lower figure shows results at the 4th week. In FIG. 5: open circles indicate distilled water administered ischemia group; and closed squares indicate red ginseng powder (0.9 g/kg/day)-administered ischemia group. For reference, the experimental results of sham operation used in FIG. 1 are indicated by closed circles.

FIG. 6 shows results of ratio of cerebrocortical infarction of animals administered orally with distilled water or red ginseng powder, 0.9 g/kg/day, after MCA permanent occlusion.

FIG. 7 shows the response latency time and the hippocampal CA1 neuronal density of gerbils administered orally with red ginseng powder or distilled water, once a day for one week before 5-minute transient forebrain ischemia. The upper figure (A) shows the response latency time of passive avoidance learning experiments, and the lower figure (B) shows the neuronal densities. Open columns indicate sham-operated groups; gray columns indicate distilled water-administered ischemia group; and closed columns indicate red ginseng powder-administered ischemia group.

FIG. 8 is photographs instead of drawings, showing results of Western blot analyses of Bcl-xL protein expression in the hippocampal CA1 field of sham-operated animals, ischemic animals administered orally with distilled water and ischemic animals administered orally with red ginseng powder (1.5 g/kg/day).

FIG. 9 shows graphs quantifying the results of Western blotting in FIG. 8 by densitometry.

FIG. 10(A) is photographs instead of drawings, showing results of Western blot analyses of BCl-xL protein expression in the liver of animals administered with distilled water or red ginseng powder (200 mg/kg/day).

FIG. 10(B) shows graphs quantifying the results of Western blotting in FIG. 10(A) by densitometry.

FIG. 11(A) is photographs instead of drawings, showing results of Western blot analyses of BCl-xL protein expression in the spleen of animals administered with distilled water or red ginseng powder (200 mg/kg/day).

FIG. 11(B) shows graphs quantifying the results of Western blotting in FIG. 11(A) by densitometry.

FIG. 12 shows the response latency time and the hippocampal CA1 neuronal density of gerbils administered with red ginseng powder or distilled water, once a day for 28 days after 3-minute forebrain ischemia. The upper figure (A) shows the response latency time of the passive avoidance learning experiments, and the lower figure (B) shows the neuronal densities. Open columns indicate sham-operated group; gray columns indicate distilled water-administered ischemia group; and closed columns indicate red ginseng powder-administered ischemia group.

FIG. 13 shows light microscopic photographs of the hippocampal CA1 field of (A) a sham-operated animal, (B) a distilled water-administered 3-minute ischemia animal, and (C) a red ginseng powder-administered 3-minute ischemia animal, respectively. Bar indicates 100 μm.

FIG. 14 shows photographs of cerebrocortical infarct lesion. The upper photographs are 8 cases of the ischemia group administered-intravenously with physiological saline and the lower photographs are 8 cases of the ischemia group administered intravenously with ginsenoside Rb1 (6 μg/day).

FIG. 15 shows chemical structures of representative saponins contained in medicinal ginseng.

FIG. 16 is photographs instead of drawings, showing rats administered intravenously with physiological saline or ginsenoside Rb1 (60 μg/day) in the day of spinal cord injury and in the next day of spinal cord injury.

FIG. 17 shows BBB scores of rats administered intravenously with physiological saline or ginsenoside Rb1 (12 μg/day and 60 μg/day) on the 7th day after spinal cord injury.

FIG. 18 is photographs instead of drawings showing a rat administered intravenously with a crude saponin fraction of medicinal ginseng (870 μg/day) during 0-7 days after spinal cord injury.

FIG. 19 is photographs instead of drawings showing a rat administered intravenously with physiological saline during 0-7 days after spinal cord injury.

FIG. 20 shows chemical derivatives of ginsenoside Rb1.

FIG. 21 is photographs instead of drawings, showing rats administered intravenously with physiological saline or ginsenoside Rb1 (60 μg/day) from 2 hours after spinal cord injury. FIG. 21 is also photographs showing the occurrence of bedsore (decubitus) in the rat administered with physiological saline after spinal cord injury. Further, FIG. 21 is also photographs showing no occurrence of bedsore in the rat administered intravenously with ginsenoside Rb1 (60 μg/day) after spinal cord injury.

FIG. 22 is photographs instead of drawings, showing results of Western blot analyses which demonstrate the cell survival-promoting effect of ginsenoside Rb1 on co-cultures of nerve cells (neurons) and oligodendrocytes. Treatment with ginsenoside Rb1 at concentrations of 1-100 fg/ml apparently made intense the MAP2 and CNPase bands which are markers for neurons and oligodendrocytes, respectively. Namely, it can be said that survival of nerve cells and oligodendrocytes was promoted by the low extracellular concentrations of ginsenoside Rb1.

FIG. 23, the upper photographs are results of RT-PCR showing an increase in BCl-xL mRNA expression in oligodendrocytes treated with ginsenoside Rb1 at a concentration of 100 fg/ml; and the lower photographs are results of Western blot analyses (immunoblotting) showing an increase in Bcl-xL protein expression in oligodendrocytes treated with ginsenoside Rb1 at concentrations of 1-100 fg/ml.

FIG. 24 is photographs instead of drawings, showing experimental results of RT-PCR wherein the expression of Bcl-xL mRNA in the brain tissue is increased by intravenous administration of ginsenoside Rb1 (60 μg/day).

FIG. 25, the upper photographs: photographs of RT-PCR showing that the expression of Bcl-xL mRNA in myocardial cells is increased by ginsenoside Rb1 at concentrations of 1-100 fg/ml. The middle photographs: photographs of immunoblot showing that the expression of Bcl-xL protein in myocardial cells is increased by ginsenoside Rb1 at concentrations of 1-104 fg/ml. The lower photograph: graph quantifying the results of immunoblotting by densitometry.

FIG. 26, the upper photograph: photograph of Western blotting of α-actinin showing that the survival of myocardial cells is promoted by treatment with ginsenoside Rb1 at concentrations of 1-104 fg/ml. The lower graph: graph quantifying the results of Western blotting (immunoblotting) by densitometry. Since numbers of cases are slightly small, i.e. n=3, significant effects are not noted in the cases treated with ginsenoside Rb1 at concentration of 0.01 fg/ml. However, if numbers of cases are increased, even such a low concentration of ginsenoside Rb1 (0.01 fg/ml) will exhibit a significant protective effect on the myocardial cells.

FIG. 27 is photographs instead of drawings, showing results of TTC staining of rat brains (2 cases) administered intravenously with physiological saline after permanent occlusion of the MCA (i.e. after the onset of cerebral infarction).

FIG. 28 is photographs instead of drawings, showing results of TTC staining of rat brains (2 cases) administered intravenously with dihydroginsenoside Rb1 (approximately 6 μg/day) after permanent occlusion of the MCA (i.e. after the onset of cerebral infarction).

FIG. 29 shows the chart of NMR of dihydroginsenoside Rb1.

BEST MODE FOR CARRYING OUT THE INVENTION

The present invention relates to a medicinal or pharmaceutical composition(s) for promoting the expression of a cell death-suppressing gene product Bcl-xL comprising ginseng, its extracts, ginseng components, metabolites thereof or salts thereof and/or a pharmaceutically acceptable carrier(s). Preferably, the present invention relates to the medicinal or pharmaceutical composition(s) for promoting the expression of a cell death-suppressing gene product Bcl-xL wherein the extracellular fluid levels of medicinal ginseng, its extracts, ginseng components, metabolites thereof or salts thereof in lesioned tissues are adjusted to 145 ng/ml or less, preferably 14.5 ng/ml or less or 1 ng/ml or less, more preferably 0.01-145000 fg/ml, further more preferably 1-145000 fg/ml.

Further, the present invention relates to a method for preventing, treating or curing diseases which can be prevented, treated or cured by promoting the expression of a cell death-suppressing gene product Bcl-xL comprising administering effective amounts of medicinal ginseng, its extracts, ginseng components, metabolites thereof or salts thereof, preferably amounts exhibiting the extracellular fluid concentrations of 145 ng/ml or less in lesioned tissues, more preferably 0.01-145000 fg/ml and more further preferably 1-145000 fg/ml, to patients with diseases which can be prevented, treated or cured by promoting the expression of a cell death-suppressing gene product Bcl-xL.

Further, the present invention relates to the use of medicinal ginseng, its extracts, ginseng components, metabolites thereof or salts thereof for production of the medicinal or pharmaceutical compositions for promoting the expression of a cell death-inhibitory gene product Bcl-xL.

Examples of tissues for promoting expression of the cell death-suppressing gene product Bcl-xL by the above medicinal or pharmaceutical compositions are brain tissue, nervous tissues, spinal cord tissue, liver and spleen. These compositions are useful for the prevention, therapy or treatment of brain and nervous diseases such as cerebrovascular dementia, cerebral infarction and cerebral apoplexy etc.

The medicinal or pharmaceutical compositions for promoting expression of the cell death-suppressing gene product Bcl-xL of the present invention can be used as the preparations for oral administrations or the preparations for intravenous administration.

The present invention relates to a medicinal or pharmaceutical composition(s) for suppressing the apoptosis of cells or apoptosis-like cell death comprising ginseng, its extracts, ginseng components, metabolites thereof or salts thereof and/or a pharmaceutically acceptable carrier(s). Preferably, the present invention relates to the medicinal or pharmaceutical composition(s) for suppressing the apoptosis of cells or apoptosis-like cell death wherein the extracellular fluid concentrations of medicinal ginseng, its extracts, ginseng components, metabolites thereof or salts thereof in lesioned tissues are adjusted to 145 ng/ml or less, preferably 14.5 ng/ml or less or 1 ng/ml or less, more preferably 0.01-145000 fg/ml, further more preferably 1-145000 fg/ml.

Further, the present invention relates to a method for preventing, treating or curing diseases which can be prevented, treated or cured by suppressing the apoptosis of cells or apoptosis-like cell death comprising administering effective amounts of medicinal ginseng, its extracts, ginseng components, metabolites thereof or salts thereof, preferably amounts exhibiting the extracellular fluid concentrations of 145 ng/ml or less in lesioned tissues, preferably 14.5 ng/ml or less or 1 ng/ml or less, more preferably 0.01-145000 fg/ml and more further preferably 1-145000 fg/ml, to patients with diseases which can be prevented, treated or cured by suppressing the apoptosis of cells or apoptosis-like cell death.

Further, the present invention relates to the use of medicinal ginseng, its extracts, ginseng components, metabolites thereof or salts thereof for production of the medicinal or pharmaceutical compositions for suppressing the apoptosis of cells or apoptosis-like cell death.

Examples of concerned cells of the present invention are brain cells, nerve cells (neurons), neuronal stem cells, glial cells, vascular endothelial cells, vascular smooth muscle cells, liver cells (hepatocytes), Kupffer's cells, sinusoid endothelial cells, fibroblasts, biliary epithelial cells, lipocytes, fat-storing cells, lymphocytes, leukocytes, reticulum cells, macrophages or plasma cells, and the medicinal or pharmaceutical compositions of the present invention are useful for therapy, prevention or treatment of diseases causing apoptosis of cells or apoptosis-like cell death.

The medicinal or pharmaceutical compositions for suppressing the apoptosis of cells or apoptosis-like cell death of the present invention can be used as the preparations for oral administration or the preparations for intravenous administration.

The present invention relates to a medicinal or pharmaceutical composition(s) for treating, preventing or curing brain and/or nervous diseases comprising ginseng, its extracts, ginseng components, metabolites thereof or salts thereof and/or a pharmaceutically acceptable carrier(s). Preferably, the present invention relates to the medicinal compositions for treating, preventing or curing brain and/or nervous diseases wherein the extracellular fluid concentrations of medicinal ginseng, its extracts, ginseng components, metabolites thereof or salts thereof in lesioned tissues are adjusted to 145 ng/ml or less, preferably 14.5 ng/ml or less or 1 ng/ml or less, more preferably 0.01-145000 fg/ml, further more preferably 1-145000 fg/ml.

Further, the present invention relates to a method for preventing, treating or curing brain and/or nervous diseases comprising administering effective amounts of medicinal ginseng, its extracts, ginseng components, metabolites thereof or salts thereof, preferably amounts exhibiting the extracellular fluid concentrations of 145 ng/ml or less in lesioned tissues, preferably 14.5 ng/ml or less or 1 ng/ml or less, more preferably 0.01-145000 fg/ml and more further preferably 1-145000 fg/ml, to patients with brain and/or nervous diseases.

Further, the present invention relates to the use of ginseng, its extracts, ginseng components, metabolites thereof or salts thereof for production of the medicinal Or pharmaceutical compositions for preventing, treating or curing brain and/or nervous diseases.

Examples of brain and/or nervous diseases of the present invention hereinbefore are injuries to the nervous tissues or spinal cord tissue such as spinal cord injury; injuries to the nervous tissues or spinal cord tissue such as head injury or neurotrauma; diseases caused by apoptosis or apoptosis-like cell death of oligodendrocytes; cerebral edema, edema of the brain and nervous tissues or edema of the spinal cord tissue caused by cerebral apoplexy, cerebral infarction, cerebral hemorrhage, subarachnoidal hemorrhage, head injury, intracranial hemorrhage, spinal cord injury or neurotrama; cerebrovascular dementia; cerebral infarction, cerebral apoplexy, transient cerebral ischemic attack; paralysis of the upper extremities or lower extremities, urination disorders, dysautonomia, hypogonadism, dyschezia or neurogenic bladder caused by injuries or trauma to the nervous tissues or spinal cord tissue.

The medicinal or pharmaceutical compositions for treatment, prevention or therapy of brain and/or nervous diseases of the present invention can be used as the preparations for oral administration or the preparations for intravenous administration.

The present invention relates to agents for treating, preventing or curing brain and/or nervous diseases or cerebral edema comprising medicinal ginseng, its extracts, ginseng components, metabolites thereof or salts thereof.

The present invention relates to a medicinal or pharmaceutical composition(s) for treating, preventing or curing cardiopathy or cardiac diseases comprising ginseng, its extracts, ginseng components, metabolites thereof or salts thereof and/or a pharmaceutically acceptable carrier(s). Preferably, the present invention relates to the medicinal or pharmaceutical composition(s) for treating, preventing or curing cardiopathy or cardiac diseases wherein the extracellular fluid concentrations of medicinal ginseng, its extracts, ginseng components, metabolites thereof or salts thereof in lesioned tissues are adjusted to 145 ng/ml or less, preferably 14.5 ng/ml or less or 1 ng/ml or less, more preferably 0.01-145000 fg/ml, further more preferably 1-145000 fg/ml.

Further, the present invention relates to a method for preventing, treating or curing cardiopathy or cardiac diseases comprising administering effective amounts of medicinal ginseng, its extracts thereof, ginseng components, metabolites thereof or salts thereof, preferably amounts exhibiting the extracellular fluid concentrations of 145 ng/ml or less in lesioned tissues, preferably 14.5 ng/ml or less or 1 ng/ml or less, more preferably 0.01-145000 fg/ml and more further preferably 1-145000 fg/ml, to patients with cardiopathy or cardiac diseases.

Further, the present invention relates to the use of ginseng, its extracts, ginseng components, metabolites thereof or salts thereof for production of the medicinal or pharmaceutical composition(s) for preventing, treating or curing cardiopathy or cardiac diseases.

Cardiac diseases of the present invention are preferably those accompanied by apoptosis of cardiac cells or apoptosis-like cardiac cell death.

The medicinal or pharmaceutical compositions of the present invention for treatment, prevention or therapy of cardiac diseases can be used as the preparations for oral administration or the preparations for intravenous administration.

The present invention relates to a preparation(s) for intravenous administration comprising medicinal ginseng, its extracts, ginseng components, metabolites thereof or salts thereof and a pharmaceutically acceptable carrier(s). More particularly, the present invention relates to the preparation(s) for intravenous administration for treating, preventing or curing brain and/or nervous diseases, such as, spinal cord injuries, head injuries, neurotrauma, cerebrovascular dementia, cerebral infarction, cerebral apoplexy or transient cerebral ischemic attack, or cardiac (heart) diseases accompanied by apoptosis of cardiac cells or apoptosis-like cardiac cell death. Preferably, the present invention relates to preparations at the low concentrations for intravenous administration wherein the extracellular fluid concentrations of medicinal ginseng, its extracts, ginseng components, metabolites thereof or salts thereof in lesioned tissues are adjusted to 145 ng/ml or less, preferably 14.5 ng/ml or less or 1 ng/ml or less, more preferably 0.01-145000 fg/ml, furthermore preferably 1-145000 fg/ml. The preparations for intravenous administration of the present invention can be any of the preparations for single intravenous infusion and the preparations for repetitive or continuous intravenous infusion.

Further, the present invention relates to a method for preventing, treating or curing brain and nervous diseases and/or cardiac diseases comprising administering the preparations for intravenous administration containing effective amounts of medicinal ginseng, its extracts, ginseng components, metabolites thereof or salts thereof, amounts exhibiting the extracellular fluid concentrations of 145 ng/ml or less in lesioned tissues, preferably 14.5 ng/ml or less, or 1 ng/ml or less more preferably 0.01-145000 fg/ml and more further preferably 1-145000 fg/ml, to patients with brain and nervous diseases and/or cardiac diseases.

Further, the present invention relates to the use of medicinal ginseng, its extracts, ginseng components, metabolites thereof or salts thereof for production of the preparations for intravenous administration for preventing, treating or curing brain and nervous diseases and/or cardiac diseases.

The present invention relates to a medicinal or pharmaceutical composition(s) for treating, preventing, curing or ameliorating edema(ta) of the biological tissues or living tissues comprising ginsenoside Rb1, metabolites thereof or salts thereof and/or a pharmaceutically acceptable carrier(s). Preferably, the present invention relates to the medicinal or pharmaceutical composition(s) for treating, preventing, curing or reducing edema(ta) of the biological tissues or living tissues wherein the extracellular fluid concentrations of ginsenoside Rb1, metabolites thereof or salts thereof in lesioned tissues are adjusted to 10 ng/ml or less or approximately 9 nM or less, preferably 1 ng/ml or less or approximately 0.9 nM or less, more preferably 0.01-100 fg/ml (approximately 0.009-90 fM), further more preferably 1-104 fg/ml (approximately 0.9-9000 fM).

Further, the present invention relates to a method for preventing, treating or curing edema(ta) of the biological tissues or living tissues comprising administering effective amounts of ginsenoside Rb1, metabolites thereof or salts thereof, preferably amounts exhibiting the extracellular fluid concentrations of 10 ng/ml or less or approximately 9 nM or less, more preferably 1 ng/ml or less or approximately 0.9 nM or less, further more preferably 0.01-100 fg/ml (approximately 0.009-90 fM), rather more preferably 1-104 fg/ml (approximately 0.9-9000 fM) in lesioned tissues, to patients with edema(ta).

Further, the present invention relates to the use of ginsenoside Rb1, metabolites thereof or salts thereof for production of the medicinal or pharmaceutical compositions for preventing, treating or curing edema(ta) of the biological tissues or living tissues.

Examples of edema of the biological tissues or living tissues are cerebral edema, edema of the brain and nervous tissues or edema of the spinal cord tissue caused by cerebral apoplexy, cerebral infarction, cerebral hemorrhage, subarachnoidal hemorrhage, head injuries, intracranial hemorrhage, spinal cord injuries or neurotrauma.

The medicinal or pharmaceutical compositions for preventing, treating, curing or reducing edema(ta) of the biological tissues or living tissues of the present invention are preferably used as the preparations for intravenous administration such as the preparation for single intravenous infusion or the preparation for repetitive or continuous intravenous infusion.

The present invention relates to a medicinal or pharmaceutical composition(s) for prevention, therapy or treatment of bedsore(decubitus) comprising ginsenoside Rb1, metabolites thereof or salts thereof and/or a pharmaceutically acceptable carrier(s). Preferably, the present invention relates to the medicinal or pharmaceutical composition(s) for preventing, curing or treating bedsores wherein the extracellular fluid concentrations of ginsenoside Rb1, metabolites thereof or salts thereof in lesioned tissues are adjusted to 10 ng/ml or less or approximately 9 nM or less, preferably 1 ng/ml or less or approximately 0.9 nM or less, more preferably 0.01-100 fg/ml (approximately 0.009-90 fM), further more preferably 1-104 fg/ml (approximately 0.9-9000 fM).

Further, the present invention relates to a method for prevention, treatment or therapy of bedsores comprising administering effective amounts of ginsenoside Rb1, metabolites thereof or salts thereof, preferably amounts exhibiting the extracellular fluid concentrations of 10 ng/ml or less or approximately 9 nM or less, more preferably 1 ng/ml or less or approximately 0.9 nM or less, further more preferably 0.01-100 fg/ml (approximately 0.009-90 fM), rather more preferably 1-104 fg/ml (approximately 0.9-9000 fM) in lesioned tissues, to patients with bedsores or decubitus.

Further, the present invention relates to the use of ginsenoside Rb1, metabolites thereof or salts thereof for production of the medicinal or pharmaceutical compositions for preventing, treating or curing bedsores(decubitus).

Example of bedsore is bedsore caused by spinal cord injury.

The medicinal or pharmaceutical compositions for preventing, treating or curing bedsore of the present invention are used preferably as the preparations for intravenous administration such as the preparation for single intravenous infusion or the preparation for repetitive or continuous intravenous infusion.

The present invention relates to a medicinal or pharmaceutical composition(s) for prevention, treatment or therapy of neuroparalysis comprising ginsenoside Rb1, metabolites thereof or salts thereof and/or a pharmaceutically acceptable carrier(s). Preferably, the present invention relates to the medicinal or pharmaceutical composition(s) for preventing, treating or curing neuroparalysis wherein the extracellular fluid concentrations of ginsenoside Rb1, metabolites thereof or salts thereof in lesioned tissues are adjusted to 10 ng/ml or less or approximately 9 nM or less, preferably 1 ng/ml or less or approximately 0.9 nM or less, more preferably 0.01-100 fg/ml (approximately 0.009-90 fM), further more preferably 1-104 fg/ml (approximately 0.9-9000 fM).

Further, the present invention relates to a method for prevention, treatment or therapy of neuroparalysis comprising administering effective amounts of ginsenoside Rb1, metabolites thereof or salts thereof, preferably amounts exhibiting the extracellular fluid concentrations of 10 ng/ml or less or approximately 9 nM or less, more preferably 1 ng/ml or less or approximately 0.9 nM or less, further more preferably 0.01-100 fg/ml (approximately 0.009-90 fM), rather more preferably 1-104 fg/ml (approximately 0.9-9000 fM) in lesioned tissues, to patients with neuroparalysis.

Further, the present invention relates to the use of ginsenoside Rb1, metabolites thereof or salts thereof for production of the medicinal or pharmaceutical composition(s) for preventing, treating or curing neuroparalysis.

Example of neuroparalysis is paralysis or paresis of the upper extremities and/or the lower extremities caused by spinal cord injury.

The medicinal or pharmaceutical composition(s) for preventing, treating or curing neuroparalysis of the present invention is preferably used as the preparations for intravenous administration such as the preparation for single intravenous infusion or the preparation for repetitive or continuous intravenous infusion.

The present invention relates to the medicinal or pharmaceutical compositions for prevention, treatment or therapy of urination disturbance or disorder, hypogonadism or dyschezia, comprising ginsenoside Rb1, metabolites thereof or salts thereof and/or a pharmaceutically acceptable carrier(s). Preferably, the present invention relates to the medicinal or pharmaceutical compositions for preventing, treating or curing urination disturbance or disorder, hypogonadism or dyschezia wherein the extracellular fluid concentrations of ginsenoside Rb1, metabolites thereof or salts thereof in lesioned tissues are adjusted to 10 ng/ml or less or approximately 9 nM or less, preferably 1 ng/ml or less or approximately 0.9 nM or less, more preferably 0.01-100 fg/ml (approximately 0.009-90 fM), further more preferably 1-104 fg/ml (approximately 0.9-9000 fM).

Further, the present invention relates to a method for prevention, treatment or therapy of urination disturbance or disorder, hypogonadism or dyschezia comprising administering effective amounts of ginsenoside Rb1, metabolites thereof or salts thereof, preferably amounts exhibiting the extracellular fluid concentrations of 10 ng/ml or less or approximately 9 nM or less, more preferably 1 ng/ml or less or approximately 0.9 nM or less, further more preferably 0.01-100 fg/ml (approximately 0.009-90 fM), rather more preferably 1-104 fg/ml (approximately 0.9-9000 fM) in lesioned tissues, to patients with urination disorder or disturbance, hypogonadism or dyschezia.

Further, the present invention relates to the use of ginsenoside Rb1, metabolites thereof or salts thereof for production of the medicinal or pharmaceutical compositions for preventing, treating or curing urination disorder or disturbance, hypogonadism or dyschezia.

The medicinal or pharmaceutical compositions for prevention, treatment or therapy of urination disorder or disturbance, hypogonadism or dyschezia of the present invention are preferably used as the preparations for intravenous administration such as the preparation for single intravenous infusion or the preparation for repetitive or continuous intravenous infusion.

The present invention relates to a medicinal or pharmaceutical composition(s) for prevention, treatment or therapy of neurogenic bladder comprising ginsenoside Rb1, metabolites thereof or salts thereof and/or a pharmaceutically acceptable carrier(s). Preferably, the present invention relates to the medicinal or pharmaceutical composition(s) for preventing, treating or curing neurogenic bladder wherein the extracellular fluid concentrations of ginsenoside Rb1, metabolites thereof or salts thereof in lesioned tissues are adjusted to 10 ng/ml or less or approximately 9 nM or less, preferably 1 ng/ml or less or approximately 0.9 nM or less, more preferably 0.01-100 fg/ml (approximately 0.009-90 fM), further more preferably 1-104 fg/ml (approximately 0.9-9000 fM).

Further, the present invention relates to a method for prevention, treatment or therapy of neurogenic bladder comprising administering effective amounts of ginsenoside Rb1, metabolites thereof or salts thereof, preferably amounts exhibiting the extracellular fluid concentrations of 10 ng/ml or less or approximately 9 nM or less, more preferably 1 ng/ml or less or approximately 0.9 nM or less, further more preferably 0.01-100 fg/ml (approximately 0.009-90 fM), rather more preferably 1-104 fg/ml (approximately 0.9-9000 fM) in lesioned tissues, to patients with neurogenic bladder.

Further, the present invention relates to the use of ginsenoside Rb1, metabolites thereof or salts thereof for production of the medicinal or pharmaceutical composition(s) for preventing, treating or curing neurogenic bladder.

The medicinal or pharmaceutical composition(s) for preventing, treating or curing neurogenic bladder of the present invention can be preferably used as the preparations for intravenous administration such as the preparation for single intravenous infusion or the preparation for repetitive or continuous intravenous infusion.

The present invention relates to a medicinal or pharmaceutical composition(s) for promoting the expression of a cell death-suppressing gene product Bcl-xL in oligodendrocytes comprising ginsenoside Rb1, metabolites thereof or salts thereof and/or a pharmaceutically acceptable carrier(s). Preferably, the present invention relates to the medicinal or pharmaceutical composition(s) for promoting the expression of a cell death-suppressing gene product Bcl-xL in oligodendrocytes wherein the extracellular fluid concentrations of ginsenoside Rb1, metabolites thereof or salts thereof in lesioned tissues are adjusted to 10 ng/ml or less or approximately 9 nM or less, preferably 1 ng/ml or less or approximately 0.9 nM or less, more preferably 0.01-100 fg/ml (approximately 0.009-90 fM), further more preferably 1-104 fg/ml (approximately 0.9-9000 fM).

Further, the present invention relates to a method for preventing, treating or curing diseases which can be prevented, treated or cured by promoting the expression of a cell death-suppressing gene product Bcl-xL in oligodendrocytes comprising administering effective amounts of ginsenoside Rb1, metabolites thereof or salts thereof, preferably amounts exhibiting the extracellular fluid concentrations of 10 ng/ml or less or approximately 9 nM or less, more preferably 1 ng/ml or less or approximately 0.9 nM or less, further more preferably 0.01-100 fg/ml (approximately 0.009-90 fM), rather more preferably 1-104 fg/ml (approximately 0.9-9000 fM) in lesioned tissues, to patients with diseases which can be prevented, treated or cured by promoting the expression of a cell death-suppressing gene product Bcl-xL in digodendrocytes.

Further, the present invention relates to the use of ginsenoside Rb1, metabolites thereof or salts thereof for production of the medicinal or pharmaceutical composition(s) for promoting the expression of a cell death-suppressing gene product Bcl-xL in oligodendrocytes.

The present invention relates to a protective agent(s) for oligodendrocytes comprising ginsenoside Rb1, metabolites thereof or salts thereof.

The medicinal or pharmaceutical composition(s) for promoting expression of the oligodendrocyte death-suppressing gene product Bcl-xL of the present invention can be preferably used as the preparations for intravenous administration such as the preparation for single intravenous infusion or the preparation for repetitive or continuous intravenous infusion.

The present invention relates to a medicinal or pharmaceutical composition(s) for suppressing apoptosis of myocardial cells or apoptosis-like cardiac cell death comprising ginsenoside Rb1, metabolites thereof or salts thereof and/or a pharmaceutically acceptable carrier(s). Preferably, the present invention relates to the medicinal or pharmaceutical composition(s) for suppressing apoptosis of myocardial cells or apoptosis-like cardiac cell death wherein the extracellular fluid concentrations of ginsenoside Rb1, metabolites thereof or salts thereof in lesioned tissues are adjusted to 10 ng/ml or less or approximately 9 nM or less, preferably 1 ng/ml or less or approximately 0.9 nM or less, more preferably 0.01-100 fg/ml (approximately 0.009-90 fM), further more preferably 1-104 fg/ml (approximately 0.9-9000 fM).

Further, the present invention relates to a method for preventing, treating or curing diseases which can be prevented, treated or cured by suppressing apoptosis of myocardial cells or apoptosis-like cardiac cell death comprising administering effective amounts of ginsenoside Rb1, metabolites thereof or salts thereof, preferably amounts exhibiting the extracellular fluid concentrations of 10 ng/ml or less or approximately 9 nM or less, more preferably 1 ng/ml or less or approximately 0.9 nM or less, further more preferably 0.01-100 fg/ml (approximately 0.009-90 fM), rather more preferably 1-104 fg/ml (approximately 0.9-9000 fM) in lesioned tissues, to patients with diseases which can be prevented, treated or cured by suppressing apoptosis of myocardial cells or apoptosis-like cardiac cell death.

Further, the present invention relates to the use of ginsenoside Rb1, metabolites thereof or salts thereof for production of the medicinal or pharmaceutical composition(s) for suppressing apoptosis of myocardial cells or apoptosis-like cardiac cell death.

The present invention relates to a protective agent(s) for oligodendrocytes comprising ginsenoside Rb1, metabolites thereof or salts thereof.

The medicinal or pharmaceutical composition(s) for suppressing apoptosis of myocardial cells or apoptosis-like cell death of the present invention can be preferably used as the preparations for intravenous administration such as the preparation for single intravenous infusion or the preparation for repetitive or continuous intravenous infusion.

The present invention relates to a medicinal or pharmaceutical composition(s) for promoting the expression of a cell death-suppressing gene product Bcl-xL in myocardial cells comprising ginsenoside Rb1, metabolites thereof or salts thereof or a pharmaceutically acceptable carrier(s). Preferably, the present invention relates to the medicinal or pharmaceutical composition(s) for promoting the expression of a cell death-suppressing gene product Bcl-xL in myocardial cells wherein the extracellular fluid concentrations of ginsenoside Rb1, metabolites thereof or salts thereof in lesioned tissues are adjusted to 10 ng/ml or less or approximately 9 nM or less, preferably 1 ng/ml or less or approximately 0.9 nM or less, more preferably 0.01-100 fg/ml (approximately 0.009-90 fM), further more preferably 1-104 fg/ml (approximately 0.9-9000 fM).

Further, the present invention relates to a method for preventing, treating or curing diseases which can be prevented, treated or cured by promoting the expression of a cell death-suppressing gene product Bcl-xL in myocardial cells comprising administering effective amounts of ginsenoside Rb1, metabolites thereof or salts thereof, preferably amounts exhibiting the extracellular fluid concentrations of 10 ng/ml or less or approximately 9 nM or less, more preferably 1 ng/ml or less or approximately 0.9 nM or less, further more preferably 0.01-100 fg/ml (approximately 0.009-90 fM), rather more preferably 1-104 fg/ml (approximately 0.9-9000 fM) in lesioned tissues, to patients with diseases which can be prevented, treated or cured by promoting the expression of a cell death-suppressing gene product Bcl-xL in myocardial cells.

Further, the present invention relates to the use of ginsenoside Rb1, metabolites thereof or salts thereof for production of the medicinal or pharmaceutical composition(s) for promoting the expression of a cell death-suppressing gene product BCl-xL in myocardial cells.

The present invention relates to a protective agent(s) for myocardial cells comprising ginsenoside Rb1, metabolites thereof or salts thereof.

The medicinal or pharmaceutical composition(s) for promoting expression of the myocardial cell death-suppressing gene product BCl-xL of the present invention can be preferably used as the preparations for intravenous administration such as the preparation for single intravenous infusion or the preparation for repetitive or continuous intravenous infusion.

The present invention relates to dihydroginsenoside Rb1 represented by the following formula (II):
or metabolites thereof or salts thereof.

The present invention relates to a medicinal or pharmaceutical composition(s) for suppressing apoptosis of cells or apoptosis-like cell death comprising dihydroginsenoside Rb1 represented by the above formula (II), metabolites thereof or salts thereof and/or a pharmaceutically acceptable carrier(s).

The present invention relates to a method for preventing, treating or curing diseases which can be prevented, treated or cured by suppressing apoptosis of cells or apoptosis-like cell death comprising administering effective amounts of dihydroginsenoside Rb1 represented by the above formula (II), metabolites thereof or salts thereof to patients with diseases which can be prevented, treated or cured by suppressing apoptosis of cells or apoptosis-like cell death.

Further, the present invention relates to the use of dihydroginsenoside Rb1, metabolites thereof or salts thereof for production of the medicinal or pharmaceutical composition(s) for suppressing apoptosis of cells or apoptosis-like cell death.

Examples of the concerned cells are brain cells or nerve cells in the ischemic penumbra.

The medicinal or pharmaceutical composition(s) for suppressing apoptosis of cells or apoptosis-like cell death of the present invention can be preferably used as the preparations for intravenous administration such as the preparation for single intravenous infusion or the preparation for repetitive or continuous intravenous infusion.

The present invention relates to a medicinal or pharmaceutical composition(s) for prevention, treatment or therapy of brain and nervous diseases. comprising dihydroginsenoside Rb1 represented by the above formula (II), metabolites thereof or salts thereof and/or a pharmaceutically acceptable carrier(s).

The present invention relates to a method for preventing, treating or curing brain and nervous diseases comprising administering effective amounts of dihydroginsenoside Rb1 represented by the above formula (II), metabolites thereof or salts thereof to patients with brain and nervous diseases.

Further, the present invention relates to the use of dihydroginsenoside Rb1, metabolites thereof or salts thereof for production of the medicinal or pharmaceutical composition(s) for preventing, treating or curing brain and nervous diseases.

Examples of brain and nervous diseases of the present invention hereinbefore are injuries to the nervous tissues or spinal cord tissue such as spinal cord injury; injuries to the nervous tissues or spinal cord tissue such as head injuries or neurotrauma; diseases caused by apoptosis or apoptosis-like cell death of oligodendrocytes; cerebral edema, edema of the brain and nervous tissues or edema of the spinal cord tissue caused by cerebral apoplexy, cerebral infarction, cerebral hemorrhage, subarachnoidal hemorrhage, head injuries, intracranial hemorrhage, spinal cord injury or neurotrauma; cerebrovascular dementia; cerebral infarction, cerebral apoplexy, transient cerebral ischemic attack; paralysis or paresis of the upper extremities or lower extremities, urination disorder, dysautonomia, hypogonadism, dyschezia or neurogenic bladder caused by injuries or trauma to the nervous tissues or spinal cord tissue.

The medicinal or pharmaceutical composition(s) for treatment, prevention or therapy of brain and nervous diseases of the present invention can be preferably used as the preparations for intravenous administration such as the preparation for single intravenous infusion or the preparation for repetitive or continuous intravenous infusion.

The present invention relates to a method for exploring novel active ingredients or compounds for prevention, therapy or treatment of diseases of the nervous tissues or spinal cord tissue comprising using ginseng, its extracts, components of ginseng, metabolites thereof or salts thereof as leading compounds.

Examples of medicinal ginseng, its extracts, components of ginseng, metabolites thereof or salts thereof of the present invention are red ginseng powder, its extracts, crude saponin fractions of ginseng, non-saponin fractions, purified saponins, saponin fraction constituents or salts thereof, and a component contained in the saponin fractions of ginseng is preferably ginsenoside Rb1. Examples of diseases of the nervous tissues or spinal cord tissue hereinbefore are diseases caused by nervous tissue injuries or spinal cord injury or cerebral infarction.

The present invention also relates to agents for prevention, therapy or treatment of diseases of the nervous tissues or spinal cord tissue, as obtained by any methods described hereinabove.

Further, the present invention relates to the use of any of constituents of saponin fractions of ginseng or metabolites thereof as leading compounds for exploring novel active ingredients or compounds for prevention, therapy or treatment of diseases of the nervous tissues or spinal cord tissue, novel agents for the therapy of neurotrauma, novel agents for the therapy of spinal cord injury, novel agents for the therapy of head injury, novel agents for protecting brain cells or novel agents for protecting nerve cells, or novel medicinal or pharmaceutical compositions for preventing, curing or treating diseases caused by injuries to the nervous tissue or spinal cord tissue.

The present invention relates to a method for detecting novel compounds having protective action on brain cells or nerve cells (neurons) by using components contained in ginseng as leading compounds or use thereof.

Examples of “medicinal ginseng, its extracts, components of ginseng, metabolites thereof or salts thereof” of the present invention are ginseng itself hereinbelow explained; extracts of ginseng; extracts comprising the said extracts; preparations containing any of them; fractions comprising ginseng or extracts thereof such as crude saponin fractions, saponin fractions and purified soponins; ginseng components; saponin fraction constituents such as saponin fractions; metabolites thereof; and salts thereof. In the explanation hereinbelow, “(medicinal)ginseng, its extracts, components of ginseng, metabolites thereof or salts thereof” of the present invention or part thereof is sometimes expressed, for convenience, as “any one or any of constituents of the crude saponin fractions of (medicinal)ginseng, metabolites thereof or salt thereof” or “crude saponin fraction(s) of (medicinal)ginseng or salts thereof”. The present invention can be expressed by using these terms as follows.

The present invention relates to a medicinal or pharmaceutical composition(s) for suppressing apoptosis or apoptosis-like cell death of oligodendrocytes comprising any or any one of constituents of the crude saponin fraction(s) of ginseng, metabolites thereof or salt thereof. The present invention also relates to the crude saponin fraction(s) of ginseng or any one of constituents thereof, metabolites thereof or salt thereof useful as an agent(s) for suppressing the secondary degeneration of the nervous tissues. These medicinal or pharmaceutical compositions of the present invention are preferably used as the preparations for intravenous administration at low doses. More particularly, the medicinal or pharmaceutical compositions are preferably used as the preparation for single intravenous administration or the preparation for repetitive or continuous intravenous administration.

The present invention also relates to the novel ginsenoside Rb1 derivative, i.e. dihydroginsenoside Rb1 useful as a cytoprotective agent, prepared by using ginsenoside Rb1 as a leading compound, which is one of physiologically active substances or active components contained in ginseng or the crude saponin fraction(s) of ginseng. More particularly, the present invention relates to a medicinal or pharmaceutical composition(s) for prevention, treatment or therapy of cerebral infarction or cerebral apoplexy comprising dihydroginsenoside Rb1, metabolites thereof or salts thereof, or a medicinal or pharmaceutical composition(s) for suppressing apoptosis of nerve cells (neurons) or apoptosis-like nerve cell death, or necrosis of nerve cells. Further, the present invention relates to a medicinal or pharmaceutical composition(s) useful as the preparations for intravenous administration comprising dihydroginsenoside Rb1, metabolites thereof or salts thereof, i.e. the preparations at low concentrations or low dosages for continuous or repetitive administration or for single intravenous infusion.

The present invention provides for the first time that the components in medicinal ginseng are active as the compounds having the therapeutic effects on neurotrauma or spinal cord injury and the protective actions on brain cells or nerve cells. Based on the novel findings of the present invention, the present invention provides a method for exploring novel compounds having protective actions on brain cells or nerve cells by using the active components in ginseng as leading compounds. Further, the present invention provides the use of the active ginseng components as leading compounds for exploring novel compounds having the protective actions on brain cells or nerve cells.

Further, the present invention provides: a preparation(s) at low doses for intravenous administration for prevention, treatment or therapy of cerebral edema, brain and nervous tissue edema or spinal cord tissue edema comprising ginsenoside Rb1, metabolites thereof or salts thereof; a preparation(s) at low doses for intravenous administration for prevention, treatment or therapy of bedsore (decubitus) accompanied by spinal cord injury comprising ginsenoside Rb1, metabolites thereof or salts thereof; a preparation(s) for intravenous administration for promoting the expression of a cell death-suppressing gene Bcl-xL in the nervous tissues comprising ginsenoside Rb1, metabolites thereof or salts thereof; a medicinal or pharmaceutical composition(s) for promoting expression of a cell death-suppressing gene Bcl-xL in oligodendrocytes comprising ginsenoside Rb1, metabolites thereof or salts thereof; a protective agent(s) for oligodendrocytes comprising ginsenoside Rb1, metabolites thereof or salts thereof; a medicinal or pharmaceutical composition(s) for promoting the expression of a cell death-suppressing gene Bcl-xL in myocardial cells comprising ginsenoside Rb1, metabolites thereof or salts thereof; and a medicinal or pharmaceutical composition(s) for suppressing apoptosis or apoptosis-like cell death of myocardial cells comprising low concentrations of ginsenoside Rb1, metabolites thereof or salts thereof.

The present invention further provides a medicinal or pharmaceutical composition(s) for prevention, therapy or treatment of diseases caused by injuries or trauma to the nervous tissues or spinal cord tissue comprising the crude saponin fraction(s) of ginseng, any or any one of constitutional components thereof, metabolites thereof or salts thereof. More particularly, the present invention provides a medicinal or pharmaceutical composition(s) for prevention, therapy or treatment of the secondary degeneration of the nervous tissues caused by injuries to the nervous tissues, a medicinal or pharmaceutical composition(s) for prevention, therapy or treatment of diseases caused by spinal cord injury, head injury or injuries (trauma) to the nervous tissues or spinal cord tissue, a medicinal or pharmaceutical composition(s) for prevention, therapy or treatment of diseases caused by nervous tissue or spinal cord tissue injuries accompanied by demyelination. The present invention also provides a medicinal or pharmaceutical composition(s) for suppressing apoptosis or apoptosis-like cell death of oligodendrocytes comprising the crude saponin fraction(s) of ginseng, any or any one of constitutional components thereof, metabolites thereof or salts thereof. The present invention further provides the crude saponin fraction(s) of medicinal ginseng, any or any one of constitutional components thereof, metabolites thereof or salts thereof useful as suppressive agents for the secondary degeneration of the nervous tissues.

The present invention provides an active ingredients for prevention, therapy or treatment of diseases or lesions hereinbefore, or a method for the use of the active ginseng components or metabolites thereof as leading compounds for exploring brain cell-protective agents or neuroprotective agents.

Further, the present invention provides a novel derivative of ginsenoside Rb1, one of components or physiologically active substances of ginseng, i.e. dihydroginsenoside Rb1 useful as a cytoprotective agent, which can be prepared by using ginsenoside Rb1 as a leading compound. More particularly, the present invention provides a medicinal or pharmaceutical composition(s) for prevention, treatment or therapy of cerebral infarction or cerebral apoplexy comprising dihydroginsenoside Rb1, metabolites thereof or salts thereof, or a medicinal or pharmaceutical composition(s) for suppressing apoptosis of neurons or apoptosis-like nerve cell death in the lesions of cerebral infarction and/or cerebral apoplexy. The present invention also provides a medicinal or pharmaceutical compositions that can be used as the preparations for intravenous administration comprising dihydroginsenoside Rb1, metabolites thereof or salts thereof, namely the medicinal or pharmaceutical composition(s) in the form of the preparations at low concentrations or low dosages for repetitive or continuous intravenous administration or for single intravenous administration.

Examples of the medicinal ginseng, extracts thereof, components of ginseng, or metabolites thereof in the present invention are ginseng, dried product thereof, part thereof, powders or granules thereof, extracts thereof such as red ginseng extract, fractions thereof such as crude saponin fractions, purified saponin fractions or non-saponin fractions, components such as purified saponins or ginsenosides isolated therefrom, and active metabolites of these components. As for preferable examples of ginseng, extracts thereof, components of ginseng, or metabolites thereof, red ginseng powder can be mentioned, but this is not limitative.

Preferable red ginseng powder of the present invention is a known substance prepared by using six year roots of Panax ginseng C. A. Meyer in Korean Tobacco Ginseng Public Corp., and stability of its quality has been confirmed by us in the published paper (Wen, T.-C. et al., Acta Neuropathol., 91, 15-22, 1996). In Japan, that is named as Seikansho red ginseng powder connected with the distributor corporation.

In the explanation hereinbelow, the red ginseng powder or extract thereof will be used and exemplified as (medicinal) ginseng, extract thereof, components of ginseng, or metabolites thereof of the present invention.

The medicinal or pharmaceutical compositions of the present invention can be used as the single preparation containing ginseng, its extract(s), components of ginseng, or metabolites thereof as an active ingredient, however a combined preparation with drugs for reducing risk factors of cerebral infarction (e.g. vitamins, cerebral circulation and metabolism-improving agents, active oxygen or free radical-scavenging agents, drugs for therapy or treatment of hyperlipidemia, etc.) can also be used.

The medicinal or pharmaceutical compositions of the present invention can contain the pharmaceutically acceptable carrier(s). Examples of these carriers which can be used are substances conventionally used in drug preparations such as diluents, lubricants, binders, and disintegrators. Using these carriers, formulations of dosage form such as tablets, powders, powder, sustained release preparations, granules, capsules and suppositories, can be prepared, and if required, coating preparations can be prepared. Parenterally administered preparations can also be prepared.

Oral administration of the red ginseng or extract(s) thereof of the present invention can significantly reduce cerebral infarct lesion as a result of suppressing apoptosis-like nerve cell death in the ischemic penumbra, and has the unique action mechanism upregulating the expression of a cell death-suppressing gene product Bcl-xL protein to protect nerve cells or neurons in the brain. It can also be applied as the neuroprotective agent for not only acute and chronic phase cerebral infarction but also acute and chronic phase cerebral hemorrhage and subarachnoidal hemorrhage or transient cerebral ischemic attack.

Namely, the red ginseng powder of the present invention or extract(s) thereof is a drug which can be administered orally at home to patients who are suspected to suffer from cerebral apoplexy as far as their consciousness and swallowing function are maintained. Further, if the aged people, who are so called the cerebral apoplexy candidates with underlying diseases such as diabetes mellitus, hypertension, cerebral arteriosclerosis, atrial fibrillation and cerebral aneurysm or anamnesis of cerebral apoplexy, ingested red ginseng powder in advance, and even if they are suffer from cerebral apoplectic attack at the worst, their cerebral apoplectic lesions and higher nervous functional disorders will be significantly improved as compared with patients who did not ingest red ginseng powder.

The pathological state of cerebral ischemia is known to occur accompanied by cardiac insufficiency, severe anemia, shock, respiratory failure, cardiac arrest, ventricular fibrillation, administration of antihypertensive drugs and hypotension etc. In order to protect the brain from such diseases and to improve prognosis of patients, the medicinal or pharmaceutical composition(s) comprising red ginseng powder or extract(s) thereof is very effective. Further, red ginseng powder or extract(s) thereof is known historically to exhibit almost no ill effects. In the present experiments, no ill effects were detected as a result of our careful observation on animals to which red ginseng powder was orally administered.

Judging from the facts that oral administration of ginseng, its extract(s), components of ginseng, or metabolites thereof, preferably red ginseng powder of the present invention promotes the expression of a cell death-suppressing gene product Bcl-xL protein in the nervous tissues and that oral administration of red ginseng powder suppresses apoptosis-like cell death in the ischemic penumbra, the medicinal or pharmaceutical composition(s) of the present invention comprising ginseng, its extracts, components of ginseng, or metabolites thereof, preferably red ginseng powder or extract(s) thereof is thought to show efficacy on primary and secondary neurodegenerative diseases accompanied with apoptosis-like nerve cell death (Alzheimer's disease, Pick' disease, spinocerebellar degeneration, Parkinson's disease, demyelinating diseases, chorea, amyotrophic lateral sclerosis, glaucoma, senile macular degeneration, diabetic retinopathy, central retinal arterial occlusion, central retinal venous occlusion, retinal detachment, pigmentary degeneration of the retina, AIDS encephalopathy, hepatic encephalopathy, encephalitis, cerebral palsy, head injuries, spinal cord injuries, carbon monoxide poisoning; asphyxia of the newborn, peripheral neuropathy, spastic paraplegia, progressive supranuclear palsy, circulatory disorders of the spinal cord, mitochondrial encephalomyopathy, meningitis, etc.).

If a dose of drug administered in the adult weighing 60 kg, is set as 1, the dose of the same drug administered in the newborn weighing 3 kg, is generally about 1/7 thereof. Namely, the dose of drug per body weight 1 kg in the newborn is about 3 times larger than that in the adult. Estimating from this fact, in rat (body weight 250-300 g) or in gerbil (body weight 70-80 g), which is lighter in body weight than the newborn, the dose amount of drug per body weight 1 kg will be increased at least about 4 times as compared with the human.

Generally, blood concentration of drug is thought to depend on the glomerular filtration rate (GFR). Since GFR is known to correlate with the area of body surface, Crawford's equation, i.e. dose amount for adult×area of body surface (m2)/1.73, can be used as for the calculation of dose amount of drug determined by the area of body surface. Since the area of body surface of human, body weight 60 kg, stature 170 cm, is about 1.7 m2 and the area of body surface of newborn, body weight 2 kg, stature 45 cm, is about 0.16 m2, according to this equation, if the dose of drug in the human, body weight 60 kg, stature 170 cm, is set as 1, the dose of drug in the newborn, body weight 2 kg, stature 45 cm, will be about 1/10. Namely, since the amount of drug administered per kg of body weight is 1/60 in the adult, body weight 60 kg, stature 170 cm, and about 1/20 in the newborn, body weight 2 kg, stature 45 cm (i.e. 3-fold of the adult), even though the dose of drug is calculated from the area of body surface, the dose of drug per kg of body weight is increased according to the decrease in body weight as described hereinbefore. Consequently, in SH-SP rats and gerbils, which are lighter in body weight than the newborn of body weight 2 kg, the amount of drug administered per kg of body weight will be at least about 4-fold larger as compared with the amount of administration of drug per kg of human adult (body weight 60 kg).

Based on the present experimental results that oral administration of red ginseng powder to SH-SP rats (body weight 250-300 g) with permanent occlusion of the middle cerebral artery (MCA), at doses of 0.75-1.2 g/kg/day, for 5 weeks before and after MCA permanent occlusion, regresses cerebral infarct lesions and improves place navigation disability (cerebrovascular dementia), the amount of administration in human patients with cerebral apoplexy of body weight 60 kg or vertebrates (pets and livestock) is calculated totally as 11.25 g -18 g in a day, if the amount of administration is calculated as a quarter per kg of body weight. Consequently, the amount of oral administration of the medicinal or pharmaceutical composition (red ginseng powder) of the present invention in human patients with cerebral apoplexy is, although depending on individual variations or disease states, 2.0 g -90 g in a day, preferably 5.625 g -36 g, more preferably 11.25 g -18 g. In case where red ginseng powder is used for prevention, treatment or therapy of the previously described primary or secondary neurodegenerative diseases as the agent for enhancing BCl-xL protein expression in the nervous tissues, preferably the similar dosage is orally administered to patients. In cases of oral administration of red ginseng powder extracts (red ginseng extracts, crude saponin fractions, non-saponin fractions and various purified saponins), the extract from the same amount of red ginseng powder hereinabove is preferably administered. Most preferable administration of ginseng (red ginseng powder) or extract(s) thereof may be 10 g -30 g/day by dividing 3-4 times a day in 60 kg of mammalian.

As explained hereinabove, for treatment, prevention or therapy of brain and nervous diseases, relatively highly doses of red ginseng powder should be administered orally, however the present inventors have found that in case of orally administering red ginseng powder as the agent for enhancing the expression of Bcl-xL in the peripheral organs, relatively low dosages are sufficient. Namely, based on the present experimental results that oral administration of red ginseng powder in a dose of 200 mg/kg/day in gerbils enhances Bcl-xL protein expression in the liver and spleen, the amount necessary for promoting Bcl-xL protein expression in the peripheral organs of human, body weight 60 kg, if calculated as ¼ per body weight, can be 50 mg/kg/day. Consequently, in case where the medicinal or pharmaceutical composition of the present invention (red ginseng powder) is used as an agent for enhancing Bcl-xL protein expression in the peripheral organs of human, the amount of oral administration in a day is, depending on individual difference and disease states of patients, 0.6 g -15 g, preferably 1.5 g -6 g, more preferably 2 g -4 g. When red ginseng extract (s) or crude saponin fractions extracted from the same amount of red ginseng powder is administered orally, similarly the expression of Bcl-xL protein in the peripheral organs can be increased.

The cell death-inhibitory gene product Bcl-xL is the protein that can be said as the last fortress for cell survival, and is distributed not only in the brain and nervous tissues but also in all peripheral organs and tissues, for example the liver, spleen, tissues of the immune system, tissues of the circulatory system and skin, and supports the survival of cells. Consequently, results of the present experiments showing increases in the expression of BCl-xL protein in the peripheral organs such as the liver and spleen by low doses of orally administered red ginseng powder, indicate that low doses of red ginseng powder are effective for treatment, prevention and/or therapy of diseases of the peripheral organs and tissues accompanied by cell death, and various symptoms accompanied by aging. Among the diseases of the peripheral organs and tissues accompanied by cell death, the following diseases are included: ischemia—reperfusion injuries of cardiac muscle, liver and kidneys, cardiomyopathy, cardiac failure, myocardial infarction, peripheral circulatory failure, bedsore, wound, burn, cutaneous ulcer, oral aphtha, stomatitis, pollinosis, vernal conjunctivitis, atopic dermatitis, AIDS, autoimmune diseases, immunodeficiency diseases, graft rejection, muscular dystrophy, corneal injury, pulmonary infarction, bone fracture, myositis, peritendinitis, polio, necrotic faciitis, ischemic contracture, spina bifida, radiation injury, disturbance by ultraviolet rays, infectious diseases, collagen diseases, aortitis syndrome, acute arterial embolism, myotenositis, compartmental syndrome, meningocele, constriction ring syndrome, pseudoarthrosis, thromboangiitis obliterans, arteriosclerosis obliterans, Raynaud's disease, Raynaud's syndrome, thrombophlebitis, epiphysiolysis, osteochondrosis, food poisoning, enterohemorrhagic E. coli infectious disease, pancreatitis, hepatitis, nephritis, diabetic nephropathy, diabetic cardiomyopathy and glossalgia. In the broad sense, wound includes bedsore, bums and skin ulcer. Other organic diseases and/or pathological conditions accompanied by cell death are described in the book (Today's guide for therapy: Ed. Hinohara, Shigeaki and Abe, Masakazu, Igaku-Shoin Publ., 1995). Red ginseng powder or components thereof are thought to be effective for prevention, treatment or therapy of all diseases and pathological conditions above described.

Red ginseng powder, its extract(s), crude saponin fractions or constitutional components thereof can be used, through their cytoprotective action, for farming of fishes and crustaceans, cultivation and rearing of farm products, cosmetic composition, bath gel, health foods, health drugs, eyewash, facial wash, cultivation of tobacco and hydroponics. Of course, they can protect cells from endocrine disruptors, trauma, toxins, microorganisms, biohazards and environmental pollution.

The medicinal or pharmaceutical composition of the present invention are less toxic and the upper limit of dosage can be set considerably high, and is 180 g per day or less, preferably 100 g or less.

The medicinal or pharmaceutical composition of the present invention comprising ginsenoside Rb1 is preferably comprised of ginsenoside Rb1, metabolites thereof or salts thereof at low concentrations. Further, the present invention is preferably the preparations for parenteral administration comprising ginsenoside Rb1, metabolites thereof or salts thereof at low concentrations.

These medicinal or pharmaceutical compositions of the present invention are preferably used as the preparations for intravenous administration. However if the extracellular fluid concentrations of the medicinal or pharmaceutical compositions in lesion can be kept low, the preparations of any optional routes of administration can be selected. These include, for example, agents for local external use in lesion, injections for local external use, preparations for oral administration, nasal drops, ophthalmic agents, ear drops, suppositories, subcutaneous injections, intracutaneous injections, intramuscular injections, inhalations, sublingual tablets and transdermal drugs.

In addition, the present invention in relation to ginsenoside Rb1 relates to agents for long term treatment, prevention or therapy of brain and nervous tissue diseases accompanied by edema, agents for treatment, prevention or therapy of decubitus, agents for protecting oligodendrocytes, agents for enhancement of Bcl-xL expression or agents for protection of myocardial cells comprising the above described preparations for intravenous administration or preparations for local external use in lesion.

Further, the present invention provides the use of ginsenoside Rb1 or metabolites thereof as a leading compounds) for exploring novel other effective components or compounds for prevention, therapy or treatment of diseases caused by nervous tissue or spinal cord tissue injuries or for prevention, therapy or treatment of cerebral infarction and cerebral apoplexy. It is also possible to select any other administration routes after preparing prodrugs by modifying part of the chemical structure of ginsenoside Rb1. Further, a target molecule (s) of ginsenoside Rb1 or metabolites thereof is identified and novel compounds for modifying function of the target molecule(s) are synthesized to direct development of drugs for the therapy or treatment of cerebral infarction, cerebral apoplexy, spinal cord injury, neurotrauma and trauma.

Consequently, the present invention provides ginsenoside Rb1 or metabolites thereof as a leading compound(s) for exploring novel active components or compouds for prevention, therapy or treatment of these diseases.

Ginsenoside Rb1 of the present invention is represented by the chemical structure (I) hereinbefore, and can be isolated and purified according to the method of Shibata et al. (Shibata, S. et al., Economic and Medicinal Plant Research, World Scientific, Philadelphia, pp. 217-284, 1985). The compound purified by such methods has its purity 98% or more, which was confirmed by thin layered chromatography and NMR spectrum (Kawashima, Y. and Samukawa, K., J. Med. Pharmacol. Soc. Wakan-Yaku, 3, 235-236, 1986).

Ginsenoside Rb1 of the present invention can be used in its free form and is also used as suitable salts thereof. The solvate such as hydrate can also be used.

Concentrations of ginsenoside Rb1 of the present invention are preferably low, more concretely, extracellular fluid concentration is 1 ng/ml or less, preferably 10 pg/ml or less, more preferably 100 fg/ml or less. In case of use in the preparation(s) for intravenous administration of ginsenoside Rb1 of the present invention, the preparation(s) is preferably adjusted so that the extracellular fluid concentrations in lesions of patients are kept at the concentrations as described hereinabove. Sufficient effects of the medicinal or pharmaceutical composition(s) and preparations of the present invention can be obtained even when the extracellular fluid concentrations in lesioned tissues are in the range of approximately 0.01-100 fg/ml or 1-10000 fg/ml.

It has already been found that the intravenously administered small amount of ginsenoside Rb1 is transferred quickly into the brain and nervous systems, unlike peripherally (intraperitoneally) administered ginsenoside Rb1 (Japanese Patent Application No. Hei 10-365560, PCT/JP99/02550, Brain cell or nerve cell-protective agents comprising ginsenoside Rb1). The preparation(s) for intravenous administration of the present invention is sufficient if it can be directly administered intravascularly, preferably intravenously, and it can be used as the preparation for single intravenous administration or as the preparation for repetitive or continuous intravenous administration after dissolving the medicinal or pharmaceutical compositions of the present invention in physiological saline, distilled water, phosphate buffer, glucose solution, liposome or lipid emulsion etc. Further, the formulations which can be used by adding to the preparations for intravenous administration such as compositions for drip-infusion may be preferable. Further, prodrugs are prepared by modifying a part(s) of the chemical structure of ginsenoside Rb1, as a result, optional routes of administration and optional methods of administration can also be selected. For example, the hydroxyl group(s) or hydroxyl base (s) of ginsenoside Rb1 is esterified to prepare the prodrug(s), passing through the blood-brain barrier, hydrolyzing with endogenous esterase(s) to increase intracerebral transfer of ginsenoside Rb1.

As described in Japanese Patent Application No. Hei 10-365560, PCT/JP99/02550 (Brain cell or nerve cell-protective agents comprising ginsenoside Rb1), repetitive or continuous intravenous administration of low doses of ginsenoside Rb1 reduces cerebral infarct lesion to about ¼ size of the non-administered group; has a unique mechanism of action indicating the upregulation of cell death-suppressing gene product Bcl-xL expression; protects nerve cells in the brain; and can be used as neuroprotective agent for not only acute phase or chronic phase of cerebral infarction (cerebral thrombosis and cerebral embolism) but also acute or chronic phase of cerebral hemorrhage and subarachnoidal hemorrhage, or transient cerebral ischemic attack. Namely, ginsenoside Rb1 at low dosages and/or at low concentrations, which does not induce hemorrhagic tendency, is the medicinal or pharmaceutical composition, which is possible to be infused intravenously, to patients, who are suspected to have cerebral apoplexy, in ambulances. Further, administration of ginsenoside Rb1 to patients with cerebral infarction who undergo thrombolytic therapy improves prognosis of the patients.

In addition, as described in Japanese Patent Application No. Hei 11-340850, PCT/JP99/06804 (Cerebrovascular regeneration/reconstruction promoters and nerve tissue secondary degeneration inhibitors comprising ginsenoside Rb1), repetitive or continuous intravenous infusion of ginsenoside Rb1 for maximum 28 days not only reduces a volume of cerebral infarct (cerebral embolism) lesion to about ¼, but also makes to recover the destroyed and decreased vascular networks to the normal condition in the ischemic penumbra. Consequently, the intravenous administration of ginsenoside Rb1 promotes regeneration and reconstruction of the destroyed or decreased cerebrovascular networks after cerebral apoplexy, and even if the intravenous administration of ginsenoside Rb1 is terminated thereafter, once rescued cerebral tissues can function normally after passing time. Namely, in addition to the direct protective effects of ginsenoside Rb1 on nerve cells(neurons), such as enhancement of Bcl-xL protein expression and suppression of apoptosis-like nerve cell death, ginsenoside Rb1 of the present invention is expected to protect damaged brain through the indirect and long-term protective mechanism mediated by the regeneration and reconstruction of cerebrovascular networks. As described above, ginsenoside Rb1 is thought to be the first substance in the history of human being as the compound which can reduce to ¼ in size of cerebral infarct lesion in the acute phase as well as in one month after the onset by intravenous administration after onset of cerebral infarction, i.e. permanent cerebrovascular occlusion. Consequently, in future, ginsenoside Rb1 or metabolites thereof can be used as a leading compound(s) and thereby various agents for protection of brain cells or nerve cells can be explored, created and produced.

In the general clinical field, there are many cases appearing repeatedly, in which the higher nervous functions are continuously deteriorated even though no new attack occurred after cerebral apoplexy. Especially there are cases with continuously deteriorating sequelae after cerebral apoplexy. A reason for this may be that the regeneration or reconstruction of the damaged or reduced cerebrovascular networks caused by cerebral apoplectic attack is sometimes insufficient. Low doses of intravenous administration, sublingual administration, rectal administration or nasal administration of ginsenoside Rb1 are expected to exhibit significant effects in ameliorating such sequelae after cerebral apoplexy.

As described in the invention of Japanese Patent Application No. Hei 11-340850, PCT/JP99/06804 (Cerebrovascular regeneration/reconstruction promoters and nerve tissue secondary degeneration inhibitors comprising ginsenoside Rb1), since the intravenous administration of ginsenoside Rb1 of the present invention exhibits a novel effect and efficacy in promoting vascular regeneration or reconstruction, it may also be effective for treatment or therapy of other diseases with symptoms of blood flow disorders (e.g. aortitis syndrome, acute peripheral arterial occlusion, thromboangiitis obliterans, arteriosclerosis obliterans, Raynaud's disease, hemorrhoids or Raynaud's syndrome). Of course, in diseases with major symptoms of these blood flow disorders, to inhibit cell death in tissues suffering from blood flow disorders is also unforgotten efficacy of ginsenoside Rb1. Consequently, ginsenoside Rb1 is expected to reduce tissue injuries or damage resulting from blood flow disorders of the peripheral tissues through at least two action mechanisms.

As described in the invention of Japanese Patent Application No. Hei 11-340850, PCT/JP99/06804 (Cerebrovascular regeneration/reconstruction promoters and nerve tissue secondary degeneration inhibitors comprising ginsenoside Rb1), since the pharmaceutical composition comprising ginsenoside Rb1 inhibits the occurrence of secondary lesions in the brain regions having synaptic contacts with the primary brain lesion, it also exhibits favorable efficacy and/or effects on the secondary lesions of many neurodegenerative diseases and demyelinating diseases (e.g. Alzheimer's disease, Pick's disease, spinocerebellar degeneration, Parkinson's disease, chorea, polyglutamine diseases, amyotrophic lateral sclerosis, multiple sclerosis, etc.), and is expected to improve QOL (Quality of Life) for patients as a result of reducing progression of higher nervous function disorders caused by these diseases. As described in Japanese Patent Application No. Hei 10-365560 and PCT/JP99/02550 (“Brain cell or nerve cell-protective agents comprising ginsenoside Rbi”), ginsenoside Rb1 is thought to exhibit efficacy against the primary lesions of these neurodegenerative diseases through its inhibitory effect against apoptosis-like nerve cell death and its enhancing effect on Bcl-xL expression.

Further, as described in the invention of Japanese Patent Application No. Hei 11-340850, PCT/JP99/06804 (Cerebrovascular regeneration/reconstruction promoters and nerve tissue secondary degeneration inhibitors comprising ginsenoside Rb1), the intravenous administration of ginsenoside Rb1 significantly ameliorates paralysis or paresis of animals with spinal cord injuries. It is well known that the nervous tissues are the most vulnerable to traumatic injuries as compared with other peripheral tissues. The fact that the pharmaceutical composition comprising ginsenoside Rb1 exhibits significant effects for treatment, prevention and/or therapy of spinal cord injuries indicates that ginsenoside Rb1 is effective for treatment or therapy of traumatic injuries to the peripheral tissues as well as the central nervous tissues. As shown in the following example, in rats with spinal cord injuries in which compression was loaded to the lower thoracic spinal cord, paralysis of both lower limbs (paraplegia) was ameliorated and the rats could stand up as a result of administering ginsenoside Rb1 after their injuries. The rats with spinal cord injuries, to which only physiological saline (i.e. vehicle) was administered, remained paralyzed in both lower limbs and could not stand up. In addition, intravenous administration of Solu-Medol (methylprednisolone), which is used for treatment or therapy of spinal cord injuries at present, could not ameliorate paralysis of both lower limbs (paraplegia) in rats with spinal cord injuries. Judging from these facts, the curative or therapeutic effects of ginsenoside Rb1 on spinal cord injuries are thought to be the most powerful known. Consequently, it is expected that, in the future, ginsenoside Rb1 or its metabolites will be used as a leading compound(s) in development of various remedies for spinal cord injuries, neurotrauma and trauma.

Low doses of ginsenoside Rb1 of the present invention exhibit novel effects and efficacy to improve brain edema, edema of the nervous tissues or edema of the spinal cord tissue by repetitive or continuous intravenous administration. Consequently, in the occasion of cerebral hemorrhage, cerebral infarction, cerebral embolism, subarachnoidal hemorrhage, head injuries, intracranial hemorrhage, spinal cord injuries, at the time of convulsive attack, after convulsive attack, during neurosurgical operations, before and after neurosurgical operations, during surgical operations of vertebral columns, before and after surgical operations of vertebral columns, during surgical operations of the spinal cord, or before and after surgical operations of the spinal cord, if ginsenoside Rb1 is administered intravenously, edema(ta) of brain and nervous tissues and spinal cord tissue accompanied by the above diseases, lesions, symptoms and syndromes, can be prevented, treated or cured.

Further, it was newly found that low doses of intravenous administration of ginsenoside Rb1 of the present invention are useful for prevention, treatment or therapy of bedsore (decubitus). Consequently, ginsenoside Rb1 exhibits excellent effects and efficacy on bedsore of the bedridden patients, especially bedsore of the bedridden patients with neurotrauma, head injury, cerebral apoplexy, spinal cord injury, peripheral nerve disorders, neuralgia, neurodegenerative diseases and demyelinating diseases.

In addition, ginsenoside Rb1 of the present invention exhibits novel actions of suppressing apoptosis of oligodendrocytes or apoptosis-like cell death in the concentration range of 104 fg/ml or less and increasing the expression of a cell death-suppressing gene product Bcl-xL in oligodendrocytes. Consequently, low concentrations and low dosages of ginsenoside Rb1 will be effective for diseases accompanied by cell death of oligodendrocytes (for example, multiple sclerosis, Binswanger's disease, chronic hypopurfusion failure of brain, leuko-encephalitis and adrenoleukodystrophy etc.).

It was also found that intravenous administration of ginsenoside Rb1 of the present invention increased expression of a cell death-suppressing gene product Bcl-xL in the brain and nervous tissues. Since the brain and nervous tissues include neurons, glial cells (astrocytes, microglia and oligodendrocytes), neuronal stem cells, vascular endothelial cells and vascular smooth muscle cells, the fact that intravenous administration of ginsenoside Rb1 increases the expression of the cell death-suppressing gene product Bcl-xL in the brain and nervous tissues indicates that any one or plural cell species of the brain and nervous tissue constituent cells hereinbefore increase the expression of Bcl-xL by intravenous administration of ginsenoside Rb1. Namely, ginsenoside Rb1 is effective for diseases and symptoms accompanied by apoptosis of cells or apoptosis-like cell death hereinbefore (e.g. collagen diseases, arteriosclerosis, nephritis, hepatitis and vascular injury). Recently, the neuronal stem cell transplantation is paid attention as one of therapeutic methods for intractable nervous diseases, and ginsenoside Rb1 can be used as the protective agent for neuronal stem cells.

In addition to the preferable effects and efficacy of ginsenoside Rb1 on the central nervous tissue or brain and nerve cells hereinbefore, ginsenoside Rb1 of the present invention suppresses apoptosis of myocardial cells or apoptosis-like myocardial cell death at the low concentration range of 1 ng/ml or less, more particularly at the low concentration range of 10 pg/ml or less, and increases the expression of a cell death-suppressing gene product BCl-xL in the myocardial cells. Consequently, low doses and low concentrations of ginsenoside Rb1, of the present invention exhibit effects and efficacy on all diseases accompanied by cell death of myocardial cells (e.g. myocardial infarction, Heart failure, cardiac insufficiency, cardiomyopathy, angina pectoris, arrhythmia, etc.).

Further, a specific feature of the medicinal preparations comprising ginsenoside Rb1 of the present invention, which should not be overlooked, is the fact that they do not show any adverse effects. For example, as described in Japanese Patent Application No. Hei 10-365560 and PCT/JP99/02550 (“Brain cell or nerve cell-protective agents comprising ginsenoside Rb1”), even though ginsenoside Rb1 is added to control cultured nerve cells or neurons, which are not treated with sodium nitroprusside (SNP), a nitric oxide (NO) donor, it shows no effect on the metabolic activity. Moreover, ginsenoside Rb1 at low extracellular concentrations (1-100 fg/ml) protects only nerve cells injured by treating with SNP. Consequently, ginsenoside Rb1 does not affect normal neuronal functions but can give favorable effects only on the lesion tissues. This point can be emphasized as a more superior property of ginsenoside Rb1 than glutamate receptor antagonists under developing as neuroprotective agents at present.

It has also been reported that intracerebroventricular administration of ginsenoside Rbi exerts no effects on brain temperature, cerebral blood flow or blood pressure (Lim J.-H. et al. Neurosci. Res., 28, 191-200, 1997; Zhang B. et al., J. Stroke Cerebrovasc. Dis., 7, 1-9, 1998). We have confirmed that intravenous infusion of ginsenoside Rb1, at the dose of 60 μg/day, does not affect the cerebral blood flow. It is also known that ginsenoside Rb1 at low concentrations or low doses does not promote bleeding tendency. No adverse effect was detected within a range of careful observation on animals, to which ginsenoside Rb1 of the present invention was administered.

As described in Japanese Patent Application No. Hei 10-365560 and PCT/JP99/02550 (“Brain cell or nerve cell protective agents comprising ginsenoside Rb1”) and in the present invention, ginsenoside Rb1 of the present invention, when intravenously administered in a repetitive or continuous way to rats with permanent MCA occlusion (body weight about 300 g), in a dose of 6 μg or 60 μg/day, causes reduction of cerebral infarct area to about ¼ of the non-administered group and significantly ameliorates ischemia-induced place navigation disability (cerebrovascular dementia) as well as brain edema. Furthermore, ginsenoside Rb1 of the present invention, in its equivalent doses, promotes cerebrovascular regeneration or reconstruction in the ischemic penumbra of the rats with permanent MCA occlusion, and significantly inhibits the secondary lesion of the thalamus (degeneration) in addition to reducing the cerebrocortical infarct lesion (the primary lesion). Repetitive or continuous intravenous administration of ginsenoside Rb1, in the doses of 60 μg/day or 12 μg/day, to rats with spinal cord injuries (lower thoracic cord-injured rats) significantly ameliorates paraplegia and nerve paralysis (neuroparalysis).

Based on these experimental results, dose range to human patients with cerebral apoplexy (body weight 60 kg) is calculated as 1.2 mg -12 mg/day. Consequently, daily doses of the pharmaceutical composition of the present invention to human patients with cerebral apoplexy or spinal cord injuries is, though depending on individual difference and disease states of patients, 0.1 mg or more, preferably 1 mg or more, more preferably 10 mg or more. However, since required dose amount per body weight is, generally, decreased as body weight of animals increases, a dose of 1/10 or less of this amount is thought to exhibit sufficient effects in human. When ginsenoside Rb1 is used for prevention, treatment or therapy of diseases other than brain and nervous diseases, it is preferable to select the equivalent dose of the above, or in doses of its 1/10 to 1/100,000. Since the medicinal or pharmaceutical composition of the present invention has less adverse effect, it can be administered considerably in large amount as an upper limit of dosage, and the upper limit of dosage is 1 g or less/day, preferably 0.1 g or less/day.

The method for administration of the medicinal or pharmaceutical composition of the present invention is preferably intravenous administration and the amount of administration hereinabove described can be administered consecutively or repetitively. Ginsenoside Rb1, an active compound or ginseng ingredient of the present invention is a sort of saponin, and can be formulated by conventional methods. For example, the aqueous medicinal or pharmaceutical composition (ginsenoside Rb1) of the present invention can be prepared as preparations for intravenous administration by dissolving lyophilized crystals of ginsenoside Rb1 in physiological saline, distilled water, phosphate buffer or glucose solution etc. Lipid microsphere or liposome preparation can also be used. The concentrations of ginsenoside Rb1 in the preparations for intravenous administration can optionally be adjusted unless so high, for example 0.01-10 mg/ml, preferably 0.1-1 mg/ml.

In the animal experiments of the present invention, ginsenoside Rb1 was intravenously administered continuously or repetitively for 28 days after permanent occlusion of the cortical branch(es) of the left middle cerebral artery (MCA). Since in the actual case of cerebral apoplexy at an acute phase, if no therapy is performed after the onset, the cerebral infarct lesion is expanded as the results of rapid progresses of cerebrovascular destruction, degeneration and atrophy in the ischemic penumbra as well as the occurrence of brain edema within 2 weeks after onset, and the secondary lesion subsequent to the primary ischemic lesion becomes irreversible. If an intravenous administration of ginsenoside Rb1 is performed during at least this period, it is profitable for reduction of cerebral infarct lesion, regeneration and reconstruction of the disrupted or destroyed vascular networks in the ischemic penumbra, suppression of the secondary lesion and for an improvement of brain edema.

The medicinal or pharmaceutical composition(s) of the present invention comprising crude saponin fraction of ginseng is preferably comprised of the crude saponin fraction(s) of ginseng, metabolites thereof or salts thereof at low concentrations. Further, the medicinal or pharmaceutical composition(s) of the present invention is preferably the preparations for parenteral administration such as those for intravenous administration and mucosal administration. More particularly, the medicinal or pharmaceutical composition(s) of the present invention is preferably the preparations for parenteral administration comprising the crude saponin fraction(s) of ginseng, components thereof, metabolites thereof or salts thereof at low concentrations.

Further, the present invention relates to the preparations for parenteral administration, preferably the preparations for intravenous administration, comprising the crude saponin fraction(s) of medicinal ginseng, components thereof, metabolites thereof or salts thereof at low concentrations.

These medicinal or pharmaceutical compositions of the present invention are preferably the preparations for intravenous administration, however if the extracellular fluid concentrations of the medicinal or pharmaceutical composition(s) in lesions are kept low, the preparations of any optional route of administration can be selected. These include, for example, agents for local external use in lesions, injections for local external use, preparations for oral administration, sustained release preparations-, nasal drops, ophthalmic agents, ear drops, suppositories, subcutaneous injections, intracutaneous injections, intramuscular injections, inhalations, sublingual tablets and transdermal drugs.

In addition, the present invention relates to the agents for long term treatment, prevention or therapy of spinal cord injury, head injury or neurorauma comprising the above described preparations for intravenous administration or preparations for local external use in lesions.

Further, the present inventors have found for the first time that the crude saponin fraction(s) of medicinal ginseng, components thereof, metabolites thereof or salts thereof exhibited excellent effects for the therapy or treatment of spinal cord injury by intravenous administration at low dose. Consequently, the present invention provides the use of crude saponin fractions of medicinal ginseng, components thereof, metabolites thereof or salts thereof as a leading compound(s) for exploring novel other effective components or compounds for prevention, therapy or treatment of diseases caused by nervous tissue or spinal cord tissue injuries or cerebral apoplexy. It is also possible to select any other administration routes after preparing prodrugs by modifying a part(s) of the chemical structure(s) of components contained in the crude saponin fractions of ginseng. Further, target molecules of components of crude saponin fraction of ginseng or metabolites thereof are identified and novel compounds for modifying -function of the target molecules are synthesized to direct development of drugs for treatment or therapy of spinal cord injury, neurotrauma and trauma.

Consequently, the present invention provides components of the crude saponin fractions of ginseng or metabolites thereof as leading compounds for exploring novel active components or compounds for prevention, therapy or treatment of these diseases.

The crude saponin fraction of the present invention is obtained by the conventional method that: red ginseng is extracted with methanol; the extract is suspended in water and washed with ether; and separated by water saturated 1-butanol. Yield: about 8%. The crude saponin fraction used in example hereinbelow is the same as is used in the previous report by one of the present inventors (Sakanaka) (Wen, T. -C. et al., Acta Neuropathol., 91, 15-22, 1996).

The crude saponin fraction(s) and components thereof of the present invention can be used in its free form and is also used as suitable salts thereof. The solvate such as hydrate can also be used.

The concentrations of the crude saponin fraction(s) of ginseng of the present invention are preferably low, and more concretely, the extracellular concentrations are 145 ng/ml or less, preferably 14.5 ng/ml or less, more preferably 145 pg/ml or less, further more preferably 1450 fg/ml or less. When the crude saponin fractions (s) of the present invention is used as a preparation for intravenous administration, the preparation should be adjusted so that the extracellular fluid concentrations of the crude saponin fraction(s) in lesioned tissues of patients are preferably kept at the levels hereinabove. The medicinal or pharmaceutical composition(s) and the preparation(s) of the present invention comprising the crude saponin fraction(s) can achieve the sufficient effect when the extracellular concentrations of the crude saponin fraction(s) in lesioned tissues are in the range of about 14.5-1450 fg/ml. Further, the components contained in the crude saponin fraction(s) of ginseng are preferably low in concentration, and more concretely, their extracellular concentrations are maintained to the levels of 10 ng/ml or less, preferably 1 ng/ml or less, more preferably 10 pg/ml or less, further preferably 100 fg/ml or less. In case where the constitutional components of the crude saponin fraction(s) are used an the preparations for intravenous administration, the extracellular concentrations in lesioned tissues of patients are preferably adjusted to the levels hereinabove described. The medicinal or pharmaceutical composition(s) or preparation(s) of the present invention comprising of any one of constitutional components of the crude saponin fraction(s) of the present invention can exhibit sufficient effects even in the extracellular concentration range of about 0.01-100 fg/ml in lesioned tissues.

The preparations for intravenous administration of the present invention are sufficient if they can be directly administered intravascularly, preferably intravenously, and they can be used as the preparation for single intravenous infusion or as the preparation for repetitive or continuous intravenous administration after dissolving the crude saponin fraction(s) or its constitutional components in physiological saline, distilled water, phosphate buffer, glucose solution, liposome and lipid emulsion etc. Further, formulations which can be used by adding to the preparations for intravenous administration such as a composition (s) for drip-infusion may be preferable. Prodrugs are prepared by modifying a part (s) of the chemical structure of ginsenoside Rb1, as a result, optional routs of administration and optional methods of administration can also be selected.

Further, the intravenous administration of the crude saponin fraction(s) of ginseng of the present invention significantly ameliorates paralysis or paraglegia of animals with spinal cord injuries. It is well known that the nervous tissues are the most vulnerable to traumatic injury as compared with other peripheral tissues. The fact that the medicinal or pharmaceutical composition comprising the crude saponin fraction(s) of ginseng exhibits significant effects for treatment and therapy of spinal cord injuries indicates that the crude saponin fraction(s) of ginseng is effective for traumatic injuries, wound and burn of the peripheral tissues other than the central nervous tissue. As shown in the following example 10, in rats with spinal cord injuries in which compression was loaded to the lower thoracic cord, paralysis of both lower limbs (paraplegia) was ameliorated and the rats could stand up as a result of administering a crude saponin fraction of medicinal ginseng after their injuries. This effect is comparable to the effect of intravenously administered ginsenoside Rb1. The rats with spinal cord injuries, to which only physiological saline (i.e. vehicle) was administered, remained paralyzed in both lower limbs and could not stand up. In addition, intravenous administration of Solu-Medol (methylprednisolone), which is used for treatment or therapy of spinal cord injuries at present, could not ameliorate paralysis of both lower limbs (paraplegia) in rats with spinal cord injuries. Judging from these facts, the therapeutic effects of the crude saponin fraction(s) of medicinal ginseng or components thereof as well as ginsenoside Rb1 for spinal cord injuries are thought to be the most powerful known. Consequently, it is expected that, in the future, constitutional components of the crude saponin fraction(s) of medicinal ginseng or metabolites thereof will be used as leading compounds in development of various remedies for spinal cord injuries, neurotrauma and trauma.

As described above, in the present invention, low doses of the crude saponin fraction(s) of medicinal ginseng exhibit, like the repetitive or continuous intravenous administration of ginsenoside Rb1 at low doses, excellent therapeutic effects on spinal cord injury by repetitive or continuous intravenous administration. Judging from this fact, the repetitive or continuous intravenous administration of the crude saponin fraction(s) of medicinal ginseng or components thereof is thought to exhibit effects and efficacy similar to those of ginsenoside Rb1 at low concentrations and low doses on the other brain and nervous tissue diseases (e.g. cerebral apoplexy and cerebral infarction). Further, the effects, efficacy, usages and actions of ginsenoside Rb1 found by us in Japanese Patent Application No. Hei 10-365560, PCT/JP99/02550 (Brain cell or nerve cell-protective agents comprising ginsenoside Rb1) and infused to see its therapeutic effects on spinal cord injury. However, in case of human spinal cord injuries, the period of 2 hours after the onset of spinal cord injury is critical, and it is said that the prognosis of patients is improved by performing some treatment within this time. Before the therapeutic effects of ginsenoside Rb1 on spinal cord injuries are invented, any compounds, which can be administered intravenously within 1 hour after the onset of spinal cord injury, to make animals with spinal cord injury-induced paraplegia of the lower limbs stand up, have not been found. Concretely, it is unknown and not demonstrated that the above described “some treatment” means what treatment or therapy is. Then, next, the present inventors initiated intravenous administration of ginsenoside Rb1 at 2 hours after the onset of spinal cord injury, and its effectiveness was investigated.

Under inhalation anesthesia by a mixture of nitrous oxide and halothane, Wistar rats (body weight about 300 g) were loaded with 20 g of compression on the lower thoracic cord for 20 minutes. After they were awakened from anesthesia, the rats with paraplegia in both hindlimbs were allowed to stay for 1 hour and 40 minutes in the cage. Namely, the rats with paraplegia in both hindlimbs were allowed to stay for about 2 hours without any managements or treatments since 20 g of compression on the lower thoracic cord was loaded. Immediately thereafter, ginsenoside Rb1 (60 μg) dissolved in physiological saline was infused once into the left femoral vein, and further, continuous intravenous administration of ginsenoside Rb1 (60 pg/day) was performed for 7 days by using an Alza osmotic minipump. Control animals with spinal cord injuries were administered with the same amount of physiological saline (vehicle) alone.

Results are shown in FIG. 21. FIG. 21 includes photographs in stead of drawing, showing progress of rats with paraplegia of lower extremities. On the middle left is a photograph showing rats immediately after the onset of paraplegia of lower extremities. Lower photographs show the rat administered with ginsenoside Rb1 (60 μg) from 2 hours after the onset of spinal cord injury. Upper photographs show the control rat administered with physiological saline alone. Left: 1 day later. Right: 1 week later.

As shown in FIG. 21, the rat with intravenous administration of ginsenoside Rb1 starting at 2 hours after initiation of the compression loading on the lower thoracic cord exhibited paraplegia in both hindlimbs and could not stand up on the day of spinal cord injury. On the next day, the rat could not still stand up, although it showed slight improvement of paraplegia in both hindlimbs. Thereafter, the paraplegia of both hindlimbs of the rat was gradually ameliorated from 3-4 days after the onset of spinal cord injury, and as shown in FIG. 21, the rat could stand up by holding the outer wall of the open field (height 8 cm) at 1 week after spinal cord injury. On the other hand, as shown in FIG. 21, in the rat with intravenous administration of physiological saline (vehicle) alone starting at 2 hours after loading compression on the lower thoracic cord, paraplegia of the hindlimbs was not ameliorated even at 1 week after spinal cord injury. In addition, in the rats administered only physiological saline, even individual differences were noted, as shown in FIG. 21, bedsore was frequently observed in the lower abdomen. However, bedsore was hardly observed in animals administered with ginsenoside Rb1.

Based on the results described above, intravenous administration of ginsenoside Rb1, starting either at 1 hour after spinal cord injury or at 2 hours or more after spinal cord injury, shows excellent therapeutic effects. Also ginsenoside Rb1 shows the effectiveness and the efficacy for bedsores accompanied by spinal cord injuries. This indicates that ginsenoside Rb1 is effective for prevention, treatment or therapy of bedsores accompanied by not only spinal cord injuries but also other neurotrauma (head injuries and peripheral nerve injuries or disorders), cerebral apoplexy, demyelinating diseases or neurodegenerative diseases. Consequently, in cases of neurotrauma other than spinal cord injuries such as head injuries and peripheral nerve injuries or trauma, ginsenoside Rb1 is likely to exhibit excellent effects even when its intravenous administration is started at 2 hours or more after onset of the injuries.

Further, it is known that in the nervous tissues with spinal cord injuries, edema frequently occurs in the said tissues and deteriorates neurological symptoms (paraplegia of upper and lower extremities, urination and defecation disorders). The present experimental finding that repetitive or continuous intravenous administration of ginsenoside Rb1 at low doses exhibits excellent therapeutic effects on spinal cord injuries, indicates that ginsenoside Rb1 is useful for prevention, treatment or therapy of edema in spinal cord tissues. Of course, ginsenoside Rb1 can be an excellent agent for treatment or therapy of hypogonadism, dysuria, dyschezia, dysautonomia and neurogenic bladder accompanied by spinal cord injuries.

As shown in the experimental results of the present invention, since the therapeutic effects of ginsenoside Rb1 on spinal cord injuries and neurotrauma are epoch-making, this suggests that novel pharmaceutical compounds for treatment or therapy of spinal cord injuries can be synthesized by using ginsenoside Rb1 or its metabolites as a leading compound(s). Further, as a result of identifying the target molecule(s) of ginsenoside Rb1 or its metabolites, novel compounds, which can modify the functions of the target molecule(s), are synthesized. Then the development of remedies for spinal cord injuries, neurotrauma or traumatic injuries can be directed.

Further, in cases of spinal cord injuries, apoptosis of glial cells, especially oligodendrocytes, occurs. This injury-induced apoptosis results in demyelination, and then in deterioration and progression of neurological symptoms (Crowe, M. J. et al., Nature Med. 3, 73-76, 1997; Emery, E. et al., J. Neurosurg. 89, 911-920, 1998). The experimental results in which intravenously administered ginsenoside Rb1 significantly ameliorates paralysis of both hindlimbs of rats with spinal cord injuries, indicate that ginsenoside Rb1 inhibits apoptosis of oligodendrocytes or apoptosis-like nerve cell death and thereby ameliorates symptoms of spinal cord injuries. Consequently, the low doses and/or the low concentrations of ginsenoside Rb1 of the present invention are thought to be useful for prevention, treatment or therapy of brain and nervous diseases accompanied by demyelination (multiple sclerosis, Binswanger's disease, acute disseminated encephalomyelitis, demyelinating encephalitis, chronic hypoperfusion of brain etc.) through protection of oligodendrocytes. Further, the experimental results, in which intravenously administered ginsenoside Rb1 at low doses and/or at low concentrations ameliorates paralysis of both hindlimbs of rats with spinal cord injuries (paraplegia), suggest that injured nerve fibers or nervous tissues can be regenerated as a result of administering low doses and low concentrations of the crude saponin fraction(s) or ginsenoside Rb1.

As generally known, in myelinated nerve fibers within brain and nervous tissues, oligodendrocytes form myelin by ensheathing axons of neurons repeatedly. Further, in unmyelinated nerve fibers, processes of oligodendrocytes surround axons of neurons only once. In the brain and nervous tissues, nerve cells (neurons) and oligodendrocytes are at any time holding close positional relationship. The present inventors performed co-cultures of nerve cells and oligodendrocytes to investigate whether or not ginsenoside Rb1 promotes survival of both cells. For that purpose, nerve cells (neurons) were isolated from cerebral cortices of fetal rats at gestational day 17. The mixed brain cell culture was initiated to isolate oligodendrocytes by using the forebrain of newborn rats. Fifty thousands of oligodendrocytes and 500,000 nerve cells were cocultured. To this culture system was added 1 fg/ml to 10 pg/ml ginsenoside Rb1 in DMEM containing 1% fetal calf serum, and the mixed cells were cultured for 5 days. Subsequently, samples for electrophoresis were prepared and contents of the neuron-specific protein MAP2 (microtubule-associated protein 2) and the oligodendrocyte-specific protein CNPase (cyclic nucleotide phosphatase) in the culture well were assayed by means of Western blotting.

Results are shown in FIG. 22. FIG. 22 is composed of photographs showing results of Western blotting, which indicate promoting effects of ginsenoside Rb1 on the survival of the co-cultured nerve cells and oligodendrocytes.

In FIG. 22, the upper photograph shows Western blotting of MAP2 and the lower photograph shows that of CNPase. A horizontal direction indicates the concentrations of ginsenoside Rb1 (fg/ml). When ginsenoside Rb1 at the concentrations from 1 fg/ml to 100 fg/ml was added to the co-culture of nerve cells and oligodendrocytes, the band of MAP 2 and the band of CNPase were obviously intense as compared with non-ginsenoside Rb1-added and 104 fg/ml ginsenoside Rb1-added groups. This indicates that when low concentrations of ginsenoside Rb1 were added to the co-culture system at the concentrations of 1 fg/ml to 100 fg/ml, amounts of MAP2 and CNPase were obviously increased. Namely, the survival of nerve cells and oligodendrocytes were promoted by ginsenoside Rb1. This fact strongly supports the effectiveness of low concentrations of ginsenoside Rb1 for -preventing, treating or curing diseases accompanied by oligodendrocyte death (multiple sclerosis, brain and nervous diseases accompanied by demyelination such as Binswanger's disease, etc.). Molecular weight of ginsenoside Rb1 is about 1109.46, and 1 fg/ml of ginsenoside Rb1 corresponds to about 0.9 fM ginsenoside Rb1.

In order to investigate whether ginsenoside Rb1 enhances the expression of Bcl-xL in oligodendrocytes or not, for example, ginsenoside Rb1 at the concentrations from 1 fg/ml to 10 pg/ml was added to the primary cultured rat oligodendrocytes. After culture for 6 hours, total RNA was extracted and Bcl-xL mRNA was assayed by RT-PCR. β-actin mRNA was used as an internal standard of RT-PCR. Further, a part of oligodendrocytes was used as a sample for SDS electrophoresis after treatment with ginsenoside Rb1, and anti-apoptotic factor Bcl-xL in the culture well was examined by immunoblotting (Western blotting). Oligodendrocytes were isolated from the mixed brain cell culture by using the forebrain of newborn rats.

Results are shown in FIG. 23. FIG. 23 is composed of photographs instead of drawings showing results of immunoblotting (Western blotting) which indicate the promoting effect of ginsenoside Rb1 on the expression of Bcl-xL in oligodendrocytes. In FIG. 23, the upper photographs show results of RT-PCR and the lower photographs show results of immunoblotting (Western blotting). On the left in the upper are cases of β-actin mRNA expression, and on the right are cases of Bcl-xL mRNA expression. In the figure, Rb1(−) indicates no addition of ginsenoside Rb1 and Rb1(+) indicates ginsenoside Rb1 added at a concentration of 100 fg/ml. Horizontal direction in the lower indicates concentration of ginsenoside Rb1 (fg/ml).

The RT-PCR indicates that when ginsenoside Rb1 was added to culture medium at the concentration of 100 fg/ml, expression of Bcl-xL mRNA in oligodendrocytes was obviously enhanced. Further, results of immunoblotting (Western blotting) indicate that Bcl-xL protein was increased by adding ginsenoside Rb1 to the oligodendrocyte culture. The results of these experiments strongly support that in brain and nervous diseases causing demyelination and spinal cord injuries, intravenous administration of low doses of ginsenoside Rb1 exhibits protective actions on oligodendrocytes.

In Japanese Patent Application No. Hei 10-365560, PCT/JP99/02550 (Brain cell or nerve cell-protective agents comprising ginsenoside Rb1), the present inventors (Sakanaka and Tanaka) demonstrated that when ginsenoside Rb1 was added to cultured neurons at the concentrations of about 1˜100 fg/ml, expression of Bcl-xL in the neurons was enhanced. The present inventors investigated whether or not intravenous administration of low doses of ginsenoside Rb1 increases expression of Bcl-xL mRNA in brain tissues. For this purpose, for example, SH-SP rats (body weight 250-300 g), at the age of 12 weeks, were used. Immediately after permanent occlusion of the MCA in SH-SP rats under inhalation anesthesia, ginsenoside Rb1 dissolved in physiological saline was infused once intravenously (60 μg), and subsequently ginsenoside Rb1 was intravenously infused continuously at the dose of 60 μg/day. Control animals with MCA permanent occlusion and sham-operated animals received the same amount of physiological saline after MCA permanent occlusion.

Results are shown in FIG. 24. FIG. 24 indicates results of RT-PCR showing the promoting effect of ginsenoside Rb1 on the expression of Bcl-xL in vivo. In FIG. 24, the upper 2 photographs: group 1 animals and the lower 2 photographs: group 2 animals. The upper photographs in individual groups: β-actin mRNA and the lower protographs: Bcl-xL mRNA. Sham indicates sham-operated animals; Rb1(−) indicates animals with cerebral infarction administered with physiological saline; and Rb1(+) indicates animals with cerebral infarction administered intravenously with ginsenoside Rb1 at the 4th hour after MCA permanent occlusion (left in Rb1(+)), and at the 6th hour after MCA permanent occlusion (right in Rb1(+)).

Group 1 shows a sham-operated animal; an animal with MCA permanent occlusion administered with physiological saline (after MCA permanent occlusion, i.e. at the 4th hour after cerebral infarction); an animal with cerebral infarction administered with ginsenoside Rb1 (at the 4th hour after MCA permanent occlusion); and an animal with cerebral infarction administered with ginsenoside Rb1 (at the 6th hour after MCA permanent occlusion). Group 2 consists of animals with the same experimental conditions. Sham indicates sham-operated animals; Rb1(−) indicates animals with cerebral infarction administered with physiological saline; and Rb1(+) indicates animals with cerebral infarction administered intravenously with ginsenoside Rb1. At the 4th hour or the 6th hour after the sham operation and MCA permanent occlusion, animals were anesthetized with chloral hydrate, and the left cerebral cortex (i.e. the cerebral cortex on the side of MCA permanent occlusion) was dissected out and total RNA was prepared for RT-PCR. The mRNA of P-actin was used as the internal standard.

As shown in FIG. 24, both in Group 1 and Group 2, the expressions of Bcl-xL mRNA in the cerebral cortex were obviously increased both at the 4th hour and the 6th hour after MCA permanent occlusion in the animals intravenously administered with ginsenoside Rb1 as compared with the sham-operated animals and the cerebral infarction animals administered with physiological saline.

The nervous tissues in the cerebral cortex include neurons, neural stem cells, glial cells (astrocytes, microglia and oligodendrocytes), vascular endothelial cells, vascular smooth muscle cells, etc. Consequently, the present experimental results showing upregulation of cerebrocortical Bcl-xL mRNA expression by intravenous administration of ginsenoside Rbi indicate that any one of cells constituting the cerebral cortex potentiates the expression of Bcl-xL mRNA in response to intravenous administration of ginsenoside Rb1. Therefore, ginsenoside Rb1 exhibits Bcl-xL expression-enhancing actions on all cell species. In rats not only with cerebral infarction but also with spinal cord injuries, intravenous administration of ginsenoside Rb1 (60 μg/day) is likely to increase the expression of Bcl-xL mRNA in the spinal cord tissues. Based on the experimental results hereinbefore that intravenous administration of the low doses and low concentrations of ginsenoside Rb1 makes bedridden rats with spinal cord injuries stand up, intravenous administration of the low doses and low concentrations of the crude saponin fraction(s) also increases the expression of Bcl-xL mRNA in the brain and nervous tissues.

The present inventors have studied effectiveness and efficacy of medicinal ginseng (red ginseng powder), crude saponin fractions and ginsenoside Rb1 using nervous tissues or neural tissue-constituent cells (nerve cells and oligodendrocytes). Next, we have studied effect of ginsenoside Rb1 on the heart. For that purpose, for example, changes in the expression of Bcl-xL mRNA and Bcl-xL protein were examined with RT-PCR and immunoblotting, when primary cultured myocardial cells were cultured for 18 hours in the presence of ginsenoside Rb1. Myocardial cells were prepared as follows. The hearts of fetal rats at gestational day 17 were treated with trypsin EDTA to prepare dispersed cells, which were cultured for several days in DMEM containing 10% FCS (fetal calf serum). In RT-PCR, β-actin mRNA was used as the internal standard. In the immunoblotting, troponin T, a striated muscle-specific protein, was used as the internal standard, and expression of Bcl-xL protein was examined. In the immunoblotting, the same experiments were repeated 10 times by using different lots of myocardial cells, and Bcl-xL immunoreaction-positive bands were analyzed by densitometry and statistical analysis was performed.

Results are shown in FIG. 25. In FIG. 25, the upper photographs show results of RT-PCR, and the middle photographs show results of immunoblotting. (Western blotting). The horizontal direction indicates concentration of ginsenoside Rb1 (fg/ml). In FIG. 25, the lower graph shows results of densitometric analysis of the bands of Western blotting. Statistical analyses were conducted by ANOVA+Fisher's PLSD. n=10.*: p<0.05, **: p<0.01

As shown in FIG. 25, the expression of Bcl-xL mRNA was obviously increased in the presence of ginsenoside Rb1 at concentrations of 1 fg/ml -100 fg/ml. With regard to the Bcl-xL protein level, ginsenoside Rb1 in the concentration range between 1 fg/ml and 104 fg/ml significantly enhanced the expression of Bcl-xL protein. In the present experiments, although a mismatch between the expression of Bcl-xL mRNA and that of Bcl-xL protein was noted at 104 fg/ml of ginsenoside Rb1, it is speculated that the expression of Bcl-xL mRNA was already down-regulated at 18 hours after administration of such a high concentration of ginsenoside Rb1 (104 fg/ml).

We have investigated whether or not ginsenoside Rb1 could actually suppress myocardial cell death in the concentration range for increasing the expression of Bcl-xL protein. For that purpose, for example, the protective effect of ginsenoside Rb1 on myocardial cells was examined when the primary cultured myocardial cells were cultured without addition of glucose. Ginsenoside Rb1 in the concentration range from 0 to 1 ng/ml was added to myocardial cells in serum-free DMEM without containing glucose, and the myocardial cells were cultured for 4 or 5 days. Subsequently, the samples for electrophoresis were prepared, and immunoblotting (Western blotting) was performed by using anti-striated muscle specific α-actinin antibody.

Results are shown in FIG. 26. In FIG. 26, the upper photograph shows results of Western blotting of α-actinin The horizontal direction indicates concentration of ginsenoside Rb1 (fg/ml). The lower graph in FIG. 26 shows densitometric analysis of the results of the Western blotting. Statistical analyses were conducted by ANOVA+Scheffe's post hoc test. n=3.*: p<0.05, **: p<0.01

As shown in FIG. 26, when the culture was conducted only with the glucose-free and serum-free medium, the myocardial cells disappeared already at 4-5 days after culture, and band of a-actinin could not be detected. When ginsenoside Rb1, was added to the culture medium in the concentration range from 1 fg/ml to 104 fg/ml, large numbers of pulsating myocardial cells were observed, and the striated muscle-specific a-actinin was significantly detected by immunoblotting.

According to the above results, it was found that ginsenoside Rb1 could increase the expression of myocardial cell Bcl-xL in the slightly broader concentration range (0.01-104 fg/ml or 1-104 fg/ml) than in the effective concentration range for nerve cells and had the protective action on myocardial cells.

In Japanese Patent Application No. Hei 10-365560, PCT/JP99/02550 (Brain cell or nerve cell-protective agents comprising ginsenoside Rb1), whether ginsenoside Rb1 at the concentrations of 1 fg/ml, 100 fg/ml and 105 fg/ml suppresses apoptosis-like nerve cell death or not, and whether it promotes the expression of Bcl-xL protein in the nerve cells or not, were investigated, and as a result significant effects were obtained at the concentrations of 1 fg/ml and 100 fg/ml. However, actually, ginsenoside Rb1 at the concentration of 104 fg/ml increases the expression of Bcl-xL protein in myocardial cells and suppresses cell death of myocardial cells. Consequently, in nerve cells or neurons, the possibility is left open that ginsenoside Rb1 in the similar concentration range (from 1 fg/ml to 1I 4fg/ml) promotes the expression of Bcl-xL protein and suppresses apoptosis-like nerve cell death.

According to the experimental results that ginsenoside Rb1 at the low concentrations of 1 to 104 fg/ml increases the expression of a cell death-suppressing gene product Bcl-xL in the myocardial cells and suppresses myocardial cell death in the glucose-free condition, low concentrations of ginsenoside Rb1 appear to exhibit effectiveness and efficacy for all diseases accompanied by myocardial cell death (e.g. myocardial infarction, myocarditis, Kawasaki's disease, cardiomyopathy, cardiac insufficiency, heart failure, cardiac arrest, angina pectoris, etc.). In cases of heart surgery, addition of low concentrations of ginsenoside Rb1 to the artificial cardiopulmonary perfusate can effectively protect myocardial cells and heart. Of course, in the occasion of cardiopulmonary resuscitation, intravenous administration of low doses and low concentrations of ginsenoside Rb1 makes damage to myocardial cells after resuscitation as small as possible. Further, if the low concentrations of ginsenoside Rb1 are administered intravenously, rectally, sublingually or nasally to patients with hypoglycemic attack or patients who are suffered from hypoglycemic attack or suffering from hypoglycemic attack frequently, the myocardial cell damage caused by hypoglycemia will be ameliorated more efficiently. Of course, preferable effects on myocardial cells mentioned above appear to be brought about by using low doses and low concentrations of the crude saponin fraction(s) as well.

In the present invention, the enhanced expression of Bcl-xL by ginseng (red ginseng powder) or ginsenoside Rb1 has been described. As is well known, Bcl-2 family proteins consist of cell death-suppressing (anti-apoptotic) factors such as Bcl-2, Bcl-xL, Bcl-w, etc. and cell death-promoting (proapoptotic) factors such as Bax, Bad, Bid, Bik, etc. It is well known that these Bcl-2 family proteins have organ-specific and cell-specific expression patterns. Consequently, although in the present invention and in Japanese Patent Application No. Hei 10-365560, PCT/JP99/02550 (Brain cell or nerve cell-protective agents comprising ginsenoside Rb1) in the name of us (Sakanaka and Tanaka), it was found that ginsenoside Rb1 increases the expression of Bcl-xL in nerve cells (neurons) or myocardial cells, in the other organs or cells, ginsenoside Rb1 is likely to promote the expression of cell death-suppressing factors other than Bcl-xL or to suppress the expression of cell death-promoting factors as described above. Of course, ginsenoside Rb1 is likely to promote the expression of cell death-suppressing factors (e.g. Bcl-2 and Bcl-w) or to suppress the expression of cell death-promoting factors in neural tissues or nerve cells, too.

In the signal transduction of cell death, the cell death-suppressing gene product Bcl-xL locates upstream of procaspase 9, caspase 9, procaspase 3 or caspase 3, and the fact that ginsenoside Rb1 increases the expression of Bcl-xL and strongly suppresses nerve cell death, demonstrates that ginsenoside Rb1 also suppresses activation of caspases.

In the prior patent application (Japanese Patent Application No. Hei 11-243378, Brain cell or, nerve cell-protective agents comprising medicinal ginseng), we have described that novel compounds having brain cell- or nerve cell-protective actions can be explored by using candidate substances of the active components contained in ginseng as a leading compound(s). We have attempted to demonstrate this fact in the present invention. For that purpose, for example, dihydroginsenoside Rb1 represented by the above chemical formula (II) was used. As far as we know, dihydroginsenoside Rb1 is a novel compound and can be produced by reducing (i.e., hydrogenating) ginsenoside Rb1, which is owned by us, in the presence of a catalyst, palladium charcoal.

In order to analyze pharmacological actions of dihydroginsenoside Rb1, male SH-SP rats, at the age of 16 weeks, weighing 300-320 g, were used. Animals were bred in a room furnished with 12 hours light and dark cycles, and water and feeds were supplied ad libitum. The cortical branch of the left middle cerebral artery (MCA) of each animal was coagulated and cut under inhalation anesthesia. Immediately after MCA permanent occlusion, dihydroginsenoside Rb1 dissolved in physiological saline was infused once intravenously (6 μg), and subsequently it was intravenously infused continuously for 24 hours by using an Alza osmotic minipump (6 μg/day).

Control animals with MCA permanent occlusion (ischemic control animals) received the same amount of physiological saline (vehicle). At 24 hours after MCA permanent occlusion, a lethal dose of pentobarbital was injected intraperitoneally into individual rats. Immediately after death of the animals, the brains were dissected out and frontal sections with 2 mm thickness were prepared. The sections were immersed in 1% 2,3,5-triphenyl-tetrazolium chloride (TTC) solution for 30 minutes at 37° C. and fixed with 10% formalin for more than 12 hours.

Results are shown in FIG. 27 and FIG. 28. In FIG. 27, 2 cases administered with physiological saline, and in FIG. 28, 2 cases administered intravenously with dihydroginsenoside Rb1 are shown.

As shown in FIG. 27, in the rats administered with physiological saline after MCA permanent occlusion, the cerebral infarct lesion, which was not stained with TTC, was observed with white color in the cerebral cortex on the left side. On the other hand, as shown in FIG. 28, in the rats administered intravenously with dihydroginsenoside Rb1 after MCA permanent occlusion, the cerebral infarct lesion was markedly reduced. Especially, the brain in the right column in FIG. 28 showed a tremendously reduced cerebral infarct lesion, which is limited only in the surface layer of the cerebral cortex. This indicates that dihydroginsenoside Rb1 not only suppresses apoptosis-like nerve cell death in the ischemic penumbra, but also suppresses necrosis of nerve cells and brain cells in the ischemic core.

The experimental results wherein dihydroginsenoside Rb1 or metabolites thereof can show an action of reducing cerebral infarct lesion as like ginsenoside Rb1 in SH-SP rats with MCA permanent occlusion, prove that novel neuroprotective agents or novel brain cell-protective agents, which act especially at low doses and low concentrations, can be prepared by using ginsenoside Rb1 as a leading compound. Furthermore, since the effective dose of dihydroginsenoside Rb1 for intravenous administration is almost identical with the effective dose of ginsenoside Rb1 for intravenous administration, it is thought that dihydroginsenoside Rb1 exhibits excellent neuroprotective actions and brain cell-protective actions at the low concentrations and at low doses as does ginsenoside Rb1. Of course, the effectiveness, efficacy and usages of ginsenoside Rb1 described by us in Japanese Patent Application No. Hei 10-365560, PCT/JP99/02550 (Brain cell or nerve cell-protective agents comprising ginsenoside Rb1), are in common with those of dihydroginsenoside Rb1. Namely, dihydroginsenoside Rb1 increases the expression of a cell death-suppressing gene product Bcl-xL as does ginsenoside Rb1, and suppresses apoptosis of nerve cells or apoptosis-like nerve cell death. Further, dihydroginsenoside Rb1 exhibits effectiveness and efficacy for all brain and nervous diseases accompanied by nerve cell death as does ginsenoside Rb1, (Alzheimer's disease, cerebral apoplexy, cerebral infarction, cerebral thrombosis, cerebral embolism, subarachnoidal hemorrhage, transient cerebral ischemic attack, Pick disease, spinocerebellar degeneration, Parkinson's disease, demyelinating diseases, polyglutamine diseases such as chorea, amyotrophic lateral sclerosis, glaucoma, senile macular degeneration, diabetic retinopathy, central retinal arteriovenous occlusion, retinal detachment, pigmentary degeneration of the retina, AIDS encephalopathy, hepatic encephalopathy, encephalitis, cerebral palsy, head injuries, spinal cord injuries, Shy-Drager disease, brain tumors, toxic neuropathies, carbon monoxide poisoning, asphyxia of the newborn, peripheral neuropathies, spastic paraplegia, progressive supranuclear palsy, circulatory disorders of the spinal cord, mitochondrial encephalomyopathy, meningitis, etc.).

The cell death-suppressing gene product BCl-xL is the protein that can be said as the last fortress for cell survival, and is distributed not only in the brain and neural tissues but also in all peripheral organs and tissues, for example liver, spleen, tissues of the immune system, tissues of the circulatory system and skin, and supports the survival of cells. Consequently, based on the above speculation that dihydroginsenoside Rb1 increases the expression of Bcl-xL in the same way as ginsenoside Rb1, dihydroginsenoside Rb1 is effective for treatment, prevention and/or therapy of all diseases of the peripheral organs and tissues accompanied by cell death. Among the diseases of the peripheral organs and tissues accompanied by cell death, following diseases are included: ischemia-reperfusion failure of cardiac muscle, liver and kidneys, cardiomyopathy, cardiac failure, myocardial infarction, angina pectoris, peripheral circulatory failures, bedsores, cutaneous ulcer, cutaneous wound, trauma, bum, radiation injuries, electric injuries, aging, damage by ultraviolet rays, depilation, alopecia, xeroderma, dry skin, autoimmune diseases, immunodeficiency diseases, graft rejection, muscular dystrophy, corneal injuries, infectious diseases, collagen diseases, aortitis syndrome, acute arterial embolism, thromboangiitis obliterans, peptic ulcer, arteriosclerosis obliterans, Raynaud's disease, Raynaud's syndrome, hemorrhoids, thrombophlebitis, pancreatitis, hepatitis, nephritis, diabetic nephropathy, diabetic cardiomyopathy, glossalgia, diabetes mellitus, arteriosclerosis, etc. Dihydroginsenoside Rb1 of the present invention can be used as health drugs for improving a variety of symptoms of immune dysfunction, circulation dysfunction, digestive dysfunction, cutaneous dysfunction and hypogonadism accompanied with aging. Further, Dihydroginsenoside Rb1 can be utilized as a cosmetic composition for preventing, treating or managing skin symptoms accompanied by aging (shrink or atrophy of skin, flabby skin, slackening or loosening of skin, scurf, dandruff, itching, white-hair, gray hair, exfoliation of the stratum corneum, exfoliation of cells in the stratum corneum, dry skin, crack, freckle, pigmentation, sunburn, dryness, lines, furrows, wrinkles, blotch, spots, etc.). In addition, dihydroginsenoside Rb1 can be used as hair-restorers, hair-grooming agents, hair-raising agents, hair tonic and agents for prevention of depilation or alopecia. Of course, the effectiveness, efficacy or usages of ginsenoside Rb1 described in Japanese Patent Application No. 2000-163026 (Agents for promoting dermal tissue regeneration comprising ginsenoside Rb1) are in common with those of dihydroginsenoside Rb1.

In Japanese Patent Application No. Hei 11-243378, PCT/JP99/06804 (Cerebrovascular regeneration/reconstruction promoters and nerve tissue secondary degeneration inhibitors comprising ginsenoside Rb1), we (Sakanaka and Tanaka) have found that repetitive or continuous intravenous administration of low doses of ginsenoside Rb1 could stand up bedridden rats with spinal cord injuries through cerebrovascular regeneration and reconstruction-promoting actions, suppressive actions on the secondary degeneration of nerve cells and through suppressive actions on apoptosis of oligodendrocytes or apoptosis-like cell death. Results of the present experiments, in which dihydroginsenoside Rb1 shows the excellent therapeutic effects on cerebral infarction as does ginsenoside Rb1, indicate that dihydroginsenoside Rb1 can be a remedy for spinal cord injuries, head injuries or neurotrauma. Namely, the effectiveness efficacy or usages of ginsenoside Rb1 described by the present inventors (Sakanaka and Tanaka) in Japanese Patent Application No. Hei 11-243378, PCT/JP99/06804 (Cerebrovascular regeneration/reconstruction promoters and nerve tissue secondary degeneration inhibitors comprising ginsenoside Rb1) are in common with those of dihydroginsenoside Rb1. Of course, as methods for administration of dihydroginsenoside Rb1 of the present invention, any route of administration can be selected like ginsenoside Rb1. Concretely, dihydroginsenoside Rb1 can be used not only as agents for intravenous administration but also as agents for external use or for injection to local lesions. Further, as methods for administration of dihydroginsenoside Rb1, any one of subcutaneous injection, intramuscular injection, eye ointment, eye drops, nasal drops, ear drops, inhalations, suppositories, oral administrations, sublingual administrations, transdermal administrations, etc. can be selected. When dihydroginsenoside Rb1 is used as agents for oral administration, if dihydroginsenoside Rb1 is administered alone, favorable effects may not always be expected. Consequently, it may be necessary that dihydroginsenoside Rb1 is mixed, encapsuled or bound with a carrier(s) which inhibits decomposition of dihydroginsenoside Rb1 in the digestive tract (shellac, gelatin, oil layer, etc.) or with a carrier(s) which promotes absorption of dihydroginsenoside Rb1 in the digestive tract, and it is administered orally. Further, if metabolites of dihydroginsenoside Rb1 are identified to have effectiveness and efficacy equal to dihydroginsenoside RID, or to have more effectiveness and efficacy than dihydroginsenoside Rb1, the active metabolites can be administered against diseases for which dihydroginsenoside Rb1 can be applied by the administration methods described above. Further, a dispersant comprising dihydroginsenoside RID, of the present invention and macromolecular compounds is prepared and spray-dried to select any route of administration. Furthermore, dihydroginsenoside Rb1 is coated with micro-particles of macromolecular compounds to select any route of administration. Further, a prodrug of dihydroginsenoside Rb1 is prepared and any route of administration can be selected. For example, a hydroxyl base(s) of dihydroginsenoside Rb1 is esterified to prepare a prodrug(s) and it is hydrolyzed with endogenous esterases after passing the blood-brain barrier to increase amount of transfer of dihydroginsenoside Rb1 to the brain.

In addition, dihydroginsenoside Rb1 appears to be effective for protection or maintenance of cultured keratinocyte sheets for skin graft. The other organs or tissues for transplantation (liver, kidney, heart, pancreas, lung, digestive tract, cornea and blood vessel, etc.) are immersed or perfused with the low concentrations of dihydroginsenoside Rb1 during a term before transplantation operation is performed. As a result, cell injury or destruction of the vascular networks of these organs can be suppressed, and results of transplantation operation can be improved. Dihydroginsenoside Rb1 is likely to be effective for protection or maintenance of blood cell components and platelets for transfusion, frozen ova, frozen sperms or stem cells.

Of course, the fact that dihydroginsenoside Rb1 has the same effectiveness, efficacy or usages as those of ginsenoside Rb1, which have been described in the present invention, is also easily accepted.

On the basis of the above experimental results on red ginseng powder, the agents for oral administration comprising red ginseng powder to potentiate the expression of Bcl-xL was demonstrated to be effective at high doses for treatment, prevention or therapy of brain or nervous diseases, for example, cerebrovascular dementia, cerebral infarction, cerebral hemorrhage, subarachnoidal hemorrhage, transient cerebral ischemic attack, neurodegenerative diseases, demyelinating diseases, cerebral palsy, spinal cord injuries, etc.

Further, oral administration of low doses of red ginseng powder was found to enhance expression of the cell death-suppressing gene product Bcl-xL protein in the peripheral organs such as liver and spleen. Consequently, oral administration of low doses of red ginseng powder is useful for peripheral organ diseases accompanied by cell death (myocardiopathy, cardiac insufficiency, heart failure, myocardial infarction, myocarditis, ischemia-reperfusion injuries of liver, kidney and heart, hepatitis, nephritis, diabetes, mellitus, immuno-deficiency diseases, bedsores, skin ulcer, wound, trauma, radiation injuries, ultraviolet injuries, etc.). Effects of oral administration of red ginseng powder for diseases of peripheral organs or tissues accompanied by cell death may be, at least in part, possibly described in Oriental medicine-related references or Chinese medicine-related references which are not known by the present inventors.

Further, according to the results of experiments using ginsenoside Rb1 described above, repetitive or continuous intravenous administration of low doses of ginsenoside Rb1 is useful for prevention, treatment or therapy of brain edema, shows excellent effects on bedsores accompanied by spinal cord injuries, and enhances the expression of Bcl-xL in brain and nervous tissues. Further, low concentrations of ginsenoside Rb1 facilitate the survival of oligodendrocytes, increase the expression of Bcl-xL in the same cells, and promote the survival of myocardial cells as well as increasing the expression of Bcl-xL in the cells. In addition, we (the present inventors) have proven that intravenous administration of low concentrations and low doses of the crude saponin fraction(s) exhibits excellent therapeutic effects on cerebral infarction and spinal cord injuries, and showed that any one of components in the said fraction(s) can be a medicinal or pharmaceutical composition for treatment or therapy of spinal cord injuries, head injuries or neurotrauma.

Finally, it is found that a novel reduced compound of ginsenoside Rb1, i.e. dihydroginsenoside Rb1, exhibits excellent therapeutic effects on cerebral infarction by intravenous administration at low doses as does ginsenoside Rb1. Namely, dihydroginsenoside Rb1 has similar effectiveness, efficacy or usages to ginsenoside Rb1 as described by us in Japanese Patent Application No. Hei 10-365560, PCT/JP99/02550 and Japanese Patent Application No. Hei 11-340850, PCT/JP99/06804. Of course, dihydroginsenoside Rb1 has all of the effectiveness, efficacy or usages of ginsenoside Rb1 reported by the other inventors and researchers. Based on the results of the present experiments using dihydroginsenoside Rb1, it was proven that by applying ginsenoside Rb1 as a leading compound various protective agents for nerve cells, protective agents for brain cells, agents for treatment or therapy of cerebral apoplexy, agents for treatment or therapy of neurodegenerative diseases, agents for treatment or therapy of spinal cord injuries, head injuries or neurotrauma, protective agents for cells, and so forth are developed.

On the other hand, red ginseng powder, low concentrations and low doses of ginsenoside Rb1 and low concentrations and low doses of the crude saponin fraction(s) are known as substances having quite less ill effects.

The present invention provides agents for treatment therapy, and/or prevention of brain and nervous diseases, and protective agents for nerve cells and nervous tissues, comprising preparations for oral administration of relatively high doses of red ginseng powder, useful not only for acute phase or chronic phase cerebral infarction (cerebral thrombosis or cerebral embolism), but also for acute phase or chronic phase cerebral hemorrhage or subarachnoidal hemorrhage, or transient cerebral ischemic attack. Namely, red ginseng powder of the present invention is a drug which can be administered orally at home to patients who are suspected to suffer from cerebral apoplexy as far as their consciousness and swallowing function are maintained. Further, if the aged people, who are the so-called cerebral apoplexy candidates with underlying diseases such as diabetes mellitus, hypertension, cerebral arteriosclerosis, atrial fibrillation and cerebral aneurysm or with anamnesis of cerebral apoplexy, ingested red ginseng powder in advance, and thereafter even if they suffer from cerebral apoplectic attack at the worst, their cerebral apoplectic lesion and functional disorders of the higher nervous system will be markedly improved as compared with the patients who did not take red ginseng powder.

Judging from the facts that oral administration of red ginseng powder of the present invention at relatively high doses promotes the expression of the cell death-suppressing gene product, i.e. Bcl-xL protein, in neural or nervous tissues, and that oral administration of red ginseng powder of the present invention at relatively high doses suppresses apoptosis-like nerve cell death in the ischemic penumbra, the medicinal or pharmaceutical composition of the present invention comprising relatively high doses of red ginseng powder is useful for primary or secondary neurodegenerative diseases accompanied by apoptosis-like nerve cell death or apoptosis (Alzheimer's disease, Pick disease, spinocerebellar degeneration, Parkinson's disease, demyelinating diseases, polyglutamine diseases such as chorea, amyotrophic lateral sclerosis, glaucoma, senile macular degeneration, diabetic retinopathy, central retinal arteriovenous occlusion, retinal detachment, pigmentary degeneration of the retina, AIDS encephalopathy, hepatic encephalopathy, encephalitis, cerebral palsy, head injuries, spinal cord injuries, carbon monoxide poisoning, asphyxia of the newborn, peripheral neuropathy, spastic paraplegia, brain tumor, encephalitis, alcohol poisoning, toxic nervous diseases, sphingolipidosis, progressive supranuclear palsy, spinal vascular disorders, mitochondrial encephalomyopathy, meningitis, etc.). Red ginseng powder of the present invention is useful for improvement of various symptoms caused by aging-induced death of brain cell or neurons (decrement of memory, tremor, decreased muscle force, decreased working ability, decreased ability of thinking, decreased ability of orientation, decreased ability of calculation, decreased ability of learning, hypovolition, suppressed motivaton, decreased recognition ability, swallowing difficulty, speech difficulty, impaired judgement, and other higher nervous functional insufficiencies) and it can be used as health food and health drug (OTC preparations). Further, the medicinal or pharmaceutical composition of the present invention has almost no ill effects, and safe drugs are provided in the present invention.

The cell death-suppressing gene product Bcl-xL is the protein that can be said as the last fortress for cell survival, and is distributed not only in the brain and nervous tissues but also in many peripheral organs and tissues, for example, liver, spleen, tissues of the immune system, tissues of the circulatory system and skin, and supports the survival of cells. Consequently, based on the present experimental results that oral administration of low doses of red ginseng powder increases the expression of Bcl-xL protein in the peripheral organs such as liver and spleen, the low doses of red ginseng powder are effective for treatment, prevention and/or therapy of all diseases of the peripheral organs and tissues accompanied by cell death. Among the diseases of the peripheral organs and tissues accompanied by cell death, following diseases are included: ischemia-reperfusion injuries of cardiac muscle, liver and kidneys, cardiomyopathy, cardiac failure, heart failure, myocardial infarction, angina pectoris, peripheral circulatory insufficiency, bedsores, wound, cutaneous ulcer, cutaneous wound, trauma, autoimmune diseases, immunodeficiency diseases, graft rejection after organ transplantation, muscular dystrophy, corneal injuries, radiation injuries, ultraviolet rays injuries, infectious diseases, collagen diseases, aortitis syndrome, acute arterial embolism, thromboangiitis obliterans, arteriosclerosis obliterans, Raynaud's disease, diabetes mellitus, Raynaud's syndrome, thrombophlebitis, pancreatitis, hepatitis, nephritis, diabetic nephropathy, diabetic cardiomyopathy, glossalgia, etc. Other diseases and/or pathologic conditions accompanied by cell death are described in the book (“Today's guide for therapy”: Ed. Shigeaki Hinohara and Masakazu Abe, Igaku-Shoin Publ., 1995). Red ginseng powder is effective for prevention, treatment or therapy of all diseases and pathological conditions above described. In a broad sense, bedsores, skin ulcer, burn, frostbite, etc. are included in cutaneous wound. Red ginseng powder of the present invention can be used as health drugs for improving immune dysfunction, circulation dysfunction, digestive dysfunction, cutaneous dysfunction, and hypogonadism accompanied with aging. Further, red ginseng powder can be utilized for prevention, treatment or therapy of not only human diseases but also diseases of pet and livestock. Further, it is applied for cultivation of marine products, (fishes, crustaceans, eel, conger, etc.) or cultivation of farm products. In this case, red ginseng powder protects ocean resources and farm products against endocrine disruptors, toxins, injuries, trauma, microorganisms, biohazards, etc.

Further, compositions or components extracted from red ginseng powder (red ginseng extract, crude saponin fractions, various purified saponins, ginsenosides and non-saponin fractions) and metabolites thereof or chemical derivatives thereof are expected to exhibit the same effectiveness and efficacy as those of red ginseng powder.

It is possible to develop novel cytoprotective agents by using a component(s) for protecting brain cells (nerve cells, glial cells, etc.) in red ginseng powder, and further as a result of identifying target molecules or receptors for the components for protecting brain cells, novel compounds that modify or regulate the functions of target molecules or receptors can be synthesized. With regard to candidates for the components for protecting brain cells in red ginseng powder, the crude saponin fraction(s) of ginseng, purified saponins such as ginsenoside Rb1, non-saponin fractions of ginseng or metabolites thereof can be taken into consideration, as described in the “detailed description of the invention”. References which described the purified saponins and their metabolites in part are: Shoji's review (Junzo Shoji, “Chemistry of Ginseng”, Ginseng '95, Akira Kumagaya, Ed., pp 251-161) and Obashi's review (Kyoichi Obashi, et al. “What is an actual active substance(s) in ginseng?—Oriental drugs are already changing in the digestive tube—”, Ginseng '95, Akira Kumagaya, Ed., pp 213-221). Consequently, the present invention is essential for development of agents or pharmaceutical compositions for prevention, treatment or therapy of all diseases accompanied by cell death as described above.

Further, among the intracellular signal transduction molecules, certain molecule groups that are involved in fate of cells are elucidated by analyzing the cytoprotective mechanism of ginseng components, metabolites thereof or red ginseng powder (ginseng) itself. Subsequently, novel compounds for promoting or inhibiting the functions of these molecules are synthesized. As a result, drugs useful for preventing, treating or curing diseases accompanied by cell death and malignant tumors can be developed.

On the other hand, in the present invention, ginsenoside Rb1 was found as an excellent agent for preventing, treating or curing brain edema. Generally, the pathological condition of brain edema or nervous tissue edema appears frequently in cases of cerebral hemorrhage, cerebral infarction, cerebral embolism, subarachnoidal hemorrhage, head injuries, brain tumors, encephalitis, heavy metal, poisoning, neurotrauma and spinal cord injuries, at convulsive attack, after convulsive attack, during neurosurgical operations, before and after neurosurgical operations, during surgical operations of spine, before and after surgical operation of spine, at resuscitation after cardiac arrest or apnea, etc., and is known to deteriorate prognosis of life or neurological symptoms of patients. Consequently, the present experimental finding that repetitive or continuous intravenous administration of ginsenoside Rb1 at low doses treats or cures brain edema after the onset of cerebral infarction (cerebral embolism) indicates that ginsenoside Rb1 is useful for prevention, treatment or therapy of edema of brain and nervous tissues accompanied by the above mentioned diseases, disorders, symptoms and syndromes.

Further, the pathological condition of biological (living body) tissue edema is known to occur not only in brain tissues with permanently occluded cerebral blood vessels but also in cases of occlusion of peripheral blood vessels and in cases of disturbance of blood flow in the peripheral organs or tissues. Consequently, based on the present experimental finding that intravenous administration of small amounts of ginsenoside Rb1 after permanent occlusion of a cerebral blood vessel (MCA) improved and cured brain edema, ginsenoside Rb1 exhibits efficacy for circulatory disorders of peripheral tissues and peripheral organs (e.g. aortitis syndrome, collagen diseases, acute occlusion of peripheral arteries, acute arteriosclerosis obliterans, thromboangiitis obliterans, arteriosclerosis obliterans, thrombophlebitis, diabetic retinopathy, diabetic nephropathy, central retinal arteriovenous occlusion, acute peripheral circulatory insufficiency, shock, Raynaud's disease, Raynaud's syndrome, hemorrhoids, myocardial infarction, bedsores, peripheral circulatory insufficiency, angina pectoris, ischemia-reperfusion injuries of liver, kidney and heart, etc.). Of course, among diseases hereinabove, for edema of lesioned tissues accompanied by hemorrhoids and bedsores, ginsenoside Rb1 is admixed with preferable base and applied as external spread, external spray or rectal use. If the extracellular fluid concentrations of ginsenoside Rb1 in lesioned tissues are maintained at 1 ng/ml or less, preferably 10 pg/ml or less, more preferably 100 fg/ml or less, routes of its administration are not limited with the intravenous administration and any route of administration can be selected as described hereinbefore.

Further, the present invention showed that repetitive or continuous intravenous administration of low doses of ginsenoside Rb1 exhibits effectiveness and efficacy against bedsores accompanied by spinal cord injuries. This indicates that ginsenoside Rb1 is useful not only for bedsores in patients with spinal cord injuries but also for bedsores in patients with neurotrauma, peripheral nerve disorders, peripheral neuralgia, peripheral neuroparalysis, cerebral apoplexy, neurodegenerative diseases and demyelinating diseases. Of course, we have already demonstrated that low doses of ginsenoside Rb1 exhibit excellent effectiveness and efficacy for the primary lesions of brain and nervous diseases.

It is known that in the nervous tissues having spinal cord injuries, edema occurs frequently in the said spinal cord tissues, and as a result, neurological symptoms are deteriorated severely (e.g. paraplegia of upper or lower extremities, dysuria, dyschezia and neurogenic bladder). Results of the present experiments showing excellent therapeutic effects on spinal cord injuries by repetitive or continuous intravenous administration of low doses of ginsenoside Rb1, indicate that ginsenoside Rb1 is not only useful for prevention, treatment or therapy of edema of spinal cord tissues but also useful for preventing, treating or curing autonomic neuropathy, dysuria, dyschezia and neurogenic bladder.

Further, low doses of ginsenoside Rb1 potentiates the expressions of a cell death-suppressing gene product Bcl-xL in oligodendrocytes and myocardial cells and promotes survival of the same cells. Consequently, intravenous administration, intravenous repetitive or continuous administration, nasal administration, sublingual administration or intrarectal administration of low doses of ginsenoside Rb1 appears to be effective for treatment or therapy of demyelinating diseases such as multiple sclerosis, Binswanger's disease, leukoencephalopathy, etc., chronic hypoperfusion disorders of brain, myocardial infarction, cardiac failure, cardiomyopathy, cardiac arrest, angina pectoris, etc. The above administration of ginsenoside Rb1 at low doses during cardiopulmonary resuscitation, before and after cardiopulmonary resuscitation, during surgical operations of heart, before and after surgical operations of heart, etc. also appears to be effective.

Ginsenoside Rb1 is, as described above, not only useful as medicinal or pharmaceutical compositions but also able to be used as compositions for health drugs or cosmetics to prevent aging in vivo, since it suppresses apoptosis-like cell death or apoptosis of all cells. Especially, ginsenoside Rb1 is admixed or added into any cosmetics so that the extracellular fluid concentrations of ginsenoside Rb1 in local regions or lesions of the skin are adjusted to 1 ng/ml or less, preferably 10 pg/ml or less, more preferably 100 fg/ml or less. Examples of cosmetics are any cosmetics, for example, skin lotion, milk lotion, foundation, cold cream, cleansing cream, face washing foam, night cream, beauty cream, face powder, gargle, eye wash, face wash, lip stick, lip cream, make-up base, UV liquid foundation, powder foundation, etc. Trace amounts of ginsenoside Rb1 are admixed or added into these cosmetics and are useful for preventing senile symptoms of skin accompanied by aging (e.g. ultraviolet damage, spots on the skin, blotch, wrinkles, lines, furrows, freckle, roughness, crack, chaps, flabby, slackening or loosening of skin, itching, sunburn, etc.). Of course, low doses and low concentrations of ginsenoside Rb1 can be used as hair-restorers, hair-raising agents, hair-grooming agents, hair tonic or as agents for preventing deterioration of depilation or alopecia.

Since the potentiating actions of ginsenoside Rb1 on the expression of Bcl-xL are noted in all cells including nerve cells, glial cells, vascular endothelial cells, vascular smooth muscle cells, neural stem cells, etc., ginsenoside Rb1 is, in this meaning, thought to be cytoprotective agents which exhibit excellent effects at low doses and low concentrations. Consequently, low doses and low concentrations of ginsenoside Rb1 are thought to be extremely useful for all diseases, syndromes and symptoms accompanied by cell death not only in the central nervous tissue but also in peripheral tissues and peripheral organs. Further, low doses and low concentrations of ginsenoside Rb1 are, in patients with cancer and sarcoma, useful for improving QOL (quality of life) and prolonging life of the patients by protecting normal cells in the healthy or intact tissues invaded by tumor cells.

We have found in the present invention that a novel and useful cytoprotective agent, dihydroginsenoside Rb1, can be prepared by using ginsenoside Rb1 as a leading compound. This indicates that by using other components in ginseng as a leading compound(s) novel and useful medicinal or pharmaceutical compositions as well as health drugs and health foods can be developed.

The results of the present experiments using rats with spinal cord injuries indicate that the therapeutic effects of the preparations for intravenous administration comprising low doses of the crude saponin fraction(s) on spinal cord injuries are almost equally excellent as compared with those of ginsenoside Rb1. Consequently, any one of purified saponins in the crude saponin fraction(s) or metabolites thereof can exhibits extremely potent therapeutic actions on spinal cord injuries. This supports that any one of purified saponins in the crude saponin fraction(s) or metabolites thereof can be a leading compound(s) to find novel substances for treatment or therapy of spinal cord injuries or neurotrauma. The results of the present experiments support that any one of the purified saponins (FIG. 15) in the crude saponin fractions suppresses secondary degeneration of the nervous tissues after spinal cord injuries. In the present experiment, a crude saponin fraction of Panax ginseng C. A. Meyer was used, but by using crude saponin fractions of other types of ginseng (e.g. Sanchi (Sanshichi)-ginseng, Denhichi ginseng, Himalayan ginseng, American ginseng, Tikusetu ginseng, etc.), similar results can be obtained. Consequently, any one of components in the aforementioned crude saponin fractions in ginseng appear to be useful for prevention, treatment or therapy of spinal cord injuries, neurotrauma, neural traumatic injuries or head injuries.

It is well known that nervous tissues are the most vulnerable to traumatic injuries when compared with other peripheral tissues. The fact that the medicinal or pharmaceutical composition comprising low doses of the crude saponin fraction(s) exhibits marked effects for treatment and/or therapy of spinal cord injuries indicates that low doses of the crude saponin fraction(s) are also effective for treatment or therapy of traumatic injuries to the peripheral tissues other than the central nervous tissue.

Further, it is reported that in cases of spinal cord injuries, the damage to glial cells, especially oligodendrocytes, results in apoptosis, then demyelination occurs to make neurological symptoms worse (Crowe, M. J. et al., Nature Med. 3, 73-76, 1997; Emery, E. et al., J. Neurosurg. 89, 911-920, 1998). The experimental results, in which intravenous administration of the crude saponin fraction(s) markedly ameliorates paralysis or paraplegia of both hindlimbs of rats with spinal cord injuries, indicate that any one of purified saponins in the crude saponin fraction(s) inhibits apoptosis of oligodendrocytes or apoptosis-like nerve cell death and thereby ameliorates symptoms of spinal cord injuries. Consequently, any one of purified saponins in low concentrations and low doses of the crude saponin fraction(s) of the present invention is thought to be useful for prevention, treatment or therapy of brain and nervous diseases accompanied by demyelination (multiple sclerosis, Binswanger's disease, chronic hypoperfusion disorder of brain, leukoencephalitis, etc.) through protection of oligodendrocytes. Further, the experimental results, in which intravenous administration of the crude saponin fraction(s) ameliorates paralysis of both hindlimbs of rats with spinal cord injuries (paraplegia), suggest that injured nerve fibers or nervous tissues can be regenerated as a result of administering the crude saponin fraction(s).

In nervous tissues with spinal cord injury, edema occurs frequently in the said spinal cord tissues, and neurological symptoms (paraplegia of lower extremities, urination disorder(s), dysuria, difficulty in urination, dyschezia, neurogenic bladder, etc.) are deteriorated. The present experimental finding that intravenous administration of the low doses of the crude saponin fraction(s) exhibits excellent therapeutic effects on spinal cord injuries, indicate usefulness of the crude saponin fraction(s) or any one of purified saponins in the crude saponin fraction(s) for prevention, treatment or therapy of spinal cord tissue edema, urination disorders, dysuria, dyschezia and/or neurogenic bladder accompanied by spinal cord injuries.

In the present experiments, further, it was found that the preparations for intravenous administration comprising the crude saponin fraction(s) or salts thereof suppress the secondary degeneration of nervous tissues caused by spinal cord injuries. Further, the medicinal or pharmaceutical composition(s) comprising low doses and low concentrations of the crude saponin fraction(s) can be expected to be an epock-making remedy for spinal cord injuries, neurotrauma, neural traumatic injuries or head injuries as well as exhibiting the effectiveness and efficacy for peripheral tissue injuries.

Since the therapeutic effects of low doses and low concentrations of the crude saponin fraction(s) on spinal cord injuries, neurotrauma and neural traumatic injuries are epoch-making, this suggests that novel pharmaceutical compounds for treatment or therapy of spinal cord injuries, neurotrauma and neural traumatic injuries can be synthesized by using components in the crude saponin fraction(s), purified saponins or metabolites thereof as leading compounds. Further, as a result of identifying the target molecules of components in the crude saponin fraction(s), purified saponins or metabolites thereof, novel compounds which can modify the functions of the target molecules, are synthesized. Then the development of remedies for spinal cord injuries, neural traumatic injuries, neurotrauma or traumatic injuries can be directed.

In the present invention, it was demonstrated that the crude saponin fraction(s) of ginseng or any one of constitutional components of the crude saponin fraction(s) exhibited an excellent protective action(s) on brain cells or nerve cells and therapeutic effects on spinal cord injuries, neurotrauma, head injuries or neural traumatic injuries as did ginsenoside Rb1 at the low doses and low concentrations. Consequently, low doses and low concentrations of the crude saponin fraction(s) or any one of constitutional components of the crude saponin fraction(s) of the present invention have all effectiveness, efficacy and usages of ginsenoside Rb1 described by the inventors (Sakanaka, Tanaka or Nakata) in Japanese Patent Application No. Hei 10-365560, PCT/JP99/02550 (Brain cell or nerve cell-protective agents comprising ginsenoside Rb1) and Japanese Patent Application No. Hei 11-243378, PCT/JP99/06804 (Cerebrovascular regeneration/reconstruction promoters and nerve tissue secondary degeneration inhibitors comprising ginsenoside Rb1) or Japanese Patent Application No. 2000-163026 (Agents for promoting dermal tissue regeneration comprising ginsenoside Rb1). Namely, the low doses and low concentrations of the crude saponin fraction(s) or any one of the constitutional components of the crude saponin fractions can increase the expression of a cell death-suppressing gene product Bcl-xL and, as a result, can suppress apoptosis of nerve cells or apoptosis-like nerve cell death, similar to ginsenoside Rb1. Further, the low doses and low concentrations of the crude saponin fraction(s) or any one of constitutional components of the crude saponin fraction(s), like ginsenoside Rb1, can exhibit effectiveness and efficacy for all brain and nervous diseases accompanied by nerve cell death. Examples of these brain and nervous diseases are Alzheimer's disease, cerebral apoplexy, cerebral infarction, cerebral thrombosis, cerebral embolism, subarachnoidal hemorrhage, transient cerebral ischemic attack, Pick disease, spinocerebellar degeneration, Parkinson's disease, demyelinating diseases, polyglutamine diseases such as chorea, amyotrophic lateral sclerosis, glaucoma, senile macular degeneration, diabetic retinopathy, central retinal arteriovenous occlusion, retinal detachment, pigmentary degeneration of the retina, AIDS encephalopathy, hepatic encephalopathy, encephalitis, cerebral palsy, head injuries, spinal cord injuries, carbon monoxide poisoning, asphyxia of the newborn, peripheral neuropathy, spastic paraplegia, progressive supranuclear palsy, circulatory disorders of the spinal cord, mitochondrial encephalomyopathy, meningitis, etc.

The cell death-suppressing gene product Bcl-xL is the protein that can be said as the last fortress for cell survival, and it is distributed not only in the brain and nervous tissues but also in many peripheral organs and tissues, for example liver, spleen, tissues of the immune system, tissues of the circulatory system and skin, and supports the survival of cells. Consequently, based on the presumption that low doses and low concentrations of the crude saponin fraction(s) or any one of constitutional components of the crude saponin fractions can increase the expression of Bcl-xL protein in the same way as ginsenoside Rb1, the low doses and low concentrations of the crude saponin fraction(s) or any one of constitutional components of the crude saponin fractions can be effectively used for treatment, prevention and/or therapy of all diseases of the peripheral organs and tissues accompanied by cell death. Among the diseases of the peripheral organs and tissues accompanied by cell death, following diseases are included: ischemia-reperfusion injuries of cardiac muscles, liver and kidneys, cardiomyopathy, cardiac failure, myocardial infarction, angina pectoris, peripheral circulatory failure, bedsores, wound, cutaneous ulcer, cutaneous wound, trauma, bum, radiation injuries, aging, ultraviolet rays disturbance, electric injuries, depilation, alopecia, xeroderma, autoimmune diseases, immunodeficiency diseases, graft rejection after organ transplantation, muscular dystrophy, corneal injuries, infectious diseases, collagen diseases, aortitis syndrome, acute arterial embolism, thromboangiitis obliterans, peptic ulcer, arteriosclerosis obliterans, Raynaud's disease, Raynaud's syndrome, hemorrhoids, thrombophlebitis, pancreatitis, hepatitis, nephritis, diabetic nephropathy, diabetic cardiomyopathy, glossalgia, etc. The low doses and low concentrations of the crude saponin fraction(s) or any one of the constitutional components of the crude saponin fractions of the present invention can be used as health drugs for improving immune dysfunction, circulation dysfunction, digestive dysfunction, cutaneous dysfunction and hypogonadism accompanied with aging. Further, the low doses and low concentrations of the crude saponin fraction(s) or any one of the constitutional components of the crude saponin fractions can be utilized as cosmetic compositions for preventing, treating or managing sanile symptoms accompanied by aging (ultraviolet rays disturbance, wrinkle, furrows, lines, spots, blotch, sunburn, etc.). Further, the low doses and low concentrations of the crude saponin fraction(s) or components thereof protect normal tissues in healthy cells invaded by tumor cells in patients with cancer or sarcoma, and are useful for improving QOL (quality of life) and prolonging survival of the patients.

In Japanese Patent Application No. Hei 11-243378, PCT/JP99/06804 (Cerebrovascular regeneration/reconstruction promoters and nerve tissue secondary degeneration inhibitors comprising ginsenoside Rb1), the present inventors (Sakanaka and Tanaka) have found that repetitive or continuous intravenous administration of low doses of ginsenoside Rb1 could stand up bedridden rats with spinal cord injuries through a cerebrovascular regeneration and reconstruction-promoting action(s), a suppressive action(s) on secondary degeneration of neural (nervous) tissues and a suppressive action(s) on apoptosis of oligodendrocytes or apoptosis-like cell death. Experimental results of the present invention, in which the low doses and low concentration of the crude saponin fraction(s) or any one of the constitutional components of the crude saponin fractions can exhibit the excellent therapeutic effects on spinal cord injuries as like ginsenoside Rb1, indicate that the low doses and low concentrations of the crude saponin fraction(s) or any, one of the constitutional components of the crude saponin fractions can be a remedy for spinal cord injuries, neurotrauma, head injuries or neural traumatic injuries. Namely, the effectiveness, efficacy or usages of ginsenoside Rb1 described by us (Sakanaka and Tanaka) in Japanese Patent Application No. Hei 11-243378, PCT/JP99/06804 (Cerebrovascular regeneration/reconstruction promoters and nerve tissue secondary degeneration inhibitors comprising ginsenoside Rb1) are in common with those of the low doses and low concentration of the crude saponin fraction(s) or any one of the constitutional components of the crude saponin fractions. Of course, as methods for administration of the crude saponin fraction(s) or constitutional components of the crude saponin fractions, any route of administration can be selected like ginsenoside Rb1, if the extracellular fluid concentrations of the crude saponin fraction(s) or any one of the constitutional components of the crude saponin fraction(s) in lesioned tissues can be kept low as described above. Concretely, low doses and low concentrations of the crude saponin fraction(s) or any one of the constitutional components of the crude saponin fractions can be used not only as agents for intravenous administration but also as agents for external use or for injection to local lesions. Further, methods for administration of the crude saponin fraction(s) or any one of constitutional components of the crude saponin fraction(s) can be selected from any route of subcutaneous injection, intramuscular injection, eye drops, nasal drops, ear drops, inhalations, suppositories, oral administrations, sublingual administrations, transdermal administrations, etc. However, when the crude saponin fractions) or any one of constitutional components of the crude saponin fraction(s) is used as agents for oral administration, if the crude saponin fraction(s) or any one of constitutional components of the crude saponin fraction(s) is administered alone, the effectiveness may not always be expected. Consequently, it may be necessary that the crude saponin fraction(s) or any one of constitutional components of the crude saponin fraction(s) is mixed, encapsuled or bound with a carrier(s) which inhibits decomposition in the digestive tract or with a carrier(s) which promotes absorption in the digestive tract, and then administered orally. Further, if metabolites of the crude saponin fraction(s) or any one of constitutional components of the crude saponin fraction(s) are identified to have equal effectiveness and efficacy with the crude saponin fraction (s) or any one of constitutional components of the crude saponin fraction(s) or to have more effectiveness and efficacy than the crude saponin fraction(s) or any one of constitutional components of the crude saponin fraction(s), the active metabolites can be administered against diseases described above for which the low doses and low concentrations of the crude saponin fraction or any one of constitutional components of the crude saponin can be applied by the administration methods described above. Further, a dispersant of the crude saponin fraction(s) or any one of constitutional components of the crude saponin fraction(s) of the present invention and macromolecular compounds is prepared, and spray dried to select any route of administration. Furthermore, the crude saponin fraction(s) or any one of constitutional components of the crude saponin fraction(s) is coated with micro-particles of macromolecular compounds to select any route of administration. Of course, a prodrug is prepared with any one of constitutional components of the crude saponin fraction(s), and any route of administration can be selected.

In addition, the low doses and/or low concentrations of the crude saponin fraction(s) or any one of constitutional components of the crude saponin fraction(s) appear to be effective for protection or maintenance of cultured keratinocyte sheets for skin graft. Further, other organs or tissues for transplantation (liver, kidney, heart, pancreas, lung, digestive tract, digestive tube, cornea, blood vessel, etc.) are immersed in or perfused with the crude saponin fraction(s) or any one of the constitutional components of the crude saponin fraction(s) during a term before transplantation operation is conducted, and as a result, cell injury or damage to the vascular networks of these organs can be suppressed, and the results of transplantation operation can be improved. Further, the crude saponin fraction(s) or any one of the constitutional components of the crude saponin fraction(s) at low doses and low concentrations appears to be effective for protection or maintenance of blood cell components and platelets for transfusion, stem cells (ES cells), neural stem cells, etc. and for protection or maintenance of frozen ova or frozen sperms.

In the present invention, a novel reduced compound of ginsenoside Rb1, i.e. dihydroginsenoside Rb1, exhibited excellent therapeutic effects on cerebral infarction by its intravenous administration at low doses as did ginsenoside Rb1. Namely, dihydroginsenoside Rb1 is considered to have effectiveness, efficacy and usages similar to those of ginsenoside Rb, described in the prior patent application by the present inventors (Sakanaka and Tanaka) (Japanese Patent Application No. Hei 10-365560, PCT/JP99/02550 and Japanese Patent Application No. Hei 11-340850, PCT/JP99/06804). Based on the present experimental results using dihydroginsenoside Rb1, it was proved that by applying ginsenoside Rb1 as a leading compound large numbers of agents can be developed, i.e. agents for protecting nerve cells, agents for protecting brain cells, remedy for cerebral apoplexy, remedies for neurodegenerative diseases, remedies for spinal cord injuries, neurotrauma, head injuries and nerve injuries, agents for protecting cells, etc. Large numbers of purified saponins in ginseng have a common chemical structure similar to ginsenoside Rb1, i.e. the side chain (carbon chain) is bound with the dammarane skeleton or structure (steroid-like skeleton or structure) (refer to FIG. 15). Consequently, with regard to purified saponins other than ginsenoside Rb1 in ginseng, reduction of the double bond in the side chain (carbon chain) provides novel compounds having pharmacological actions, effectiveness, efficacy and usages similar to those of the original purified saponins.

The present experimental finding that dihydroginsenoside Rb1 or metabolites thereof, like ginsenoside Rb1, can reduce cerebral infarct lesion in SH-SPrats with permanent occlusion of the MCA, proves that novel agents for protecting nerve cells or novel agents for protecting brain cells can be prepared by applying ginsenoside Rb1 as a leading compound. Furthermore, since the effective doses of intravenously administered dihydroginsenoside Rb1 are almost identical with those of intravenously administered ginsenoside Rb1, dihydroginsenoside Rb1 is likely to exhibit at low concentrations and low doses excellent neuroprotective actions and brain cell-protective actions, similar to ginsenoside Rb1. Consequently, dihydroginsenoside Rb1 has all effectiveness, efficacy and usages of ginsenoside Rb1 described by the inventors (Sakanaka and Tanaka) in Japanese Patent Application No. Hei 10-365560, PCT/JP99/02550 (Brain cell or nerve cell-protective agents comprising ginsenoside Rb1). Namely, dihydroginsenoside Rb1 is likely to increase the expression of a cell death-suppressive gene product Bcl-xL, and as a result, it suppresses apoptosis of nerve cells or apoptosis-like nerve cell death, similar to ginsenoside Rb1. Further, dihydroginsenoside Rb1 exhibits effectiveness and efficacy for all brain and nervous diseases accompanied by nerve cell death as does ginsenoside Rb1. Examples of these brain and nervous diseases are Alzheimer's disease, cerebral apoplexy, cerebral infarction, cerebral thrombosis, cerebral embolism, subarachnoidal hemorrhage, transient cerebral ischemic attack, Pick disease, spinocerebellar degeneration, Parkinson's disease, demyelinating diseases, polyglutamine diseases such as chorea, amyotrophic lateral sclerosis, glaucoma, senile macular degeneration, diabetic retinopathy, central retinal arteriovenous occlusion, retinal detachment, pigmentary degeneration of the retina, AIDS encephalopathy, hepatic encephalopathy, encephalitis, cerebral palsy, head injuries, spinal cord injuries, carbon monoxide poisoning, asphyxia of the newborn, peripheral neuropathy, spastic paraplegia, peripheral nerve paralysis, peripheral neuralgia, progressive supranuclear palsy, circulatory disorders of the spinal cord, mitochondrial encephalomyopathy, meningitis, etc.

The cell death-suppressing gene product Bcl-xL is the protein that can be said as the last fortress for cell survival, and it is distributed not only in the brain and nervous tissues but also in almost all peripheral organs and tissues, for example liver, spleen, tissues of the immune system, tissues of the circulatory system and skin, and supports the survival of cells. Consequently, based on the presumption described above that dihydroginsenoside Rb1 increases the expression of Bcl-xL protein as ginsenoside Rb1 does, dihydroginsenoside Rb1 appears to be effective for treatment, prevention and/or therapy of all diseases of the peripheral organs and tissues accompanied by cell death. Among the diseases of the peripheral organs and tissues accompanied by cell death, following diseases are included: ischemia-reperfusion injuries of cardiac muscles, liver and kidneys, cardiomyopathy, cardiac failure, myocardial infarction, angina pectoris, peripheral circulatory failure, bedsores, cutaneous ulcer, cutaneous wound, trauma, burn, radiation injuries, aging, injuries or damage by ultraviolet rays, electric injuries, depilation, alopecia, xeroderma, autoimmune diseases, immunodeficiency diseases, graft rejection after organ transplantation, muscular dystrophy, corneal injuries, infectious diseases, collagen diseases, aortitis syndrome, acute arterial embolism, thromboangiitis obliterans, peptic ulcer, arteriosclerosis obliterans, Raynaud's disease, Raynaud's syndrome, hemorrhoids, thrombophlebitis, pancreatitis, hepatitis, nephritis, diabetic nephropathy, diabetic cardiomyopathy, glossalgia, etc. Other diseases and pathological conditions accompanied by cell death are described in the book (“Today's guide for therapy”: Ed. Shigeaki Hinohara and Masakazu Abe, Igaku-Shoin Publ., 1995). Dihydroginsenoside Rb1 protects normal cells in healthy tissues invaded by tumor cells in patients with cancer or sarcoma, and is useful for improving QOL (quality of life) and prolonging survival of the patients. Dihydroginsenoside Rb1 of the present invention can be used as health drugs for improving immune dysfunction, circulation dysfunction, digestive dysfunction, cutaneous dysfunction and hypogonadism accompanied with aging. Further, dihydroginsenoside Rb1 can be utilized as cosmetic compositions for preventing, treating or managing sanile symptoms accompanied by aging (shrink or atrophy of skin, white-hair, gray hair, scurf, dandruff, exfoliation of the stratum corneum exfoliation of cells in the stratum corneum, dry skin, senile xerosis, asteatotic dermatitis, slackening or loosening of skin, itching, roughness, dryness, crack, freckle, pigmentation, furrows, wrinkles, lines, spots, blotch, sunburn, etc.). Further, dihydroginsenoside Rb1 can be used for chemical peeling. Dihydroginsenoside Rb1, can also be used as hair-restorers, hair tonic, hair-raising agents, hair-grooming agents and/or agents for preventing deterioration of depilation or alopecia.

In Japanese Patent Application No. Hei 11-243378, PCT/JP99/06804 (Cerebrovascular regeneration/reconstruction promoters and nerve tissue secondary degeneration inhibitors comprising ginsenoside Rb1), we (Sakanaka and Tanaka) have found that repetitive or continuous intravenous administration of low doses of ginsenoside Rb1 could stand up bedridden rats with spinal cord injuries through a cerebrovascular regeneration and reconstruction promoting-action(s), a suppressive action(s) on the secondary degeneration of nervous tissues and a suppressive action(s) on apoptosis of oligodendrocytes or apoptosis-like cell death. The present experimental results, in which dihydroginsenoside Rb1 exhibits the excellent therapeutic effects on cerebral infarction as does ginsenoside Rb1, indicate that dihydroginsenoside Rb1 can be a remedy for spinal cord injuries, head injuries, neurotrauma or neural traumatic injuries. Namely, the effectiveness, efficacy or usages of ginsenoside Rb1 described by the present inventors (Sakanaka and Tanaka) in Japanese Patent Application No. Hei 11-243378, PCT/JP99/06804 (Cerebrovascular regeneration/reconstruction promoters and nerve tissue secondary degeneration inhibitors comprising ginsenoside Rb1) are in common with those of dihydroginsenoside Rb1. Of course, as methods for administration of dihydroginsenoside Rb1, any route of administration can be selected , like ginsenoside Rb1. Concretely, dihydroginsenoside Rb1 can be used not only as agents for intravenous administration but also as agents for external use, for injection to local lesions or for spray on local lesions. Further, as methods for administration of dihydroginsenoside Rb1, any one of subcutaneous injection, intramuscular injection, eye drops, eye ointments, nasal drops, ear drops, inhalations, suppositories, oral administrations, sublingual administrations, transdermal administrations, etc. can be selected. However, when dihydroginsenoside Rb1 is used as agents for oral administration, if dihydroginsenoside Rb1 is administered alone, the effectiveness may not always be expected. Consequently, it may be necessary that dihydroginsenoside Rb1 is mixed, encapsuled or bound with a carrier(s) which inhibits decomposition in the digestive tract (shellac, gelatin, oil layer, etc.) or with a carrier(s) which promotes absorption in the digestive tract, and then administered orally. Further, if metabolites of dihydroginsenoside Rb1 is identified to have equal effectiveness and efficacy with dihydroginsenoside Rb1 or to have more effectiveness and efficacy than dihydroginsenoside Rb1, the active metabolites can be administered against diseases described above for which dihydroginsenoside Rb1 can be applied by the administration methods described earlier. Further, a dispersant of dihydroginsenoside Rb1 of the present invention and macromolecular compound is prepared, and spray-dried to select any route of administration. Furthermore, dihydroginsenoside Rb1 is coated with micro-particles of macromolecular compound to select any route of administration.

In addition, dihydroginsenoside Rb1 appears to be effective for protection or maintenance of cultured keratinocyte sheets for skin graft. Other organs or tissues for transplantation (liver, kidney, heart, pancreas, lung, digestive tract, digestive tube, cornea, blood vessel, etc.), are immersed in or perfused with dihydroginsenoside Rb1 during a term before transplantation operation is conducted, and as a result, cell injury or damage to the vascular networks of these organs can be suppressed, and the results of transplantation operation can be improved. Further, dihydroginsenoside Rb1, like ginsenoside Rb1, appears to be effective for protection or maintenance of blood cell components and platelets for transfusion, stem cells (ES cells), neural stem cells, etc. and for protection or maintenance of frozen ova, frozen sperms, frozen cells and frozen tissues.

EXAMPLES

The present invention will be explained in detail by concrete examples, but the present invention is not limited within these examples.

Example 1 Experiment on Oral Administration of Red Ginseng Powder Before and After Cerebral Infarction

Male SH-SP rats at the age of 12-13 weeks, weighing 250-300 g, were used. Animals were bred in a room furnished with 12 hours light and dark cycles and water and feeds were supplied ad libitum. The cortical branch of the left middle cerebral artery (MCA) of each animal was coagulated and cut under inhalation anesthesia according to the method described by the present inventors (Sakanaka and Tanaka) (Igase, K., et al., J. Cereb. Blood Flow Metab., 19, 298-306, 1999; Sadamoto, Y., et al., Biochem. Biophys. Res. Commun., 253, 26-32, 1998). Red ginseng powder was mixed with distilled water and administered orally once a day for one week before MCA permanent occlusion and for 32 days after MCA permanent occlusion (0.6 g/kg/day, 0.75 g/kg/day, 0.9 g/kg/day or 1.2 g/kg/day, n=5-8)

Control animals with MCA permanent occlusion (ischemic control animals) and sham-operated animals were orally administered with the same amount of distilled water.

After MCA permanent occlusion, according to the method of the inventors (Sakanaka and Tanaka) (Zhang B. et al., J. Stroke Cerebrovasc. Dis., 7, 1-9, 1998; Igase, K., et al., J. Cereb. Blood Flow Metab., 19, 298-306, 1999; Sadamoto, Y., et al., Biochem. Biophys. Res. Commun., 253, 26-32, 1998), water maze tests were performed for 4 days at the 2nd week and at the 4th week, respectively, and the place navigation abilities of SH-SP rats were determined.

Results are shown in FIG. 1. In FIG. 1, the upper drawing is the results of the 2nd week and the lower drawing is the results of 4th week. In FIG. 1, open circles indicate the results of ischemic rats administered with distilled water; closed circles indicate the results of rats with sham operation; open squares indicate the results of ischemic rats administered with red ginseng powder in a dose of 0.6 g/kg/day; closed squares indicate the results of ischemic rats administered with red ginseng powder in a dose of 0.75 g/kg/day; open triangles indicate the results of ischemic rats administered with red ginseng powder in a dose of 0.9 g/kg/day; and closed triangles indicate the results of ischemic rats administered with red ginseng powder in a dose of 1.2 g/kg/day.

As shown in FIG. 1, the place navigation abilities of animals after MCA-permanent occlusion (after cerebral infarction) were significantly improved in the groups administered with red ginseng powder in doses of 0.75-1.2 g/kg/day, as compared with the group of ischemic animals administered with distilled water. The most favorable effect was observed in the group administered with red ginseng powder in a dose of 0.9 g/kg/day. Data are represented as mean±SE. Statistical analyses were conducted by ANOVA+Fisher's PLSD. No significant differences in swimming speed of SH-SP rats were observed among the six experimental groups.

After termination of water maze tests at the 4th week, the SH-SP rats were anesthetized with chloral hydrate, and they were perfused and fixed transcardially with 0.1 mole phosphate buffer containing 4% paraformaldehyde. The brains of the animals were dissected out and the cerebrocortical infracted lesions were photographed. The left cerebrocortical infracted areas were divided by the left cerebral hemispheric areas to calculate ratios of the cerebrocortical infarction (%). Results are shown in FIG. 2. Data are represented as mean±SE. Statistical analyses were conducted by Mann-Whitney U-test.

As shown in FIG. 2, ratios of the cerebrocortical infarction were also significantly decreased in the groups of ischemic animals administered with red ginseng powder in the doses of 0.75-1.2 g/kg/day, as compared with the group of ischemic animals administered with distilled water. The most favorable effect was observed in the group administered with red ginseng powder in a dose of 0.9 g/kg/day, and the mean value of the ratio of the cerebrocortical infarction was reduced to less than ½ of the group of ischemic animals administered with distilled water. Accordingly, the actual infarcted volume was reduced to about ¼ by the oral administration of red ginseng powder in a dose of 0.9 g/kg/day.

In FIG. 3, the upper photographs show cerebral infarct lesions in the group of ischemic animals administered with distilled water (4 cases), and the lower photographs in FIG. 3 show cerebral infarct lesions in the group of ischemic animals administered with red ginseng powder in a dose of 0.9 g/kg/day (4 cases).

FIG. 4 shows schematic illustration of the summarized results of the experiments. In the group of ischemic animals administered with distilled water, the large cerebral infarcted lesion as well as cerebral edema was observed, but in the group of ischemic animals administered with red ginseng powder, cerebral infarcted area was decreased and cerebral edema was also reduced. As a result, animals arrived at the objective platform within a short time in the water maze test.

Example 2 Experiments on Oral Administration of Red Ginseng Powder After Cerebral Infarction

The cortical branch of the left middle cerebral artery (MCA) of each male SH-SP rat at the age of 12-13 weeks, weighing 250-300 g, was coagulated and cut under inhalation anesthesia, and red ginseng powder in a dose of 0.9 g/kg/day was administered orally once a day for 32 days (n=7). Control animals with permanent MCA occlusion (infarcted control animals; n=8), were administered with only distilled water.

After MCA permanent occlusion, according to the method of the inventors (Sakanaka and Tanaka) (Zhang B. et al., J. Stroke Cerebrovasc. Dis., 7, 1-9, 1998; Igase, K., et al., J. Cereb. Blood Flow Metab., 19, 298-306, 1999; Sadamoto, Y., et al., Biochem. Biophys. Res. Commun., 253, 26-32, 1998), water maze tests were performed for 4 days at the 2nd week and at the 4th week, respectively, and the place navigation abilities of SH-SP rats were determined.

Results are shown in FIG. 5. In FIG. 5, the upper drawing is the results of the 2nd week and the lower drawing is the results of 4th week. In FIG. 5, open circles indicate the results of ischemic rats administered with only distilled water (n =8); closed squares indicate the results of ischemic rats administered with red ginseng powder in a dose of 0.9 g/kg/day (n=8). For reference, the experimental values of the group of the sham-operated animals used in FIG. 1 are shown with closed circles.

As shown in FIG. 5, the place navigation abilities of animals after MCA-permanent occlusion (after cerebral infarction) were significantly improved in the group orally administered with red ginseng powder in a dose of 0.9 g/kg/day, as compared with the group of ischemic animals administered with distilled water. Preferable effect was observed at the 4th week after MCA occlusion. Data are represented as mean±SE. Statistical analyses were conducted by ANOVA+Fisher's PLSD.

After termination of water maze tests at the 4th week, the SH-SP rats were anesthetized with chloral hydrate, and they were perfused and fixed transcardially with 0.1 mole phosphate buffer containing 4% paraformaldehyde. The brains of the animals were dissected out and cerebrocortical infarcted lesions were photographed. Areas of the left cerebral hemisphere and the left cerebrocortical infarct lesions were measured on the photographs by using an image analyzer. The left cerebrocortical infarcted areas were divided by the left cerebral hemispheric areas to calculate ratios of the cerebrocortical infarction (%). Results are shown in FIG. 6. Data are represented as mean±SE. Statistical analyses were conducted by Mann-Whitney U-test.

As shown in FIG. 6, the ratio of the cerebrocortical infarction was also significantly decreased in the group of ischemic animals administered with red ginseng powder in a dose of 0.9 g/kg/day, as compared with the group of ischemic animals administered with distilled water.

Example 3 Experiments for Analyzing Upregulation by Red Ginseng Powder at High Dose of Bcl-xL Protein Expression in Neural Tissues

Whether or not oral administration of red ginseng powder increases the expression of Bcl-xL protein was investigated by using the transient forebrain ischemic model of gerbils. In our previous report (Wen, T. -C., et al. , J. Exp. Med., 188, 635-649, 1998), the experimental system for investigation of Bcl-xL expression in the hippocampal CA1 field after transient forebrain ischemia has been established, and effects of oral administration of red ginseng powder were examined with the use of this system.

As shown in FIG. 7, one of the present inventors (Sakanaka) had reported that when red ginseng powder was administered orally in a dose of 0.9 g/kg/day or 1.5 g/kg/day, once a day for 7 days before transient forebrain ischemia for 5 minute in gerbils, nerve cell death in the hippocampal CA1 field was significantly prevented and the response latency time in the passive avoidance test was extended, as compared with the group of animals administered with distilled water (Wen, T. -C., et al., Acta Neuropathol., 91, 15-22, 1996). Especially, a good effect was observed in the group of ischemic animals administered with red ginseng powder in the dose of 1.5 g/kg/day, as compared with the group of animals administered with 0.9 g/kg/day. Therefore, in the present experiments, red ginseng powder was administered orally in the dose of 1.5 g/kg/day, once a day for 7 days from 1 week before transient forebrain ischemia for 5 minute, and red ginseng powder was further administered orally after 5 minute ischemia (n=4). Tissues of the hippocampal CA1 field were collected at the 24th hour after the final administration of red ginseng power. Thereafter cells were lysed with sample buffer for electrophoresis and electrophoresed. Proteins separated by the electrophoresis were transferred to nitrocellulose membrane to perform Western blotting by using anti-Bcl-xL protein antibody. For the animals undergone sham operation (n=4) and the control animals with transient forebrain ischemia for 5 minute (ischemic control animals, n=4), the equal amount of distilled water was given orally. In order to investigate whether oral administration of red ginseng powder at the high dose of 1.5 g/kg/day affects the expression of Bcl-xL protein in peripheral organs or not, liver and spleen were collected and Western blotting was performed by the same procedures. Details of the above experimental procedures are described in our previous report (Wen, T. -C., et al., J. Exp. Med., 188, 635-649, 1998). Results are shown in FIG. 8.

Further, bands reacted with the anti-Bcl-xL protein antibody were quantified by using an image analyzer. Results are shown in FIG. 9.

As shown in FIG. 8, when red ginseng powder was administered orally in the dose of 1.5 g/kg/day, once a day for 7 days from 1 week before transient forebrain ischemia for 5 minute, and the equal amount of red ginseng powder was further administered orally after the ischemic insult, expression of Bcl-xL protein in the tissues of the hippocampal CA1 field after 24 hours was increased in all cases as compared with the sham-operated group and the ischemic group administered with distilled water. As a result of quantifying the bands reacted with the anti-Bcl-xL protein antibody with the use of an image analyzer, as shown in FIG. 9, it was found that oral administration of red ginseng powder significantly increased the expression of BCl-xL protein in the hippocampal CA1 field. However, even though such the high dose of red ginseng powder was administered orally, the expression of Bcl-xL protein in the liver and spleen was not increased. Statistical analyses were conducted by ANOVA+Scheffe's post hoc test.

Example 4 Experiments for Analyzing Upregulation by Red Ginseng Powder at Low Dose of BCl-xL Protein Expression in Liver and Spleen

We further investigated whether or not oral administration of low dose of red ginseng powder for a term longer than one week increased the expression of BCl-xL protein in the hippocampal CA1 field. For example, red ginseng powder was administered orally in the dose of 200 mg/kg/day, once a day for 4 weeks before transient forebrain ischemia for 5 minute in gerbils, and immediately after 5 minute ischemia, red ginseng powder was further orally administered once (n=4). The hippocampal CA1 field was collected after 24 hours, and Western blotting by using anti-Bcl-xL protein antibody was performed in the same manner as shown in FIG. 8. The animals undergone sham operation and the control animals with transient forebrain ischemia for 5 minute (ischemic control animals) were administered orally with the equal amount of distilled water alone (n=4 in each group). In order to investigate whether oral administration of red ginseng powder at the dose of 200 mg/kg/day affects expression of Bcl-xL protein in peripheral organs or not, liver and spleen were collected and Western blotting was performed by the same procedures (n=4 in each group).

However, no significant increase in the expression of Bcl-xL protein in the hippocampal CA1 field was observed even in case of the oral administration of red ginseng powder in the dose of 200 mg/kg/day for 4 weeks. Further, red ginseng powder was administered orally in the dose of 200 mg/kg/day, once a day for 4 weeks before 5 minute ischemia, and the same dose of red ginseng powder was further administered orally for one week after 5 minute ischemia. However, the passive avoidance learning disability and nerve cell death in the hippocampal CA1 field of gerbils could not be ameliorated. This fact means that if increase in the expression of Bcl-xL protein is not induced by the oral administration of low dose of red ginseng powder, no protective effect on nerve cells is exhibited.

As described above, when red ginseng powder was administered orally for 4 weeks at the dose of 200 mg/kg/day in gerbils before cerebral ischemia, the expression of Bcl-xL protein in the hippocampal CA1 was not increased. However, when the same amount of red ginseng powder was administered orally in the same dosing schedule, the expression of Bcl-xL protein in the liver and the spleen was significantly increased as shown in FIG. 10 and FIG. 11. Statistical analyses were conducted by ANOVA+Scheffe's post hoc test.

Example 5 Long Term Degeneration-Suppressing Effect of Oral Administration of High Dose of Red Ginseng Powder on Hippocampal CA1 Neurons

One of the present inventors reported that when the brain temperature of gerbils was maintained at 37° C.±0.2° C. and blood flow of the bilateral common carotid arteries was clamped for 3 min and reperfused, about one half of nerve cells in the hippocampal CA1 field degenerated after one week (Sakanaka, M., et al., Proc. Natl. Acad. Sci. USA, 95, 4635-4640, 1998). Further, the present inventors (Sakanaka and Tanaka) demonstrated that fragmentation of nerve cell nuclei, an index of apoptosis-like cell death, was further in progress in the remaining nerve cells at this moment as revealed by TUNEL staining (Wen, T. -C., et al., J. Exp. Med., 188, 635-649, 1998; Peng, H., et al. , J. Cereb. Blood Flow Metab., 18, 349-360, 1998). Consequently, it was demonstrated that in the hippocampal CA1 field of gerbils with transient forebrain ischemia for 3 min different from the case of 5 min ischemia, the degeneration of nerve cells also progressed even at one week and later after ischemia. We investigated the effect of oral administration of red ginseng powder for 4 weeks after ischemia using 3-min transient forebrain ischemia model in which nerve cell death continued for relatively long term.

According to the method of the present inventors (Sakanaka, M., et al., Proc. Natl. Acad. Sci. USA, 95, 4635-4640, 1998; Wen, T. -C., et al., J. Exp. Med., 188, 635-649, 1998; Peng, H., et al., J. Cereb. Blood Flow Metab., 18, 349-360, 1998), blood flow of the bilateral common carotid arteries was clamped for 3 min while maintaining the brain temperature of gerbils at 37° C.±0.2° C. under inhalation anesthesia. After awakening from anesthesia, red ginseng powder was administered orally at the dose of 1.5 g/kg/day once a day for 28 days (n=11). The animals undergone sham operation (n=12) and the control animals with 3-min forebrain ischemia (ischemic control animals) (n=8) were orally administered with the equal amount of distilled water alone. Thereafter, the step-down passive avoidance task experiments were performed, and the animals were anesthetized with pentobarbital, and they were perfused and fixed transcardially with phosphate buffer containing 4% paraformaldehyde and 2.5% glutaraldehyde. The brains were dissected out, embedded in paraffin and paraffin sections with 5 μm thickness were prepared. The neuronal density in 1 mm of the hippocampal CA1 field in each animal was measured according to the method of the inventors (Sakanaka, M., et al. , Proc. Natl. Acad. Sci. USA, 95, 4635-4640, 1998; Wen, T. -C., et al., J. Exp. Med., 188, 635-649, 1998; Peng, H., et al., J. Cereb. Blood Flow Metab., 18, 349-360, 1998). Hereinafter, outlines of the step-down passive avoidance task experiment described in the above reference are described.

On 28 days after 3-min ischemia, the gerbil was placed on the safe platform of a conventional step-down passive avoidance apparatus, but at the beginning, the gerbil stepped down onto the lower grid floor several times, and it received electric shock, then returned back to the safe platform. During 5-minute training, most of the gerbils eventually stayed on the safe platform. 24 hours later, the gerbil was again placed on the safe platform while the shock generator was turned off, and the time until it stepped down onto the grid floor (the response latency) was measured to define as the learning ability of animal.

Results are shown in FIG. 12 and FIG. 13. FIG. 12(A) shows the response latency in the passive avoidance task experiments and FIG. 12(B) shows the neuronal density per 1 mm of the hippocampal CA1 field. As shown in FIG. 12(A), when red ginseng powder was administered orally for 4 weeks after 3-min ischemia, the response latency of the passive avoidance task experiment was significantly prolonged as compared with that in the group of ischemic animals administered with distilled water. Further, as shown in FIG. 12(B), when red ginseng powder was administered orally, the neuronal density in the hippocampal CA1 field was significantly increased as compared with the group of ischemic animals administered with distilled water.

FIG. 13 shows light microscopic photographs of the hippocampal CA1 field of (A) a sham-operated animal, (B) an ischemic animal administered with distilled water, and (C) an ischemic animals administered with red ginseng powder. As shown in FIG. 13, in the 3-min ischemic animals administered with distilled water (B), nerve cells (neurons) further degenerated (to die) on the later days after 1 week and the surviving neurons in the hippocampal CA1 field at one week after ischemia which were about 1/2 of the normal neurons in number, were decreased up to about ¼ of the normal neurons at the 28th day after ischemia, as compared with the sham-operated animals (A). However, when red ginseng powder was administered orally for 28 days after 3-min ischemia, the neuron death that occurred from the 1 st week to 28th day after ischemia was significantly suppressed.

Example 6 Treatment, Prevention or Therapy of Chorea by Red Ginseng Powder

Chorea (Huntington's chorea) is known to be the representative single gene disease in neurodegenerative diseases and was suspected to be caused by the repeated sequence of CAG coding polyglutamine, but no methods for therapy have been developed. Transfection of the causal gene of chorea, mutant huntingtin, into cultured neural cells (neurons) originating in the striatum makes the cells enter apoptosis-like neuronal death. However, it has been reported that if Bcl-xL protein is forcibly expressed in the cultured nerve cells together with the mutant huntingitin, the neuron death can be almost completely suppressed (Saudou, F., et al., Cell, 95, 55-66, 1988). Consequently, if red ginseng powder, which has the promoting action on the expression of Bcl-xL protein in the brain and nervous tissues, is administered orally before or after onset of chorea, the effectiveness and efficacy are highly expected. The oral administration of red ginseng powder appears to be also effective for other polyglutamine diseases (Machedo-Jaseph disease, dentatorubral-pallidoluysian atrophy, etc.) besides chorea.

To human subjects (estimated body weight 60 kg), who have been ascertained to onset chorea or other polyglutamine diseases in future by gene diagnosis, or to patients (estimated body weight 60 kg), who have already developed polyglutamine diseases, red ginseng powder is administered orally in doses of 2.0 g -90 g a day, preferably 5.625 g -36 g a day, more preferably 1 1.25 g -18 g a day. When red ginseng powder is administered before onset of chorea or other polyglutamine diseases, even if the diseases are developed unluckily, it is desirable to continue the oral administration of red ginseng powder until the pathologic conditions are ameliorated or stabilized. Further, when red ginseng powder is administered orally to the patients who developed chorea or other polyglutamine diseases, the oral administration of red ginseng powder is continued until the pathologic conditions are ameliorated or stabilized.

Example 7 Treatment, Prevention or Therapy of Dilated Cardiomyopathy by Oral Administration of Red Ginseng Powder

Dilated cardiomyopathy is a disease which shows decreased heat function and cardiac dilation as a result of myocardial cell death (myocardial cell degeneration) from an unknown cause. The decreased heart function is deteriorated progressively and develops cardiac failure to death. When cardiac failure is deteriorated, it has been thought that no other methods for therapy except heart transplantation are present. Perhaps, when myocardial cells of patients with dilated cardiomyopathy are going to death, the cell death-suppressing gene product BCl-xL protein, which is contained abundantly in myocardial cells, is considered to decrease. Consequently, as a result that the decrease in Bcl-xL protein is prevented by oral administration of red ginseng powder, the myocardial cell death of patients can be delayed, and then the heart function of patients may be preserved for long time.

For patients (estimated body weight 60 kg), who have been diagnosed as dilated cardiomyopathy, red ginseng powder is promptly administered orally in doses of 0.6 g -15 g a day, preferably 1.5 g -6 g a day, more preferably 2 g -4 g a day, every day. The oral administration is preferably continued until the pathologic conditions of patients are ameliorated or the progress of the pathologic conditions is arrested. Red ginseng powder and the other drugs for the circulatory system such as β-blockers, calcium antagonists, ACE-inhibitors, angiotensin receptor inhibitors, etc. can be administered orally in combination.

Example 8 (Treatment or therapy of brain edema by repetitive or continuous intravenous administration of low doses of ginsenoside Rb1)

After the experiments with oral administration of red ginseng powder, the present inventors investigated whether brain edema after cerebral infarction (cerebral embolism) is improved by repetitive or continuous intravenous administration of low doses of ginsenoside Rb1 or not.

Male SH-SP rats (weighing 250-300 g), at the age of 12-13 weeks, were used. Animals were bred in a room furnished with 12 hours light and dark cycles and water and feeds were supplied ad libitum. The cortical branch of the left middle cerebral artery (MCA) of each animal was coagulated and cut under inhalation anesthesia. Immediately after MCA permanent occlusion, ginsenoside Rb1 dissolved in physiological saline was infused once intravenously (6 fig or 60 μg), and subsequently intravenously infused in a continuous manner for 28 days by using an Alza osmotic minipump (6 μg/day or 60 μg/day).

Control animals with MCA permanent occlusion (ischemic control animals) and sham-operated animals received the same amount of physiological saline.

At 32 days after the MCA permanent occlusion, the SH-SP rats were anesthetized with chloral hydrate, and they were perfused and fixed transcardially with 0.1 M phosphate buffer containing 4% paraformaldehyde. The brains of the animals were dissected out and cerebrocortical infarcted lesions were photographed.

Results are shown in FIG. 14.

In FIG. 14, the upper photographs are stereomicroscopic photographs of brains of 8 animals with cerebral infarction (cerebral embolism) administered with physiological saline, which were taken from the dorsal side. In FIG. 14, the lower photographs are stereomicroscopic photographs of brains of 8 animals with cerebral infarction (cerebral embolism) administered with ginsenoside Rb1 (6 μg/day), which were taken from the dorsal side. Since the frontal edge of the brain is arranged toward the direction of right side, the left cerebral hemisphere with darkened cerebral infarct lesion is observed on the upper side of the longitudinal cerebral fissure. Normal right cerebral hemisphere observed on the lower side of the longitudinal cerebral fissure was included, in part, in the stereomicroscopic photographs. As shown in the upper photographs of FIG. 14, in case of cerebral infarction administered with physiological saline, darkened cerebral infarct lesion of the left cerebral hemisphere expanded largely, and the left cerebral hemisphere is larger than the right cerebral hemisphere in all cases, though some difference is observed among the cases. Especially, among the cases of cerebral infarction administered with physiological saline, in the brain of the right end on the first row and in the second brain from the left on the second row, the left cerebral hemisphere is obviously larger than the right cerebral hemisphere. This indicates that brain edema appears in the left cerebral hemisphere with MCA occlusion and the brain pressure or intracranial pressure is increased.

On the other hand, as shown in the lower photographs of FIG. 14, in the cases of cerebral infarction (cerebral embolism) administered intravenously with ginsenoside Rb1 (6 μg/day), cerebral infarcted lesions are obviously reduced in all cases and no difference in size between the left cerebral hemisphere and the right cerebral hemisphere is observed. Namely, cerebral edema is not observed by repetitive or continuous intravenous administration of ginsenoside Rb1.

Example 9 Treatment or Therapy of Spinal Cord Injury by Repetitive or Continuous Intravenous Administration of Ginsenoside Rb1

Wistar rats (body weight about 300 g) loaded with 20 g of compression on the lower thoracic cord for 20 minutes were used as a spinal cord-injured model.

The rats were anesthetized with inhalation of halothane and nitrous oxide and were loaded with 20 g of compression on the lower thoracic cord for 20 minutes. After more than 30 minutes passed, ginsenoside Rb1 (12 μg or 60 μg) dissolved in physiological saline was infused once into the left femoral vein, thereafter continuous or repetitive intravenous administration of ginsenoside Rb1 (12 μg/day or 60 μg/day) was performed for 7 days by using an Alza osmotic mini pump. Control animals and sham-operated animals were administered with the same amount of physiological saline (vehicle) in the same schedule. The open field locomotor scores [Basso, Bettie and Bresnakan (BBB) scores] as an index of motor functions (Basso D. M. et al., J. Neurotrauma, 13, 343-359, 1996) were measured before loading spinal cord injury, on the day of spinal cord injury and from 1 st day to 7th day after the spinal cord injury. The BBB scores of the sham-operated rats (normal rats) were 20-21. Results are shown in FIG. 16 and FIG. 17.

FIG. 16 shows a control rat administered with physiological saline and a rat administered with ginsenoside Rb1 (60 μg/day) on the day of spinal cord injury and on the next day after spinal cord injury. As shown in FIG. 16, the rats, to which 20 g of compression was loaded on the lower thoracic cord for 20 minutes, obviously exhibited paraplegia in both hindlimbs immediately after the compression loading. However, when ginsenoside Rb1 (60 μg/day) was intravenously administered after passing more than 30 minutes from loading 20 g of compression on the lower thoracic cord for 20 minutes, the paraplegia of both hindlimbs was significantly ameliorated 1-2 days later, and the rat could stand up with the aid of a holding bar as shown in FIG. 16. However, paraplegia of the hindlimbs of the rat administered with physiological saline was not ameliorated at all.

FIG. 17 shows a graph in which the motor ability of rats is quantified at the 7th day after spinal cord injuries by using the BBB scores. As shown in FIG. 17, the motor ability of rats with spinal cord injuries was significantly ameliorated in a dose-dependent manner by intravenously administered ginsenoside Rb1. Data are represented as mean i SE. Statistical analyses were performed by Mann-Whitney U-test.

Example 10 Treatment or Therapy of Spinal Cord Injury by Repetitive or Continuous Intravenous Administration of Low Dose of Crude Saponin Fraction of Ginseng

Wistar rats (body weight about 300 g) loaded with 20 g of compression on the lower thoracic cord for 20 minutes were used as the spinal cord-injured model.

The rats were anesthetized with inhalation of halothane and nitrous oxide and were loaded with 20 g of compression on the lower thoracic cord for 20 minutes. After more than 30 minutes passed, a crude saponin fraction of medicinal ginseng (870 μg) dissolved in physiological saline was infused once into the left femoral vein, thereafter continuous or repetitive intravenous administration of the crude saponin fraction (870 μg/day) was performed for 7 days by using an Alza osmotic mini pump. Control animals with spinal cord injury were administered with the same amount of physiological saline (vehicle) in the same shedule. Results are shown in FIG. 18 and FIG. 19. FIG. 18 shows a rat administered with the crude saponin fraction and FIG. 19 shows a control rat administered with physiological saline (vehicle).

As shown in FIG. 18, on the day of loading spinal cord injury, the rat exhibited paraplegia in both hindlimbs and could not stand up in spite of the intravenous administration of the crude saponin fraction. However, the paraplegia of both hindlimbs of the rat was significantly ameliorated thereafter, and the rat at the 7th day after spinal cord injury could stand up by holding the outer wall of the open field (height 8 cm). On the other hand, as shown in FIG. 19, in the rat administered with physiological saline alone after loading spinal cord injury, paraplegia of the hindlimbs was not ameliorated at all in spite that 1 week passed after spinal cord injury.

According to the present experimental results using rats with spinal cord injuries, the therapeutic effects of the preparations comprising low doses of the crude saponin fraction(s) for intravenous repetitive administration on spinal cord injury are thought to be as excellent as those of ginsenoside Rb1.

Example 11 Treatment or Therapy of Spinal Cord Injury and Bedsore by Repetitive or Continuous Intravenous Administration of Low Dose of Ginsenoside Rb1

Wistar rats (body weight about 300 g) were anesthetized with inhalation of halothane and nitrous oxide and were loaded with 20 g of compression on the lower thoracic cord for 20 minutes. After they were awakened from anesthesia, the rats with paraplegia in both hindlimbs were allowed to stay for 1 hour and 40 minutes in the cage. Namely, the rats with spinal cord injury were allowed to leave for about 2 hours without any management and treatment from the time when 20 g of compression to the lower thoracic cord was loaded. Immediately thereafter, ginsenoside Rb1 (60 μg) was infused once into the left femoral vein, and further, continuous or repetitive intravenous administration of ginsenoside Rb1 (60 μg/day) was performed for 7 days by using an Alza osmotic minipump. Control animals with spinal cord injury were administered with the same amount of physiological saline (vehicle). Results are shown in FIG. 21.

As shown in FIG. 21, the rats administered intravenously with ginsenoside Rb1 from 2 hours after initiation of the compression loading on the lower thoracic cord exhibited paraplegia in both hindlimbs on the day subjected to spinal cord injury and could not stand up, and on the next day, they could not still stand up, although the paraplegia in both hindlimbs was slightly improved. However, the paraplegia of both hindlimbs of the rats was gradually ameliorated from 3-4 days after the onset of spinal cord injury, and as shown in FIG. 21, the rats could stand up by holding the outer wall of the open field (height 8 cm). On the other hand, as shown in FIG. 21, in the rats administered with physiological saline (vehicle) alone since 2 hours passed after loading compression on the lower thoracic cord, paraplegia of the hindlimbs was not ameliorated at all in spite that 1 week passed after spinal cord injury. In addition, in the rats administered with physiological saline alone, as shown in FIG. 21, bedsore was frequently observed in the lower abdomen though individual differences were noted. However, bedsore (decubitus) was hardly observed in the animals administered with ginsenoside Rb1.

Example 12 (Protective action of ginsenoside Rb1 on oligodendrocyte)

Nerve cells (neurons) and oligodendrocytes were cocultured and the investigation of whether or not ginsenoside Rb1 promotes survival of both cells was performed. For that purpose, nerve cells were isolated from cerebral cortices of fetal rats at gestational day 17. The mixed brain cell culture of the forebrain of newborn rats was initiated to isolate oligodendrocytes. Fifty thousands of oligodendrocytes to 500,000 nerve cells were cocultured. To this culture system was added 1 fg/ml to 10 pg/ml ginsenoside Rb1 in DMEM containing 1% fetal bovine serum and the mixed cells were cultured for 5 days. Subsequently, samples for electrophoresis were prepared and contents of the neuron-specific protein MAP2 (microtubule-associated protein 2) and the oligodendrocyte specific-protein CNPase in the culture well were assayed by means of Western blotting. Results are shown in FIG. 22.

In FIG. 22, the upper photograph shows Western blotting of MAP2 and the lower photograph shows that of CNPase. When ginsenoside Rb1 at the concentrations of 1 fg/ml to 100 fg/ml was added to the coculture system of nerve cells and oligodendrocytes, the band of MAP 2 and the band of CNPase were obviously intense as compared with non-ginsenoside Rb1-added and 104 fg/ml ginsenoside Rb1-added groups. This indicates that when low concentrations of ginsenoside Rb1 were added to the coculture system at the concentrations of 1 fg/ml to 100 fg/ml, amounts of MAP2 and CNPase were obviously increased. Namely, the survival of nerve cells and oligodendrocytes were promoted by ginsenoside Rb1. This fact strongly supports the effectiveness of low concentrations and low doses of ginsenoside Rb1 for preventing, treating or curing diseases accompanied by oligodendrocyte cell death (multiple sclerosis, Binswanger's disease and brain and nervous diseases causing demyelination such as leukoencephalitis).

Example 13 Upregulation of Bcl-xL Expression in Oligodendrocytes by Ginsenoside Rb1

In order to investigate whether ginsenoside Rb1 enhances the expression of Bcl-xL in oligodendrocytes or not, for example, ginsenoside Rb1 at the concentration from 1 fg/ml to 10 pg/ml was added to the primary cultured rat oligodendrocytes. After culture for 6 hours, Total RNA was extracted and Bcl-xL mRNA was assayed by RT-PCR. β-actin mRNA was used as an internal standard of RT-PCR. Further, a part of oligodendrocytes was used as a sample for SDS electrophoresis after treating with ginsenoside Rb1, and the amount of anti-apoptotic factor Bcl-xL in the culture well was examined by immunoblotting (Western blotting). The mixed brain cell culture was initiated to isolate oligodendrocytes by using the forebrain of newborn rats. Results are shown in FIG. 23. In FIG. 23, the upper photographs show results of RT-PCR and the lower photograph shows results of the immunoblotting (Western blotting); Rb1 (−) indicates no addition of ginsenoside Rb1 and Rb1 (+) indicates addition of ginsenoside Rb1 at 100 fg/ml.

The RT-PCR indicates that when ginsenoside Rb1 was added at the concentration of 100 fg/ml, expression of Bcl-xL mRNA in the oligodendrocytes was obviously enhanced. Further, results of immunoblotting (Western blotting) indicate that Bcl-xL protein was also increased by the addition of ginsenoside Rb1. The present experimental results strongly support that in spinal cord injuries and brain and nervous diseases accompanied by demyelination, intravenous administration of small doses of ginsenoside Rb1 exhibits a protective action on oligodendrocytes.

Example 14 Enhancement of Bcl-xL Expression by Intravenous Administration of Ginsenoside Rb1

We (the present inventors) investigated whether intravenous administration of ginsenoside Rb1 increases the expression of Bcl-xL mRNA in brain tissues or not. For that purpose, for example, SH-SP rats (body weight 250-300 g) at the age of 12 weeks were used. Immediately after permanent occlusion of the MCA in SH-SP rats under inhalation anesthesia, ginsenoside Rb1 dissolved in physiological saline was infused once intravenously (60 μg), and subsequently ginsenoside Rb1 was intravenously infused continuously at the dose of 60 μg/day. Control animals with MCA permanent occlusion and sham-operated animals were administered with the same amount of physiological saline after MCA permanent occlusion. Results are shown in FIG. 24. Group 1 shows a sham-operated animal, an animal with MCA permanent occlusion administered with physiological saline (after MCA permanent occlusion, i.e. at the 4th hour after cerebral infarction); an animal with cerebral infarction administered with ginsenoside Rb1 (at the 4th hour after MCA permanent occlusion); and an animal with cerebral infarction administered with ginsenoside Rb1 (at the 6th hour after MCA permanent occlusion). Group 2 consists of animals under the same experimental conditions. Sham indicates sham-operated animals; Rb1 (−) indicates animals with cerebral infarction administered with physiological saline alone; and Rb1 (+) indicates animals with cerebral infarction administered intravenously with ginsenoside Rb1. After the sham operation and at the 4th hour or the 6th hour after MCA permanent occlusion, the rats were anesthetized with chloral hydrate, and the left cerebral cortex (i.e. the cerebral cortex on the MCA permanent occluded side) was dissected out and total RNA was prepared for RT-PCR. The mRNA of β-actin was used as the internal standard.

As shown in FIG. 24, in Group 1 and Group 2, the expressions of Bcl-xL mRNA in the cerebral cortex were obviously increased both at the 4th hour and the 6th hour after the MCA permanent occlusion in the animals administered intravenously with ginsenoside Rb1 as compared with the animals with sham operation and the cerebral infarcted animals administered with physiological saline.

Example 15 Enhancement of Bcl-xL Expression in Myocardial Cells by Low Concentrations of Ginsenoside Rb1

We (the present inventors) have studied the effectiveness and efficacy of medicinal ginseng (red ginseng powder), crude saponin fraction(s) and ginsenoside Rb1 using nervous tissues or constituent cells in nervous tissues (nerve cells and oligodendrocytes). Subsequently we studied the effectiveness of ginsenoside Rb1 on heart. For that purpose, for example, changes in the expressions of Bcl-xL mRNA and Bcl-xL protein were examined with the use of RT-PCR and immunoblotting, when the primary cultured myocardial cells were cultured for 18 hours in the presence of ginsenoside Rb1. Myocardial cells were prepared as follows. The hearts of fetal rats at gestational day 17 were treated with trypsin EDTA to prepare the dispersed cells, which were cultured for several days in DMEM containing 10% FCS (fetal calf serum). In RT-PCR, β-actin mRNA was used as the internal standard. In the immunoblotting, troponin T, a striated muscle-specific protein, was used as the internal standard, and expression of Bcl-xL protein was examined. In the immunoblotting, the same experiments were repeated 10 times by using different lots of myocardial cells, and Bcl-xL immunoreaction-positive bands were analyzed by densitometry and statistical analysis was performed. Results are shown in FIG. 25. In FIG. 25, the upper photographs show results of RT-PCR, and the middle photographs show results of immunoblotting (Western blotting), and the lower graph shows results of densitometric analysis of the data of Western blotting.

As shown in FIG. 25, the expression of Bcl-xL mRNA was obviously increased in the presence of ginsenoside Rb1 at concentrations of 1 fg/ml -100 fg/ml. With regard to the BCl-xL protein level, ginsenoside Rb1 in the concentration range between 1 fg/ml and 104 fg/ml significantly enhanced the expression of Bcl-xL protein. In the present experiments, although a mismatch between the expression of Bcl-xL mRNA and that of Bcl-xL protein was noted at 104 fg/ml of ginsenoside Rb1, it is speculated that the expression of BCl-xL mRNA was already down-regulated at 18 hours after administration of such a high concentration of ginsenoside Rb1 (104 fg/ml). Statistical analyses were conducted by ANOVA+Fisher's PLSD.

Example 16 Protective Action of Low Concentrations of Ginsenoside Rb1 on Myocardial Cells

We (the present inventors) investigated whether ginsenoside Rb1 could actually suppress myocardial cell death in the concentration range for increasing the expression of Bcl-xL protein or not. For that purpose, for example, the protective effect of ginsenoside Rb1 on myocardial cells was examined when the primary cultured myocardial cells were cultured without addition of glucose. Ginsenoside Rb1 in the concentration range from 0 to 1 ng/ml was added to serum-free DMEM without containing glucose, and myocardial cells were cultured for 4 or 5 days. Subsequently, the sample for electrophoresis was prepared, and immunoblotting (Western blotting) was performed by using anti-striated muscle specific α-actinin antibody. Results are shown in FIG. 26. In FIG. 26, the upper photographs show results of Western blotting of α-actinin, and the lower graph shows results of densitometric analysis of the Western blotting. Statistical analyses were conducted by ANOVA+Scheffe's post hoc test.

As shown in FIG. 26, when the culture was conducted only with the glucose-free and serum-free medium, the myocardial cells disappeared already at 4-5 days after culture, and when ginsenoside Rb1 was added to the culture medium at the concentrations from 1 fg/ml to 104 fg/ml, large numbers of pulsating myocardial cells were observed even at 4-5 days after culture, and the striated muscle specific a-actinin was significantly detected by immunoblotting. According to the above results, it was found that ginsenoside Rb1 could increase the expression of myocardial cell BC1-xL in a slightly broader concentration range (1-104 fg/ml) than the effective concentration range of ginsenoside Rb1 for nerve cells and had the protective action on myocardial cells.

Example 17 Therapeutic Effect of Dihydroginsenoside Rb1 on Cerebral Infarction

In the prior patent application (Japanese Patent Application No. Hei 11-243378, Brain cell or nerve cell-protective agents comprising ginseng), we, the present inventors, have described that compounds having brain cell or nerve cell-protective action can be newly explored by using candidate substances of the active components contained in ginseng as a leading compound(s). We attempted to demonstrate this fact in the present invention. For that purpose, for example, dihydroginsenoside Rb1 represented by the above chemical formula (II) was used. As far as we know, dihydroginsenoside Rb1 is considered to be a novel compound and can be produced by reducing ginsenoside Rb1.

A process for production of dihydroginsenoside Rb1 and NMR data thereof are shown as follows.

10.2 mg of 10% Pd/c (as a catalyst) was weighed and was poured into a two-neck flask with stopper cocks. One ml methanol (GR) was added to suspend. Balloon filled with hydrogen gas (about 1.1 atm.) was attached to the flask and the catalyst was activated at 0° C. for 30 minutes. 19.9 mg ginsenoside Rb1 dissolved in 1 ml methanol was put into the flask by using a syringe. The mixture was vigorously stirred at 0° C. for 10 hours and 30 minutes (with a magnetic stirrer). The reaction mixture was filtered through filter paper and membrane filter with pores 0.45 μm in diameter. Methanol was removed off under reduction of pressure. The residue was dissolved in 10 ml pure water, and lyophilized to obtain 19.1 mg dihydroginsenoside Rb1 (yield 97%) as white powder. The melting point was 193-195° C. Incidentally, the melting point of ginsenoside Rb1 is 197-198° C. (Reference value).

In FIG. 29, the NMR chart (400 MHz, CD3OD) is shown.

Male SH-SP rats, at the age of 16 weeks, weighing 300-320 g, were used. Animals were bred in a room furnished with 12 hours light and dark cycles and water and feeds were supplied ad libitum. The cortical branch of the left middle cerebral artery (MCA) of each animal was coagulated and cut under inhalation anesthesia. Immediately after MCA permanent occlusion, dihydroginsenoside Rb1 dissolved in physiological saline was infused once intravenously (6 μg), and subsequently it was intravenously infused continuously for 24 hours by using an Alza osmotic minipump (6 μg/day).

Control animals with MCA permanent occlusion (ischemic control animals) were administered with the same amount of physiological saline (vehicle). At 24 hours after MCA permanent occlusion, a lethal dose of pentobarbital was injected intraperitoneally into rats. Immediately after death of animals, the brains were dissected out and frontal sections 2 mm thick were prepared. The sections were immersed in 1% 2,3,5-triphenyl-tetrazolium chloride (TTC) solution for 30 minutes at 37° C. and fixed with 10% formalin for more than 12 hours. Results are shown in FIG. 27 and FIG. 28. In FIG. 27, 2 cases administered with physiological saline, and in FIG. 28, 2 cases administered intravenously with dihydroginsenoside Rb1 are shown.

As shown in FIG. 27, in the rats administered with physiological saline alone after MCA permanent occlusion, cerebral infarct lesions, which were not stained with TTC, were observed with white color in the cerebral cortex on the left side. On the other hand, as shown in FIG. 28, in the rats administered intravenously with dihydroginsenoside Rb1 after MCA permanent occlusion, cerebral infarct lesions were markedly reduced. This effectiveness is thought to be equal to the therapeutic action of ginsenoside Rb1 on cerebral infarction.

Example 18 Prevention, Treatment and/or Therapy of Bedsore by Dihydroginsenoside Rb1

Bedsore (decubitus) of the bedridden patients and aged people is a cutaneous disease being a cause for deteriorating general condition and significantly damaging QOL (quality of life). In the early stage of bedsore, flare of the lesioned skin is observed. At this stage, there are few agents for external use which can be applied to the local lesion and penumbra thereof or few agents for intravenous administration to exhibit effectiveness and efficacy. This is a great problem in the dermatological field. Of course, the treatment or therapy of bedsore lesion deficient in cutaneous tissues is extremely difficult.

The external preparation(s) for skin (cream or ointment) is prepared by mixing dihydroginsenoside Rb1), with any water-soluble base or any fat-soluble base with glucose or without containing glucose. The preparation(s) is applied at any time to the local lesion of bedsore and penumbra thereof until the bedsore lesion is cured, reduced or not deteriorated. At that time, the amount of dihydroginsenoside Rb1 added to the base is adjusted to keep the extracellular fluid concentrations of dihydroginsenoside Rb1 in the local lesion at 100 ng/ml or less, preferably 10 pg or less, more preferably 100 fg/ml or less. If necessary, intravenous administration of dihydroginsenoside Rb1 is used together as described in example 17.

Example 19 Prevention, Treatment or Therapy of Corneal Injury by Dihydroginsenoside Rb1

It is well known that corneal injuries occur at the application of contact lens or after corrective operation for myopia using excimer laser. However, eye drops, which can protect keratic or corneal tissues, are rarely known at present.

Ophthalmic lotions (eye drops) or ophthalmic ointments are prepared by mixing dihydroginsenoside Rb1 with basal ophthalmic lotions or base, and they are applied for necessary times every day to the patients with keratic or corneal injuries, and the application is continued until ameliorating or healing keratic or corneal lesion. In that occasion, the amount of dihydroginsenoside Rb1 in the base is adjusted to keep the extracellular fluid concentrations of dihydroginsenoside Rb1 in the keratic or corneal lesioned tissues at 100 ng/ml or less, preferably 10 pg/ml or less, more preferably 100 fg/ml or less. Of course, dihydroginsenoside Rb1 can be replaced by ginsenoside Rb1.

Example 20 Protection of Cornea for Transplantation by Dihydroginsenoside Rb1

The keratoplasty is frequently carried out in the ophthalmological field as the remedy with the highest success rate in the transplantation medicine. However, since the cells composing corneal tissues for transplantation are certainly going to death during the term from collecting cornea from the dead body to performing keratoplasty, and thus such term is the greatest factor restricting the time from collecting cornea to grafting. After collecting the cornea for transplantation, dihydroginsenoside Rb1, can be admixed to the conventional corneal preservative solution at concentrations of 100 ng/ml or less, preferably 10 pg/ml or less, and more preferably 100 fg/ml or less to protect cornea for transplantation.

Example 21 Prevention, Therapy or Treatment of Chorea by Dihydroginsenoside Rb1

Chorea (Huntington's chorea) is known to be a representative single gene disease among the neurodegenerative diseases and is suspected to be caused by repetitive sequence of CAG coding polyglutamine. However, no methods for therapy have been developed. Transfection of the causal gene of chorea, mutant huntingtin, into cultured neurons originating in the striatum makes the neurons enter apoptosis-like death. However, it has been reported that if Bcl-xL is forcibly expressed in the cultured nerve cells together with the mutant huntingtin, the neuron death can be almost completely suppressed (Saudou, F., et al., Cell, 95, 55-66, 1988). Consequently, if dihydroginsenoside Rb1, which has a Bcl-xL protein expression-promoting action in the brain and nervous tissues, is nasally, rectally or intravenously administered before or after onset of chorea, the effectiveness and efficacy is highly expected. For other polyglutamine diseases (Machedo-Jaseph disease, dentatorubral-pallidoluysian atrophy, etc.) besides chorea, nasal, rectal or intravenous administration of dihydroginsenoside Rb1 appear to be effective. Further, dihydroginsenoside Rb1 is expected to inhibit development of the secondary degeneration expanding from the primary lesion (striatal lesion) of chorea to the other cerebral regions having fiber connections with the striatum, as ginsenoside Rb1 does.

To human subjects (estimated body weight 60 kg), who have been ascertained to onset chorea or other polyglutamine diseases in future by gene diagnosis, or to patients (estimated body weight 60 kg), who have already developed polyglutamine diseases (estimated body weight 60 kg), a preferable amount of dihydroginsenoside Rb1 is administered nasally, rectally or intravenously until the pathologic conditions are ameliorated or stabilized. The amount of intravenous administration of dihydroginsenoside Rb1 for treatment or therapy of polyglutamine diseases is equivalent to, or 5-10 times higher than that required for treatment or therapy of acute cerebral apoplexy. Dosage of nasal or rectal administration can be adjusted to maintain the blood concentrations of dihydroginsenoside Rb1 equal to those of intravenously administered dihydroginsenoside Rb1.

Example 22 Prevention, Treatment or Therapy of Dilated Dardiomyopathy by Dihydroginsenoside Rb1

Dilated cardiomyopathy is a disease which shows decreased heat function and cardiac dilation as a result of myocardial cell death (myocardial cell degeneration) from an unknown cause(s). The decreased heart function is deteriorated progressively and develops cardiac failure to death. When cardiac failure is developed, it has been thought that no other methods for therapy except heart transplantation are present. Perhaps, when myocardial cells of patients with dilated cardiomyopathy is going to death, the cell death-suppressing gene product Bcl-xL protein, which is contained abundantly in myocardial cells, is considered to decrease. Consequently, decrease in Bcl-xL protein is prevented by intravenous, rectal or nasal administration of dihydroginsenoside Rb1 and thereby myocardial cell death in the patients can be delayed, and then heart function of the patients can be preserved for a long time.

For patients (estimated body weight 60 kg), who have been diagnosed as dilated cardiomyopathy, a proper amount(s) of dihydroginsenoside Rb1 is promptly administered nasally, rectally or intravenously until the pathologic conditions or symptoms are ameliorated or the progress of the pathologic conditions is arrested. Dihydroginsenoside Rb1 and drugs for ingestion such as β-blockers, calcium antagonists, ACE-inhibitors, etc., can be administered in combination. When dihydroginsenoside Rb1 is administered for therapy or treatment of diseases of peripheral organs and tissues such as cardiac diseases, the amount equal to the amount of dose to patients with central nervous diseases or 1/10- 1/10,000 of amount thereof can preferably be selected.

Example 23 Prevention of Senescence of Skin by Ginsenoside Rb1 as a Cosmetic Composition

Senescence of skin accompanied by aging is mainly caused by ultraviolet irradiation, and it shows symptoms such as atrophy or shrink of skin, slackening of skin, white-hair, gray hair, exfoliation of the stratum corneum, exfoliation of cells in the stratum corneum, dandruff, scurf, dry skin, senile xerosis, asteatosis, oligosteatosis, asteatotic dermatitis, crack, itching, roughness, rhagade, ephelis, blotch, spots on the skin, furrows, lines, wrinkles, freckle, pigmentation, sunburn, dryess, etc. Ginsenoside Rb1 exhibits protective actions on cells of skin including epidermal cells, keratinocytes, sebaceous gland cells, hair follicular cells, sweat gland cells, fibroblasts, stem cells, mesenchymal cells, adipose cells, etc, when its extracellular fluid concentrations in lesioned tissues are kept at 1 ng/ml or less, preferably 10 pg/ml or less, more preferably 100 fg/ml or less. Thus, excellent effects on the aging symptoms of skin can be exhibited by adding trace amounts of ginsenoside Rb1 to any cosmetics, for example lotion (skin lotion), milky liquid (milky lotion), foundation, cold cream, cleansing cream, cleansing foam, night cream, beauty cream, face powder, lipstick, lip cream, foundation cream (make-up base), gargle, eye lotion, face lotion, UV liquid foundation, powder foundation, etc. if the local extracellular fluid concentrations of ginsenoside Rb1 in skin are kept low as described above.

When ginsenoside Rb1 is admixed with or added to the liquid cosmetics, for example conventional UV liquid foundation, its concentration is adjusted at 1000 ng/ml or less, preferably 10 ng/ml or less, more preferably 10 fg/ml -100 pg/ml or less, and the cosmetics is externally applied or externally sprayed every day on the skin. Then, the extracellular concentrations of ginsenoside Rb1 in the local area of the skin can be maintained at low levels, and it is useful for improvement of aging symptoms of skin, prevention from the progress of aging symptoms of skin or prevention from the deterioration of aging symptoms of skin (shrink or atrophy of skin, white-hair, gray hair, scurf, dandruff, exfoliation of the stratum corneum, exfoliation of cells in the stratum corneum, senile xerosis, asteatosis, oligosteatosis, asteatotic dermatitis, dry skin, easiness to infect, vulnerability to infection, slackening or loosening of skin, itching, roughness, crack, dryness, blotch, spots on the skin, ephelis, wrinkles, furrows, lines, freckle, pigmentation and sunburn). Further, when ginsenoside Rb1 is admixed or added to solid or gel cosmetics such as conventional foundation cream and night cream, the amount of admixing ginsenoside Rb1 is adjusted at 1000 ng/g of cream or less, preferably 10 ng/g or less, more preferably about 10 fg -100 pg/g. The preparation(s) or cosmetics is applied externally on the skin every day and is useful for preventing, treating or managing the aging symptoms of skin (shrink, atrophy, slackening, loosening, itching, roughness, dryness, crack, rhagade, dry skin, ephelis, blotch, spot, wrinkle, furrow, line, freckle, pigmentation, sunburn, etc.). The upper limit for admixing or adding ginsenoside Rb1 into the above cosmetics for the purpose of prevention, improvement or management of the aging symptoms of skin is less than 10 μg/ml in case of liquid cosmetics and less than 10 μg/g in case of solid or gel cosmetics. Namely, ginsenoside Rb1 should be admixed with the above cosmetics at the concentrations less than 0.001%. Otherwise, the membrane of skin cells may be damaged. Of course, the cosmetics containing trace amounts of ginsenoside Rb1 can be not only applied or sprayed externally to the face but also applied or sprayed externally to the other cutaneous tissues frequently irradiated with sun light (e.g. limbs or trunk). In this way, long term and continuous use of cosmetics or skin agents for external use containing low concentrations of ginsenoside Rb1 can prevent or improve symptoms accompanied by the aging of the skin.

In addition, the various symptoms accompanied with the aging of skin can be prevented by admixing almost equal amounts of dihydroginsenoside Rb1, crude saponin fraction of ginseng or components thereof in cosmetics or skin agents for external use, instead of ginsenoside Rb1. Ginsenoside Rb1, dihydroginsenoside Rb1, extract(s) of ginseng, crude saponin fraction(s) and components thereof can be admixed in all ready-made conventional cosmetics and skin agents for external use, as long as they are used at low concentrations as described above. Of course, in case that cosmetic base containing any one of active ingredients is newly developed, the various symptoms caused by aging of the skin can be prevented, managed or improved by admixing any one of ginsenoside Rb1, dihydroginsenoside Rb1, extract (s) of ginseng, crude saponin fraction (s) and components thereof at low concentrations as described above. Further, as described above, any one of low concentrations of ginsenoside Rb1, dihydroginsenoside Rb1, extract(s) of ginseng, crude saponin fraction(s) and components thereof are combined together and they admixed with ready-made cosmetics or skin agents for external use or admixed with newly developed cosmetic base containing any other active ingredients, and, as the results, the cosmetics or the skin agents for external use for preventing, managing or improving the various symptoms caused by aging of the skin can be prepared. When admixing any one of ginsenoside Rb1, dihydroginsenoside Rb1, extract (s) of ginseng, crude saponin fraction(s) and components thereof with the cosmetics or skin agents for external use in the multiple combination, any concentration can be selected, as far as each concentration in the cosmetics or skin agents for external use is low level as described above. Further, in case that known cosmetic compositions other than the above ginseng components are admixed with the cosmetics for prevention of aging of the skin, the concentrations of the known cosmetic compositions should be preferably lower than previously reported.

In addition, any one of ginsenoside Rb1, dihydroginsenoside Rb1, extract(s) of ginseng, crude saponin fraction(s) and components thereof is admixed at low concentrations with ready-made hair-growing agents or hair-restoration agents, or with novel hair growers or hair restorers containing any other active ingredients, in the same manner as described in cases of cosmetics. These preparations or agents can be used for preventing deterioration of hair growing and hair restoration or hair loss, or for preventing progress of alopecia or depilation. Further, instead of the crude saponin fraction(s) of ginseng admixed in the cosmetics, hair growing agents or hair restoration agents, ginseng extract(s) can be used in an amount of 5 to 6 times excess or less. Of course, as far as low concentration of ginseng extract(s) is used, the crude saponin fraction (s) of ginseng and ginseng extract (s) are combined together and these can be admixed with the above cosmetics or with hair growing agents, hair restoration agents or agents for preventing progress of depilation or alopecia. Further, in case that any one of natural products or compositions thereof containing ginsenoside Rb1 or other ginseng components are admixed with cosmetics, hair growing agents, hair restoration agents or agents for preventing progress of depilation or alopecia, and if the final content of ginsenoside Rb1 and other ginseng components can be maintained at low concentrations as described above, the mixed preparation(s) or agent(s) can be used for improving, preventing or managing the aging symptoms of skin and loss of hair. Ginseng extract(s), crude saponin fraction(s), and constitutents of crude saponin fraction(s), ginsenoside Rb1, dihydroginsenoside Rb1 and chemical derivatives thereof can be also used for chemical peeling.

INDUSTRIAL APPLICABILITY

The present invention relates to (medicinal) ginseng, extracts thereof, ginseng components or metabolites thereof useful as cytoprotective agents. More particularly, the present invention relates to medicinal or pharmaceutical compositions for suppressing apoptosis or apoptosis-like cell death or for promoting the expression of a cell death-suppressing gene product Bcl-xL protein, comprising ginseng, its extracts, ginseng components, metabolites thereof or salts thereof.

Further, the present invention relates to the medicinal or pharmaceutical composition(s) for protecting cells,-comprising ginsenoside Rb1, metabolites thereof or salts thereof. More particularly, the present invention relates to the medicinal or pharmaceutical composition (s) for preventing, treating or curing brain edema, nervous tissue edema or spinal cord tissue edema, comprising ginsenoside Rb1, metabolites thereof or salts thereof, the medicinal or pharmaceutical composition(s) for preventing, treating or curing bedsores caused by spinal cord injuries, comprising ginsenoside Rb1, metabolites thereof or salts thereof, the medicinal or pharmaceutical composition(s) for promoting the expression of a cell death-suppressing gene Bcl-xL in nervous tissues, comprising ginsenoside Rb1, metabolites thereof or salts thereof; the medicinal or pharmaceutical composition(s) for promoting the expression of a cell death-suppressing gene product Bcl-xL in oligodendrocytes, comprising ginsenoside metabolites thereof or salts thereof; protective agents for oligodendrocytes, comprising ginsenoside Rb1, metabolites thereof or salts thereof; the medicinal or pharmaceutical composition(s) for promoting the expression of a cell death-suppressing gene product Bcl-xL in myocardial cells, comprising ginsenoside Rb1, metabolites thereof or salts thereof; and the medicinal or pharmaceutical composition(s) for suppressing apoptosis or apoptosis-like cell death of myocardial cells, comprising ginsenoside Rb1, metabolites thereof or salts thereof.

Further, the present invention relates to preparations for intravenous administration comprising ginseng, its extract(s), ginseng components, metabolites thereof or salts thereof. More particularly, the present invention relates to the preparations at low concentrations and low doses for intravenous administration.

Further, the present invention relates to the use of components of ginseng or metabolites thereof as leading compounds for exploring novel active ingredients or compounds for preventing, curing or treating the diseases or lesions hereinbefore, or for exploring protective agents for brain cells or protective agents for nerve cells.

Further, the present invention also relates to a novel chemical derivative prepared from ginsenoside Rb1 as a leading compound, namely dihydroginsenoside Rb1 which is useful as a cytoprotective agent. Further, the present invention relates to a medicinal or pharmaceutical composition (s) for preventing, treating or curing cerebral infarction or cerebral apoplexy or a medicinal or pharmaceutical composition(s) for suppressing necrosis, apoptosis or apoptosis-like cell death of nerve cells, comprising dihydroginsenoside Rb1, metabolites thereof or salts thereof. The present invention further relates to a medicinal or pharmaceutical composition(s) that can be used as preparations for intravenous administration, comprising dihydroginsenoside Rb1, metabolites thereof or salts thereof, namely, the medicinal or pharmaceutical composition(s) useful as the preparations for repetitive or continuous intravenous administration or the preparations for a single intravenous infusion at low concentrations and low doses.

Claims

1-73. (canceled)

74. Dihydroginsenoside Rb1 represented by the following formula (II): or metabolites thereof or salts thereof.

75-90. (canceled)

91. A medicinal or pharmaceutical comprising dihydroginsenoside Rb1, metabolites thereof of salts thereof.

92. The composition of claim 91 further comprising a pharmaceutically acceptable carrier.

93. A method for treating a mammal suffering from or susceptible to a disease. causing apoptosis of cells or apoptosis-like cell death, comprising administering to the mammal a composition of claim 91.

94-120. (canceled)

Patent History
Publication number: 20080020988
Type: Application
Filed: Mar 22, 2007
Publication Date: Jan 24, 2008
Applicant: Japan Science and Technology Corporation (Saitama)
Inventors: Masahiro Sakanaka (Ehime), Nobuji Maeda (Ehime), Junya Tanaka (Ehime), Kimihiko Nakata (Ehime)
Application Number: 11/728,283
Classifications
Current U.S. Class: 514/26.000; 536/5.000
International Classification: A61K 31/7028 (20060101); A61P 43/00 (20060101); C07J 41/00 (20060101);